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                                  ABSTRACT 
 
Introduction: HIV/AIDS is a pandemic disease and its scourge has had a 
devastating impact on health, nutrition, food security and overall socioeconomic 
development in countries that have been greatly affected by the disease. The 
engagement of HIV/AIDS with under nutrition form a symbiotic relationship and 
one increases the prevalence and severity of the other.  
Aim: The main goal of the study was to evaluate the effectiveness of public 
health-nutrition intervention programme designed to attenuate the progression of 
HIV to AIDS among people living with HIV in Abuja, Nigeria. 
Methods: Local foods, which were known for their availability, accessibility, 
micro and macronutrient strengths were selected and optimised into a nutritional 
functional meal (Amtewa). 1000 PLWHIV were invited to participate in the 
research from all the HIV treatment centres in Abuja, Nigeria. Based on the 
sample size calculation, inclusion and exclusion criteria, 400 participants (adult, 
male and female from different religious background) were selected through 
simple randomisation. Out of these 400 participants, 100 were randomly 
selected for the pilot study. The participants in the pilot study overlapped to form 
part of the scale-up participants. The effect of daily consumption of Amtewa 
meal (354.92 kcal/d) for six and twelve months was ascertained through the 
nutritional status and biochemical   indices of the study participants (n=100 pilot 
and n=400 scale-up interventions) who were/were not taking anti-retroviral drug 
therapy (ART). 
Results: Mean CD4 cell count (cell/mm3) for ART-Test group at baseline and 
sixth months increased by 12.12%. Mean mid upper arm circumference (MUAC) 
(cm) also increased by 2.52% within the same period (n=400). On the contrary, 
there were decreases in control groups of 14.9% CD4 count and 2.28% MUAC. 
Student‘s t-test analysis suggests a strong association between the intervention 
meal and mean CD4 count (It increased by 54.40 cells/mm3 in the ART Test 
group (p=0.05)) on prolong use of Amtewa (up to 12 months). 
Conclusion: These results ascertained the effectiveness of Amtewa meal on 
health status of HIV infected subjects and also underpinned its significant 
position within the National Health Services framework as innovative nutritional 
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Contextualising the current PhD research 
In 1986, the first case of HIV report in Nigeria was documented (FMOH, 2008). 
In line with guidelines from the World Health Organisation (WHO), the 
government adopted antenatal clinic (ANC) sentinel surveillance as the system 
for assessing the epidemic. The national HIV seroprevalaence level obtained 
from sentinel surveys of antenatal care attendees, increased from 1.8 percent in 
1991 to 5.8 percent in 2001 and then declined to 5.0 percent in 2003 and further 
to 4.4 percent in 2005. This was followed by a rise to 4.6 percent in 2008 and 
then a recent decline to 4.1 percent in 2010 (NACA, 2012). Statistics obtained 
from attendance records at national antenatal clinics is used to gather 
information on HIV prevalence: although this is biased in as far as it does not 
capture information on men or non-child bearing women, it enables capture of 
comprehensive information on new cases of the disease.  In addition, it allows 
the opportunity to strengthen seronegativity among pregnant women.   
The impact of the HIV/AIDS pandemic on the children, families, communities, 
Nigerian work forces and the national GDP scores is considerable. For example, 
the number of children orphaned by AIDS in Nigeria was an estimated 1.6 million 
in 2005 and 2.1 million in 2012 (FMOH, 2007; NACA, 2012).  
In 2005 the WHO reported complex interactions between nutrition and 
HIV/AIDS.  Evidence highlights that undernutrition weakens the immune system, 
and in those living with HIV/AIDS in particular, this increases their susceptibility 
to the disease. Evidence from author groups including USAIDS (2004); Piwoz 
(2004); Drain et al. (2007) and Ivers (2014) indicates that the prevalence of 
macro and micronutrient (magnesium, selenium, zinc, vitamin C) deficiencies 
impacts negatively on optimal immune function, by a progressive depletion of the 
CD4 T-lymphocyte cells thus increasing susceptibility to morbidity and mortality 
among PLWH. Evidence also indicates that most HIV nutrition intervention 
programmes focus on the use of single or two synthetic micronutrients to delay 
the progression of the disease (Fawzi et al., 2005; Drain et al., 2007). 
Given the economic instability evident in Nigeria, there is an inherent difficulty for 
drug manufacturing industries to purchase sufficient resources to manufacture 
and distribute synthetic micronutrients. More so, where synthetic micronutrients 
are available, they are not cost effective, less bioavailable and may not be 
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sustainable in the developing countries like Nigeria, compared to the natural 
micronutrients (Thiel, 2000). 
It must be acknowledged that individual nutrients have been identified in the 
literature for their positive impacts on CD4 cell count in HIV infected individuals 
(Fawzi et al., 2004; Kaiser et al., 2006). Potential effects of nutrient supplement 
on the anthropometric profiles of HIV-positive patients and micronutrients 
supplementation in HIV- 1 disease progression are also documented in HIV 
management (Baum et al., 1995; Oguntibeju et al., 2008). However, there is a 
clear ‗effect‘ of selected nutrients on outcome; we consume food, not nutrients.   
Modifications to diet are required, and have variable effects (increasing intakes 
of fat may be offset reductions in sugar intakes to maintain energy balance) 
cannot be expected to have huge effects on outcome but additively given its 
acknowledged ability to impact various aspects of HIV pathology. These 
modifications have potential for positive effect for example: micronutrients 
attenuate HIV type 1 disease progression among adults and children (Fawzi, 
2003); nutritional interventions for reducing morbidity and mortality in people with 
HIV (Mahlungulu, 2009). The concern is that in Nigeria, this cannot be financed 
unless the approach is cost effective and sustainable.  For the purpose of this 
thesis, the concept of a naturally occurring, accessible and affordable nutrition 
intervention that demonstrates physiological and biochemical benefits in 















1.1 Background to HIV 
Human Immunodeficiency Virus (HIV) is a severely infectious and fast replicating 
retro-virus, genetically made–up of a single stranded RNA molecule, which 
impairs and deteriorates the functioning of the immune system‘s cells (WHO, 
2006; AIDS, 2009; WHO, 2013; CDC, 2014). Acquired immunodeficiency 
syndrome (AIDS) is a progressive deterioration of the immune status of the 
individual. It is characterised by the progressive depletion of the CD4 T-
lymphocyte population (cells that produces a specific immunity to a particular 
antigen), which represents a major target of viral infection by the causative HIV 
(Table 1.1) (Vajpayee et al., 2005). In 2006, World Health Organization (WHO) 
provided a simplified HIV case definition designed for reporting and surveillance 
(Box 1.1). 
 
Table 1. 1: Centre for Disease Control and Prevention classification system for HIV 
infection 
 Clinical categories 
  
 A B C 
CD4+ T-cell count 
(cells/mm3) (CD4%) 
Asymptomatic, acute 
(primary) HIV or PGL* 
Symptomatic, not A 
or C conditions† 
AIDS-indicator 
conditions‡ 
> 500 (28%) A1 B1 C1 
200–499 (15–28%) A2 B2 C2 
< 200 (14%) A3 B3 C3 
 
*
Category A: asymptomatic HIV infection, persistent generalised lymphadenopathy (PGL). 
†
Category B: oropharyngeal and vulvovaginal candidiasis, constitutional symptoms such as fever 
(38·5°C) or diarrhea lasting >1 month, herpes zoster (shingles). 
‡
Category C: Mycobacterium tuberculosis (pulmonary and disseminated), Pneumocystis carinii 
pneumonia, candidiasis of bronchi; trachea or lungs, extrapulmonary cryptococcosis, CMV, HIV-
related encephalopathy, Kaposi's sarcoma, wasting syndrome due to HIV. 
 
In Nigeria, CD4+ cell counts in healthy individuals have been found to range 
from 324 - 1160 cells/mm3 of blood (FMOH, 2007). In Western countries, the 
mean value reported to be 1,000 - 1,100 cells/mm3. Thus constant exposure to a 
number of other pathogens in sub-Saharan Africa may result in an overall less 








Box 1.1: WHO case definition for HIV infection (WHO, 2006) 
 
Adult and children 18 months or older: 
 HIV infection is diagnosed based on: Positive HIV antibody testing (rapid 
or laboratory based enzyme immunoassay). This is usually confirmed by 
a second HIV antibody test (rapid or laboratory – based enzyme 
immunoassay) relying on different operating characteristics 
and/or;  
 A positive virological test for HIV or its components (HIV – RNA or HIV – 
DNA or ultrasensitive HIV p24 antigen) confirmed by a second virological 
test obtained from a separate determination. 
 
Children younger than 18 months 
 HIV infection is diagnosed based on: A positive virological test for HIV or 
its components (HIV – RNA or HIV – DNA or ultrasensitive HIV p24 
antigen) confirmed by a second virological test obtained from a separate 
determination taken more than four weeks after birth. 
and/or; 
 Positive antibody testing is not recommended for definitive or confirmatory 
diagnosis of HIV infection in children until 18 months of age. 
 
1.2 Global epidemiology of HIV disease 
At the end of 2010, an estimated 34 million people were living with HIV 
worldwide up by 17% from 2001(Figure 1.1) (UNAIDS, 2011). This reflects the 
continued large number of new HIV infections and a significant expansion of 
access to antiretroviral therapy, therefore declining mortality rates. Globally, 
there were 2.7 million new HIV infections in 2010, including an estimated 
390,000 among children. However, sub-Saharan Africa (SAA) accounted for 
70% of new HIV infections in 2010 (UNAIDS, 2011). 
In many countries surveyed in SSA, more than half the people estimated to be 
living with HIV are not aware of their HIV status (WHO, 2013). Furthermore, in 
2013, 67% (62-73%) of the estimated 1.4 (1.3-1.6) million pregnant women living 
with HIV in low and middle income countries received effective antiretroviral 
drugs to avoid transmission to their children while the remaining 33% had no 
access to ART (WHO, 2013). WHO (2013) also reported that close to half the 
people who test HIV-positive in SSA were lost between testing and being 
assessed for eligibility of ART and 32% of the people considered eligible were 
lost between being assessed for eligibility and initiating ART.  
In WHO, UNAIDS and UNICEF (2011) report, AIDS had become one of the 
leading causes of adults dying in SSA and the full onslaught of the epidemic 
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could not be felt until 2006, when more than 2.2 million people died each year 
from AIDS-related causes such as undernutrition, tuberculosis and other 




Figure 1. 1: A global view of HIV infection and malnutrition. (Source: UNAIDS, 2010; FAO, 
2010) 
Sixty one percent of people infected with HIV in SSA are women and several 
population based survey in Africa have found extremely high rates of infection 
amongst young women e.g.: The HIV infection rate among women between 25 
and 29 years in rural South Africa was estimated at 5.1% (Pribram, 2011; NACA, 
2012). HIV remains the single greatest cause of death in SSA and the disease is 
responsible for more than 20% of death in the region (Pribram, 2011). Globally, 
Nigeria ranks second most affected by HIV/AIDS after South Africa (Table 1.2) 
(CIA, 2012). Nigeria is among the 15-focus countries, which collectively 
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represent 50% of HIV infections worldwide. Although the HIV prevalence of 
approximately 3.1% appears relatively low compared with other countries in 
SSA, it nevertheless translates into over 3.4 million people infected with HIV in 
Nigeria (UNAIDS, 2009 and 2010; CIA, 2012). 
1.3 HIV disease progression in Nigeria 
The first case of HIV in Nigeria report was in 1986. Since then the number of 
people living with HIV or AIDS (PLWHA) steadily increased and the epidemic 
moved into a ‗generalised‘ state with an increase in seroprevalence from 1.8% in 
1991 to 5.8% in 2001 (Figures 1.3 & 1.4) (FMOH, 2007, NACA, 2012). With 
initiation of some national intervention programmes (employing mainly ART: 
Lamivudine, Nevirapine, Zidovudine, Tenofovir and Efavirenz) there was slight 
drop by 0.8% which was recorded in 2003 that was sustained in 2005 with a 
seroprevalence rate of 4.4% (UNAIDS and WHO, 2009).  
 
Table 1. 2: Estimate of all people (adults and children) alive at year end with HIV infection  
(CIA World Factbook 2012). 
 
Rank Country HIV/AIDS People Living With 
HIV/AIDS 
1    South Africa  6,070,800 
2    Nigeria 
3    India 
4    Kenya 
5    Mozambique 
6   Uganda 
7   Tanzania 
8   Zimbabwe 
9   United States 











In 2007, it was estimated that 200,000 people were receiving antiretroviral 
therapy out of the approximately 750,000 PLWH that required antiretroviral 
treatment (CD4 count is <350 cells/mm3). This figure represented about 27% of 
all the people who need the treatment leaving 73% to suffer and die without 
medical intervention. This presents a serious challenge to the Government of 
Nigeria (GON) and its health programmes (Figure 1.2).  Between 2005 and 
2009, the AIDS related deaths fell from 220,000 to 170,000 while those 
orphaned as a result of the disease rose from 1.6 million in 2005 to 2.1 million in 
2012. Estimates also show a cumulative death of 2.82 million people as at 2010 
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Many factors are responsible for only 200,000 receiving ART in 2007, such as: 
quality of diagnosis, accurate prescribing, selection, distribution, and dispensing 
of ARVs. One of the most significant barriers to access is the price of ARVs. 
Currently, in most developing countries like Nigeria, high price of second line 
ARVs condemn people with AIDS to a premature death. 
NACA (2012) also reported the trend of HIV across age groups in male and 
female. The prevalence rate of 5.7% (female) and 5.1% (male) between the age 
group of 30 – 39 years is an indication of the impact of the disease on Nigeria 
work force (Figure 1.4).  
The impact of the political will in Nigeria have direct repercussions on the price 
of ARVs. Countries which imports ARVs (e.g. South Africa, Nigeria) have much 
higher prices than countries like Brazil and Senegal. Brazil settled a national 
protocol on HIV treatment while Senegal negotiated the Accelerated Access 
Initiative. The initiative by Brazil and Senegal proved that the price of ARVs can 
be brought at affordable level for the population. 
 
Figure 1.2: Number of PLWH who received ART against those who needed it   
(Source: FMOH, 2007; UNAIDS, 2009). 
 
 








Figure 1. 3: National HIV Prevalence Trend (1991 - 2010). Source: National Agency for 




Figure 1. 4: National HIV Prevalence Trend across age groups (years) in male and female 
PLWHIV in Nigeria. Source: National Agency for Control of AIDS, 2012. 
1.4 HIV/AIDS as a public health problem in Nigeria 
In Nigeria, the high burden of the disease with its associated morbidity and 
mortality continues to constitute a major public health concern for the country 


























Table 1. 3: Cumulative HIV deaths in Nigeria (FMOH, 2005; FMOH, 2007) 
 
 2005 2006 2010 
No. of people infected 2.86 million 2.99 million 3.4 million 
No. of new HIV infections: 
 Adults 










No. requiring ART: 
 Adults 










Annual HIV (+ve) births 73,550 74,520 75,780 
Cumulative deaths 1.45 million 1.70 million 2.82 million 
 
The HIV/AIDS epidemic has further weakened and threatened to overwhelm the 
Nigerian health care system. Additionally, it increased the number of orphans 
and increased the cost of achieving set developmental goals by decreasing the 
size of the workforce, affecting as it does, mainly adults in their most productive 
years of life (15-60 years). The high manpower-intensive sectors of the economy 
are most affected; in Nigeria this includes the agricultural, educational and health 
sectors as well as the rural economy (Table 1.4) (FMOH, 2007; FMOH, 2010).  
Table 1. 4: HIV/AIDS Burden: Socio-economic implications in Nigeria (FMOH, 2007) 
 2005 2010 
Number of children orphaned due to AIDS 1,640,000 2,680,000 
Number of orphans 7,820,000 9,130,000 
Number of HIV positive pregnant women 227,900 223,300 
Life expectancy 47 years 43.4 years 
 
Interestingly, Stillwagon (2002), in her pioneering work, found falling calorie and 
protein consumption to be strongly correlated (R-squared is 0.545 or 0.517) with 
HIV prevalence in 44 SSA countries. The more severe the decrease in nutrition 
and the more unequal the distribution of income in a country, the higher is the 
rate of HIV. In Stillwagon‘s regression analysis, the prevalence of HIV is strongly 
correlated with income inequality, falling protein consumption, falling calorie 
consumption. Similarly, Fawzi et al. (2004) proposed that multivitamin 
supplements (Vitamins A, B, C, D and E) as low-cost immunomodulating 
interventions may slow the progression of HIV disease by significantly (P=0.02) 
increasing CD4+ and CD8+ cell counts and significantly decreasing (P=0.003) 
viral loads. Numerous studies also reported micronutrient deficiencies impair 
responses, weaken epithelial integrity, and are associated with HIV disease 
progression (Tang and Smit, 1998; Jiamto et al., 2003; Gillespie and Kadiyala, 
2005; Kaiser et al., 2006 and Drain et al., 2007). Therefore, this research was 
intended to demonstrate the efficacy of macro and micro- nutrients derived from 
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food sources in Nigeria to delay the onset of advanced HIV disease and the 
need for antiretroviral therapy, saving antiretroviral drugs for when they may be 
most needed and reducing drug-related adverse events and costs. 
In summary, the impact of HIV/AIDS on Nigeria‘s social fabric and on its 
economic development and well-being country to be pervasive and, unless 
controlled through multidimensional approaches to include nutritional 
intervention as proposed in this research, will continue to undermine the quality 
of life of Nigerians (Table 1.5) (FMOH, 2007; FMOH, 2010).  
Table 1. 5: Contribution of HIV/AIDS to morbidity in Nigeria (FMOH, 2007) 
 
S/N Disease conditions Contribution (%) 
1 HIV/AIDS 16.0% 
2 Respiratory diseases 14.0% 
3 Malaria 11.0% 
4 Cardiovascular diseases 10.0% 
5 Childhood diseases 9.0% 
6 Diarrhea diseases 7.0% 
7 Injuries (Road accidents, drowning, violence) 7.0% 
8 Prenatal conditions 4% 
9 Others (cancer, urinary diseases, TB, etc) 22% 
 
1.5 Research Aim and objectives 
1.5.1 Aim 
To design and evaluate a public health-nutrition intervention programme which 
aims to delay the progression of human immune-deficiency virus (HIV) to AIDS 
(acquired immune-deficiency disease syndrome) among people living with HIV in 
Abuja, Nigeria.  
1.5.2 Objectives 
The objectives of the study are: 
1. To assess the quality and quantity of specific macro/micronutrients in 
local vegetables and grains consumed by People Living with HIV/AIDS 
and compare these values with age-specific recommended intakes 
2. To design and optimise a nutritionally functional meal (Amtewa meal) that 
contains known concentrations of macro and micronutrients to be 
employed in the public health nutrition intervention. 
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3. To assess the nutritional intake and biomedical indices prior and post the 
pilot intervention (N=100) (baseline vs. end point; with follow-up at three 
and six months interval)  
4. To appraise the outcomes of Amtewa meal on health status of HIV 
infected subjects (with CD4 values above 200/mm3) at baseline and 
compare these at post-pilot and larger scale intervention (N= 400) 
5. To evaluate the effectiveness of macro and micronutrient interventions as 
possible measure to attenuate the progression of HIV to AIDS. 





























This chapter includes the current knowledge and substantive findings in the 
literature, as well as theoretical and methodological contributions to HIV/AIDS 
disease and the symbiotic relationship between HIV and nutrition. It explains and 
justifies how public health nutrition intervention may help answer some of the 
questions or gaps in this area of research in Nigeria. 
2.1 Classification and Structure of HIV 
The aetiology of AIDS has been identified as HIV-1 and HIV-2 (FMOH, 2007; 
AIDS, 2012). These viruses belong to the Lentivirus group and Retroviridae 
family (Figure 2.1). The Family Retroviridae of viruses includes three sub-
families: Oncovirinae, Lentivirinae and Spurnavirinae. All the members of the 
family contain an enzyme called reverse transcriptase that is used for the 
synthesis of proviral DNA from the infecting viral RNA. The provirus (also called 
the complimentary or cDNA) integrates itself into the chromosome of the host 
cell with the aid of additional enzymes encoded by the viral pol gene. 
The integration of the viral cDNA into the host cell genome serves as the basis 
for the continuous viral replication characteristic of retroviruses as well as the 
unconventional (reverse) method of transcription by these groups of viruses than 
the conventional flow (transcription) of the genetic information from DNA to RNA. 
This group of Retroviruses is associated with many diseases including rapid and 
long latency, malignancies, wasting disease, neurological disorders, 
immunodeficiency as well as long viraemia in the absence of any obvious clinical 




Figure 2. 1: Structure of HIV. (Source: AIDS info., 2014) 
  
The HIV particle contains three components: the core, the surrounding protein 
matrix and the outer lipid envelop. The core contains genetic material, RNA, 
encapsulated by the capsid protein p24, which contains enzyme (reverse 
transcriptase, integrase and protease) involved in viral replication. The glycol 
proteins gp41 and gp120, which is attached to the envelop enable HIV to bind 
and fuse with target host cells (Pribram, 2011). 
2.2 Cellular Receptors of HIV 
The primary receptor for HIV is the CD4 molecule on the human T-helper cells. 
CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary 
targets of HIV. The CD4 count and the CD4 percentage mark the degree of 
immune compromise. The CD4 count is the number of CD4 cells per micro liter 
(µL) of blood. It is used to stage the patient's disease, determine the risk of 
opportunistic illnesses, assess prognosis, and guide decisions about when to 
start antiretroviral therapy (ART) (HRSA, 2011). Variation in CD4 receptor 
molecule on T-cell surface may influence the ability of HIV to bind and eventually 
penetrate the target cell (AIDS, 2013). In addition, attachment to and fusion with 
the target cells is determined not only by its binding with CD4 molecules, but 
also other secondary binding sites known as Beta chemokine such as CCR5 and 
CXCR4.There are several reports to show that individuals who are homozygous 
for a deletion in the CCR5 or CXCR4 gene are less frequently infected with HIV, 
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whereas individuals who are heterozygous for the same mutation become 
infected but can be protected against rapid progression to disease compared 
with infected individuals homozygous for the normal CCR5 or CXC gene 
(FMOH, 2007). Because HIV infects CD4 cells and uses them to produce more 
HIV copies, HIV infection is characterised by a progressive fall in the number of 
T-helper/inducer CD4 positive cells (Pribram, 2011). Helper T cells are clearly 
critical to the operation of the immune system. If they are destroyed because of 
an HIV infection, the whole system is crippled. The immune system is described 
as having two ―arms‖: the cellular arm, which depends on T cells to mediate 
attacks on virally infected or cancerous cells; and the humoral arm, which 
depends on antibodies to clear antigens circulating in blood and lymph. As an 
HIV infection progresses, destroying helper T cells, both arms of immunity are 
impaired. 
2.3 Natural History of HIV infection 
The course of HIV infection varies within a population (FMOH, 2007). 
Nonetheless, a typical infection can be divided into three stages: primary (acute) 
infection, asymptomatic (clinical latency) stage and symptomatic (AIDS) stage.  
Only certain fluids—blood, semen (cum), pre-seminal fluid (pre-cum), rectal 
fluids, vaginal fluids, and breast milk—from an HIV-infected person can transmit 
HIV. These fluids must come in contact with a mucous membrane or damaged 
tissue or be directly injected into the bloodstream (from a needle or syringe) for 
transmission to possibly occur (Figure 2.2). Mucous membranes can be found 
inside the rectum, the vagina, the opening of the penis, and the mouth (AIDS, 

















During early infection, HIV remains concentrated in the lymph nodes, where it 
replicates in huge numbers and infects more CD4 T cells. Swollen lymph nodes 
are often the only clinical feature seen in a person with HIV infection for the first 
months or years of infection. The immune system gradually deteriorates to the 
point that the human body is unable to fight off other infections. The HIV viral 
load in the blood dramatically increases while the number of CD4+ T cells drops 
to dangerously low levels (Figure 2.3). An HIV-infected person is diagnosed with 
AIDS when he or she has one or more opportunistic infections, such as 
pneumonia or tuberculosis, and has fewer than 200 CD4+ T cells per cubic 









2.3.1 Acute infection stage 
Within 2-4 weeks after HIV infection, many, but not all, patient develops flu-like 
symptoms, often described as ―the worst flu ever.‖ Symptoms can include fever, 
swollen glands, sore throat, rash, muscle and joint aches and pains, fatigue, and 
headache. This is called ―acute retroviral syndrome‖ (ARS) or ―primary HIV 
infection,‖ and it‘s the body‘s natural response to the HIV infection. During this 
early period of infection, large amounts of virus are being produced in the body. 
The virus uses CD4 cells to replicate and destroys them in the process. Because 
of this, theCD4 count can fall rapidly. Eventually the immune response will begin 
to bring the level of virus in the body back down to a level called a viral set point, 
which is a relatively stable level of virus in the body. At this point, the CD4 count 
begins to increase, but it may not return to pre-infection levels (WHO, 2006; 
AIDS, 2013). 
2.3.2 Clinical latency stage 
After the acute stage of HIV infection, the disease moves into a stage called the 
―clinical latency‖ stage. ―Latency‖ means a period where a virus is living or 
developing in a person without producing symptoms. During the clinical latency 
stage, people who are infected with HIV experience no HIV-related symptoms, 
Figure 2. 3: Clinical progression of HIV to AIDS (Source: The naked scientist, 2007). 
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or only mild ones. (This stage is sometimes called ―asymptomatic HIV 
infection‖ or ―chronic HIV infection‖). During the clinical latency stage, the HIV 
virus continues to reproduce at very low levels, although it is still active. Patients 
on ART may live with clinical latency for several decades because treatment 
helps keep the virus in check. For those who are not on ART, the clinical latency 
stage lasts an average of 10 years, but some people may progress through this 
stage faster. Therefore intervention means to delay /attenuate the progressions 
of latency stage through adequate nutritional assistance warrant research 
investigation by health authorities (WHO, 2006; Pribram, 2011). It is important to 
remember that patients in this symptom-free stage are still able to transmit HIV 
to others, even if they are on ART, although ART greatly reduces the risk of 
transmission. 
2.3.3 AIDS Stage 
This is the stage of HIV infection that occurs when the immune system is badly 
damaged and become vulnerable to infections and infection-related cancers 
called opportunistic infections. When the number of your CD4 cells falls 
below 200 cells per cubic millimeter of blood (200cells/mm3), patients are 
considered to have progressed to AIDS. In someone with a healthy immune 
system, CD4 counts are between 500 and 1,600 cells/mm3. A patient is also 
considered to have progressed to AIDS if he/she develops one or more 
opportunistic illnesses, regardless of the CD4 count (WHO, 2006). Without 
treatment, patients who progress to AIDS typically survive about three years. 
Once you have a dangerous opportunistic illness, life-expectancy without 
treatment falls to about one year. However, if a patient is taking ART and 
maintains a low viral load, then he/she may enjoy a near normal life span and 
will most likely never progress to AIDS (WHO, 2006). 
Despite repeated exposure, some individuals never become infected with HIV.  
These individuals often have unusual helper T cells with a less-efficient variant 
of the co-receptor CCR5, which is necessary for viral entry into helper T cells 
(FMOH, 2007). There are also individuals who become infected, but do not 
progress to AIDS. These long-term survivors, or long-term non-progressors 
(LTNP), include individuals who have been AIDS-free as long as eighteen years 
after infection (FMOH, 2007; Praveen, 2013). Five percent of total HIV 
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populations are LTNP (Praveen, 2013). A variety of factors may be responsible; 
for example, infection with less-virulent viruses. Some long-term non-
progressors seem to have CD8 cells, which are particularly adept at curtailing 
HIV infection (FMOH, 2007; Praveen, 2013). 
2.4 Replication of HIV 
Replication of the virus particle begins with attachment of gp 120 to the CD4 on 
the surface of a target cell (Figure 2.4). Following the gp 120-CD4 binding, a 
structural change allows for the interaction of the V3 loop region in the gp 120 
with a chemokine receptor, including CCR5 and CXCR4 (WHO, 2006; FMOH, 
2007). 
The reaction with the co-receptor results in another conformational change in the 
viral surface glycoprotein, which exposes a fusion domain contained within the 
envelop trans-membrane glycoprotein. Exposure of the fusion domain results in 
the insertion of the gp41 into the cellular membrane. Subsequent to the fusion 
event, the viral core is released into the cytoplasm of the host cell. Once in the 
cytoplasm, the viral RNA genome is uncoated and reverse transcribed by the 
virally encoded Reverse Transcriptase (RT) enzyme to generate a double-








The double stranded DNA is then transported into the host cell nucleus and via 
catalysis by integrase, becomes integrated into the host cell chromosome, where 
it resides as provirus. Once the viral genome has been integrated into the host 
cell genome, it can remain in the latent state for many years or can begin the 
production of new viral RNA. If the host cell is activated, the host cell enzyme 
RNA polymerase II will transcribe the proviral DNA into messenger RNA 
(mRNA). The mRNA is then translated into viral proteins that undergo extensive 
post-translational modifications. The viral RNA becomes the genetic material for 
the next generation of viruses. Viral RNA and viral proteins assemble at the cell 
membrane. After proper assembly and processing, new infectious virus particles 
are released by budding from the cell membrane (FMOH, 2007; FMOH, 2010). 
2.5 Variability of HIV isolates 
The human immunodeficiency virus exhibits marked genetic diversity among 
different isolates. This heterogeneity is distributed throughout the viral genome 
and most of it is located in the env gene. Based on this variability, HIV has been 
classified into types 1 and 2. HIV 1 has a global distribution while HIV -2 is 
limited to West Africa. Nevertheless, HIV-1 is still the predominant type in this 
sub-region. The 2 sub-types of the virus also vary in their biological 
characteristics. The rate of transmission (sexually and MTCT) as well as 
progression to disease of HIV-1 is faster than that of HIV-2. 
HIV-1 isolates are classified into subtypes using the nucleotide sequence of the 
gag, pol and env genes. Subtypes of HIV-1 isolates using the env gene has 
been based mainly on the third variable region (V3 loop) of the Gp 120, known to 
be important in viral cell type tropism, virus cell fusion and cytopathology. Based 
on the nucleotide of the V3 loop of the Gp 120, HIV-1 has been classified into 
three major groups, the group M (major), N (non-M, non-O) and group O 
(Outlier). The group M virus has been further classified into at least 11 different 
subtypes (A to K). In addition, recombination of the virus subtypes is a well 
known phenomenon and many recombinant forms including the A/G which is the 
most predominant subtype in West Africa have been identified. In Nigeria, the 
A/G and the G subtypes are predominant. HIV-2 is classified into 5 subtypes, A-
E and recombinant forms have not been identified (FMOH, 2007). 
Co-infection or super-infection of an individual by HIV-1 and HIV-2 has been well 
documented (FMOH, 2007). Infection of an individual with different HIV-1 and 
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HIV-2 subtypes has also been identified. This large number of variants makes 
the virus more difficult to treat and hinders vaccine development.  
In addition, because of its rapid rate of evolution, even within a single individual, 
HIV can quickly evolve resistance to the drugs the individual is taking to combat 
the virus. 
2.6 Laboratory diagnosis and HIV Counselling and testing 
Laboratory diagnosis of HIV infection is based on the demonstration of antibody 
in plasma or serum, and a virus in the blood. The virus can be demonstrated in 
the blood with nucleic acid-based test (PCR for proviral DNA and RT-PCR for            
plasma viral RNA), culture and p24 antigen assay. HIV antibodies are detectable 
within four to six weeks of infection, and within 24 weeks in virtually all infected 
individuals. However, virus can be detected in plasma at least one week earlier. 
The period of absent antibody in the presence of virus in the plasma is called the 
―window period‖.  
2.6.1 Antibody Assays 
The antibody assays that are used for HIV diagnosis consist of screening tests: 
rapid tests or ELISA, and confirmatory tests: Western blot and indirect immune 
fluorescent assay. Routine antibody testing is performed with the serial or 
parallel testing algorithm using rapid or ELISA test kits 
Rapid Rests 
Rapid tests are suitable for use in laboratories that have limited facilities and 
process few samples. They are technically simple to perform, do not require any 
major equipment, but have a sensitivity and specificity comparable to ELISA. 
This commonly used rapid antibody tests in laboratories are based on the 
principles of dot immunoassay, or particle agglutination (e.g. gelatin or latex). 
Enzyme linked immunosorbent Assay (ELISA) 
The ELISA procedure is carried out to screen for HIV IgG antibodies in plasma 
or serum. The principles of ELISA are classified as direct, competitive and 
sandwich test. The competitive principle is not popular because of the low 
sensitivity. Antigens derived from HIV grown in human T-lymphocytes or 
recombinant proteins or synthetic peptides are used to coat beads or microtitre 
plates. To perform an ELISA, the patient‘s serum is incubated with the antigens 
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on the beads or in the microtitre plates. A conjugate, i.e., enzyme-labelled 
antibody specific for human immunoglobulin is then added. Detection of the 
enzyme-labelled antibody is carried out by the addition of a substrate that 
produces a colour reaction. ELISA requires a plate washer and ELISA Reader 
and printer. It is a suitable test for use in the laboratories where large numbers of 
samples are tested each time (FMOH, 2007). 
Western Blot  
Western blot is the standard confirmatory test for HIV antibody assays. The test 
utilizes HIV antigens from purified viruses that have been electrophoretically 
separated and ―blotted‖ (transferred) onto a nitrocellulose paper. The paper is 
then cut into strips, each containing all the separated HIV antigens. To carry out 
a Western blot assay, a strip is incubated with the patient‘s serum. Antibody in 
the serum binds to the HIV antigens on the strip, and is detected with the aid of a 
conjugate consisting of labeled anti-human immunoglobulin. Studies have shown 
that combinations of ELISAs or rapid assays can provide results as reliable as 
the Western blot at a much lower cost (FMOH, 2007).  
Indirect Immunofluorescent Antibody Assay (IFA) 
IFA employs HIV-infected cells (lymphocytes) fixed to the microscope slide. The 
patient serum is added and reacts (if antibody is present) with the intracellular 
HIV antigen. After washing the slide, a conjugate consisting of anti-human 
immunoglobulin labeled with FITC added, and the reaction is visualised under a 
fluorescent microscope. IFA has been used to confirm diagnosis in sera 
producing indeterminate results in Western blot (FMOH, 2007). 
Serial testing 
Algorithm refers to the use of 2 screening tests employed sequentially to test for 
HIV antibody. If the initial screening is negative, no further testing is required. If 
the initial test is positive, it is followed by one more test. The first test should be 
the most sensitive test and the second test should be very specific, and be 
based on an antigen source different from that of the first test. Samples that 






Involves two screening tests performed simultaneously. Samples reactive to 
both tests are regarded as positive. However, those with discordant results 
require further testing. Parallel testing is performed to minimize the chances of 
false negative results and to guard against technical errors. It is often used when 
a very sensitive test is not available for the initial screening, and when the 
concordance of two tests is to be evaluated. 
2.6.2 Nucleic Acid-based Tests 
These consist of DNA Polymerase Chain Reaction (DNA PCR) and reverse 
transcriptase Polymerase Chain Reaction (RT-PCR). These tests are not 
routinely used for laboratory diagnosis of HIV infection in adults and adolescents 
in Nigeria (FMOH, 2007). 
HIV DNA Polymerase Chain Reaction 
The DNA PCR involves the amplification of specific DNA sequences in the 
proviral DNA that has been integrated in the host cell. This test is the preferred 
procedure for diagnosing HIV infection in infants less than 18 months of age. 
Due to the high sensitivity of the test, false positive results may occur as a result 
of contamination by minute quantities of extraneous DNA. 
RT – PCR 
RT-PCR is used to detect and quantify the amount of HIV RNA in plasma. The 
assay requires the conversion of viral RNA to DNA and amplification of specific 
sequences in the DNA produced by a process known as reverse transcriptase 
polymerase chain reaction (RT-PCR). 
2.6.3 Other Tests 
These tests are not routinely used for laboratory diagnosis of HIV infection. 
Antigen detection 
Detection of p24 antigen is an ELISA-based test. The reliability of the test is in 






HIV is usually isolated in PBMCs. The procedure involves co-cultivating the 
PBMCs from a patient with those obtained from a healthy donor. HIV isolation in 
PBMC is quite sensitive and is comparable to DNAPCR in sensitivity. 
2.7 Antiretroviral Therapy 
Standard antiretroviral therapy (ART) consists of the combination of at least 
three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop 
the progression of HIV disease (WHO, 2014). Huge reductions have been seen 
in rates of death and suffering when use is made of a potent ARV regimen, 
particularly in early stages of the disease. 
2.7.1 Pre-treatment evaluation  
This includes: 
 Complete history and physical examination  
 Clinical and Immunological classification of the patient 
 Check Laboratory results (FBC with differentials, ALT, Creatinine, CD4+ 
cell count, pregnancy test 
 Evaluation of nutritional and psychosocial status 
 Assessment of readiness for therapy 
 Development of patient-specific adherence strategy  
2.7.2 Criteria for initiation of ART 
Initiation of therapy depends on CD4+ cell count and WHO clinical staging 
(Table 2.1) 
 WHO Stage IV disease irrespective of CD4+ cell count 
 WHO Stage III disease with CD4+ cell counts <350/mm3 
 WHO Stage I or II disease with CD4+ cell count =200/mm3 












Table 2. 1: WHO Adult HIV Clinical Staging 
 

























Weight loss 5-10% 
Sores or cracks 




infections such as 
sinusitis or otitis, 
Recurrent mouth 
ulcers 
Weight loss >10%. 
Oral thrush,  










HIV wasting syndrome, 
Oesophageal thrush, 












     
 








Other prophylaxis  
on treatment plan 
     
ARV 
therapy 
Only if CD4  
<200  
Only if CD4 <200 or 




Treat if more than 
one sign or 
repeated/chronic 
stage 3 problems or 
CD4 <200 
Evaluate for ART 
Prepare for 
adherence  
All in stage 4 are medically 
Eligible for ART 
Evaluate for ART 






Nutrition support ‡ 
 
Nutrition support ‡ 
 
Nutrition support ‡ 
 
 
‡  Piwoz and Preble, 2000; WHO, 2003; USAID, 2004; WHO, 2005;  FANTA/USAID 2007; WHO, 2009; 
Pribram, 2011 
 
2.8 Nutrition role in HIV 
Nutrition has always been an important aspect of HIV care (Pribram, 2011). 
Similarly, HIV as a pandemic disease its impact is worsened by the presence of 
other conditions such as under-nutrition and opportunistic infections (Anabwani  
and Nazario, 2005). HIV/AIDS scourge has had a devastating impact on health, 
nutrition, food security and overall socioeconomic development in countries that 
have been greatly affected by the disease. There is a need for renewed focus on 
and use of resources for nutrition as a fundamental part of the comprehensive 
package of care at the country level (Anabwani and Nazario, 2005; FMOH, 




In human beings, HIV/AIDS and undernutrition form a symbiotic relationship and 
one increases the prevalence and severity of the other (Bijlsma, 2000; Yale 
University, 2007; Pribram, 2011; Ivers, 2014). Moreover, despite the 
effectiveness of highly active antiretroviral therapy (HAART), there is evidence 
that HIV-related wasting remains an important co-morbidity factor in many 
patients (FAO/WHO, 2002; Tang et al., 2002; Yale University, 2007; Pribram, 
2011; Ivers, 2014). 
Micronutrient deficiencies significantly contribute to HIV progression to AIDS; 
deficiencies of essential vitamins (A, B-complex, C and E) and minerals 
(selenium and zinc), are common in People Living with HIV (PLWH) and these 
micronutrients are required by the immune system to combat infection (WHO, 
2005; Hurwitz et al., 2007; Duggal, 2012). Furthermore, deficiencies of 
antioxidants, vitamins and minerals contribute to oxidative stress (a condition 
that may accelerate immune cell damage), increase risk of diarrhea and 
therefore associated mortality in HIV positive children (USAIDS, 2004; Piwoz, 
2004; Drain et al., 2007 and Ivers, 2014).  
The effects of under-nutrition on the immune system are well documented and 
include decreases in CD4 T cells, suppression of delayed hypersensitivity and 
abnormal B-cell responses (USAIDS, 2004; Drain et al., 2007). Interestingly, the 
immune suppression caused by protein-energy malnutrition (PEM) mechanism is 
similar in many ways to the effects of HIV infection in PLWH as illustrated in 














Figure 2. 5: The vicious cycle of malnutrition in the HIV patient (Source: RCQHC and FANTA 2003) 
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Action and investment to improve the nutritional status of People Living with 
HIV/AIDS (PLWHA) should be based on sound scientific evidence, local 
resources, and programmatic and clinical experience with the prevention, 
treatment, and management of the disease and related infections (USAID, 2004; 
UNAIDS, 2008; Tewfik et al., 2010; UNAID, 2010; WHO 2010). Although there 
are gaps in scientific knowledge, much can and should be done to improve the 
health, nutrition and quality of care for PLWHA and their families and 
communities (WHO, 2005; Hurwitz, et al., 2007). 
An earlier review by Piwoz and Preble (2000) examined preliminary evidence 
that improving nutrition status may improve some HIV-related outcomes. HIV 
infection increases energy requirements through increases in resting energy 
expenditure (REE 12% higher), while reduced food intake, nutrient mal-
absorption, negative nitrogen balance and metabolic alterations exacerbate 
weight loss and wasting, perpetuating the cycle (Melchior et al., 1991; 
FAO/WHO, 2002; Piwoz, 2004; WHO, 2009). Increase in REE may be due to the 
production of tumor necrosis factor- alpha and /or interleukin-l in patients with 
AIDS. However, potential mechanisms of wasting invoked in AIDS patients and 
their impact on energy intakes (e.g., severe oral and /or esophageal candidiasis, 
viral esophagitis or extensive oral kaposis sarcoma) are perhaps more relevant.  
Anorexia can occur in response to systemic infection or mental depression, and 
intestinal mal-absorption, increased loss of nutrients; muscle wasting and 
weakness were identified in AIDS (Melchior et al., 1991). 
2.9 Current intervention programmes at international level 
The number of people dying of AIDS-related causes fell to 1.8 million in 2010, 
down from a peak of 2.2 million in the mid-2000s. A total of 2.5 million deaths 
have been averted in low- and middle-income countries (e.g. Nigeria, South 
Africa) since 1995 due to progresses that resulted from expanded access to 
antiretroviral therapy, antiretroviral prophylaxis and safe infant-feeding 
interventions (WHO, 2010; UNAIDS, 2011). 
The revised recommendation for antiretroviral therapy (ART) included an earlier 
start to treatment for all HIV-infected individuals with a CD4-cell count of 350 
cells/mm3 or chronic hepatitis B irrespective of CD4-cell count. They are based 
on evidence of both individual and public health benefits of starting treatment 
earlier (WHO, 2010). However, WHO recommends that nutritional care and 
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support with macro/micronutrients must be started at the early stages of the 
infection prior to the initiation of ART in order to prevent weight loss and 
undernutrition (Piwoz and Preble, 2000; WHO, 2009; Pribram, 2011). 
2.10 Current intervention programmes in Nigeria 
There are four major HIV interventions programmes in Nigeria: HIV counselling 
and testing (HCT), HIV and AIDS treatment and care in adolescents and adults, 
paediatric HIV and AIDS treatment and care, prevention of mother-to child 
transmission of HIV (PMTCT). Current antiretroviral drug treatments in these 
programmes control HIV infection and prevent severe wasting, as well as other 
AIDS-related conditions (FMOH, 2007 and 2010). Emaciated people tend to 
regain weight once they begin treatment. Nevertheless, the drugs do not 
eliminate wasting. 
In addition, some antiretroviral drugs have been linked to lipodystrophy. 
Whereas HIV-related wasting tends to deplete lean tissue, lipodystrophy 
involves changes in fat distribution. Nutrition intervention programme may 
improve strategies to ameliorate these limitations associated with the current 
HIV intervention programmes in Nigeria.  
2.10.1 HIV Counselling and Testing (HCT) 
During the past 15 years, the introduction of effective ART and its demonstrated 
medical benefits has shown the usefulness and importance of expanding HCT 
services to facilitate early diagnosis and treatment of HIV- infected persons 
(FMOH, 2007; NACA, 2012). It has also been shown that early knowledge of 
HIV infection can result in tremendous public health benefits through decreasing 
risk behaviors that could transmit HIV to uninfected persons. Furthermore, 
uninfected persons may benefit from HIV testing if knowing their HIV status 
assists them in modifying or reducing risk behaviours. 
All patients undergoing HIV testing must receive pre- and post- test counselling, 
and give their consent before the test is performed on their specimens. Post- test 
counselling should be done irrespective of the test result (FMOH, 2007). Testing 
may be performed without consent if the patient is unable to give his/her consent 
and the test result is needed in an emergency to provide medical care. 
A high level of confidentiality must be maintained during testing (for ethical 
reason). Careful record keeping is essential to ensure confidentiality. HCT 
30 
 
includes counselling and testing in a variety of settings. Traditional Voluntary 
Counselling and Testing (VCT), provider- initiated counselling and testing, opt-
out counselling and testing are examples of HCT methods. VCT is a client-
initiated approach by an individual to find out his HIV status and in the process 
receive Counselling. Provider-initiated Counselling and testing is done based on 
the recommendation of the care provider to the client. The opt-out approach 
occurs where HCT is routinely offered with the patient having the option to 
decline testing and is utilised in the health care setting to capture all patients 
presenting for other health care services. HCT should be considered whenever 
there is care provider/patient contact (FMOH, 2007; NACA, 2012).  
Benefits of HCT for individual include; Improved health through educational and 
nutritional advice; early access to care (including ART) and prevention of HIV-
related illnesses; emotional support and better ability to cope with HIV-related 
anxiety; awareness of safer options for reproduction and infant-feeding; 
motivation and initiate or maintain reduced risk behaviors (FMOH, 2007). 
Benefits of HCT for the public health of the nation include: Reduced transmission 
following increased knowledge; reduced stigmatization as a result of widespread 
Counselling services; improved health and productivity of PLWHA as a result of 
utilisation of care, support and ART services (FMOH, 2007).        
HCT is being rapidly scaled up using innovative, ethical and practical 
approaches. Services can be provided at free-standing, mobile, primary, 
secondary and tertiary facilities. These facilities must meet national minimum 
standards for HIV testing applicable to their various levels. For instance, 
category one laboratories will carry out voluntary counselling and testing using 
rapid kits. In the case of free- standing, mobile, and primary facilities, referral of 
seropositive individuals to secondary or tertiary facilities for pre-assessment for 
ART should be done (FMOH, 2007). 
HCT long-term impact on other outcomes is mixed. These include: Increased 
sexual risk following receipt of a negative result may be a serious unintended 
consequence of HCT intervention. The new strategy for HIV prevention, 
―Universal Test and Treat‖, whereby everyone is tested for HIV once a year and 
treated immediately with antiretroviral therapy (ART) if they are infected should 
be enforced. This strategy could eliminate the epidemic and reduce ART costs in 
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the long-term as substantial proportion of HIV-infected individuals do not present 
for HIV testing until late in infection; these individuals are often ill, have a high 
mortality risk, and are less likely to respond to treatment when initiated. 
Stigmatised attitudes among health care workers, family and friends of PLWH 
influence the decision-making process of PLWH and stop them from accessing 
HCT care, support, and treatment services (FMOH, 2007; NACA, 2012).. 
2.10.2 HIV and AIDS Treatment and Care in Adolescents and Adults 
An increasing challenge today is the need to standardize HIV treatment to 
ensure the highest quality of care. With current advances in technology and 
better understanding of the infection, case management of HIV and AIDS will 
continue to improve and guidelines on HIV and AIDS care and treatment will 
continue to be subject to regular review as indications emerge from scientific 
research and advancement. The National ART Guidelines (FMOH, 2007) has 
been updated based on literature review and relevant local experiences and is 
meant for the treatment of adults and adolescents. It is hoped that it will provide 
relevant, simplified but adequate information required for the effective 
management of PLWHA in Nigeria. 
It is also expected that the Nigeria ART Guidelines will assist building capacity 
among clinicians who have the primary responsibility of managing the patients. 
2.10.3 Paediatric HIV and AIDS treatment and care 
The World Health Organization (WHO) in 2008 estimated that 2.1 million 
children <15 years were living with HIV infection largely acquired through mother 
to child transmission (FMOH, 2010). It is estimated that over 1150 children <15 
years are infected with HIV every day all over the world (FMOH, 2010). In 2008, 
390,000 children were newly infected. Recent data from WHO and Joint United 
Nations Programme on HIV and AIDS (UNAIDS) indicate that only 15% HIV 
positive African children needing Antiretroviral therapy (ART) in West and 
Central Africa were receiving it in 2008 (FMOH, 2010). 
In Nigeria, seroprevalence Sentinel Surveys showed HIV prevalence of 1.8% in 
1992, 5.8% in 2001, and 4.4% in 2005, a slight rise to 4.6% in 2008 and 
currently in 2010, the prevalence is 4.1% (FMOH, 2010; NACA, 2012). 
Estimates from the Survey also showed that 52,000 new infections occurred in 
children <15 years. The number of HIV positive children requiring ART in 2009 
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was estimated to be 92,000 of which <15% actually received it. According to the 
2009 Universal Access Report, Nigeria accounts for 30% of the global burden of 
mother-to-child transmission of (MTCT) of HIV and 10% of Paediatric HIV and 
AIDS. As at the end of 2009, the human immunodeficiency virus accounts for 
3% of deaths in children younger than five years in Nigeria. 
In 2007, the first Paediatric Guidelines was developed. With the WHO, (2010) 
recommendations on antiretroviral therapy for infants and children, it becomes 
necessary for the National Guidelines for Paediatric HIV and AIDS Treatment 
and Care to be updated accordingly.    
Objectives of the Paediatric National Guidelines 
The overall objectives of the National Guidelines on Paediatric HIV and AIDS 
Treatment, Care and Support are: 
1. To provide standardised management protocols based on current 
evidence for children infected with or exposed to HIV infection. 
2. To provide guidelines for monitoring and evaluation of comprehensive 
Paediatric HIV and AIDS services 
3. To serve as a reference document to advisory boards, programme 
managers and other policy makers involved in paediatric HIV/AIDS 
programming.  
2.10.4 Prevention of Mother-to-Child Transmission of HIV (PMTCT) 
Most children less than 15 years living with HIV acquire the infection through 
mother-to-child transmission (MTCT). This can occur during pregnancy, labour 
and delivery or during breast-feeding. In the absence of interventions, the risk of 
such transmission is 30 – 45% (FMOH, 2010). 
The high burden (2.1 million children orphaned by AIDS) of MTCT (Figure 2.6) in 
sub-Saharan Africa (compared to the rest of the world) is due to higher (336,379 
infection in 2008) rates of heterosexual transmission, higher (4.6% National ANC 
Median HIV prevalence) prevalence of HIV in women of reproductive age, high 
(56,681 annual HIV positive births) total fertility rate, characteristically prolonged 
breast feeding culture, as well as poor access to PMTCT interventions. The risk 
of MTCT can be reduced to less than 2% by interventions that include the use of 
antiretroviral (ARV) as either prophylaxis or therapy given to women in 
pregnancy, labour and during breastfeeding (FMOH, 2010). In situations where a 
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mother is not receiving ARVs during the breastfeeding period, the breast-fed 
infant should receive ARV prophylaxis until one week after cessation of all 
breast- feeding. Where breastfeeding is not possible however, it should be noted 




Figure 2. 6: HIV among pregnant women by geopolitical zone in Nigeria (Source: NACA, 
2012) 
The Nigerian National goal for PMTCT as contained in the 2003 AIDS Policy is 
to reduce the transmission of the HIV through MTCT by 50% by the year 2010 
and to increase access to quality HIV Counselling and testing services by 50% 
by   the same year. To achieve this goal, a comprehensive four-pronged strategy 
to prevent HIV infection among infants and young children is being implemented 
in Nigeria since 2001. The strategy includes the following elements: 
 Primary prevention of HIV infection in women of reproductive age group 
and their partners 
 Prevention of unintended pregnancies among HIV positive women 
 Prevention of HIV transmission from HIV infected mothers to their infants 
 Care and support for HIV infected mothers, their infants and family 
members. 
2.11 Nutrition problems in Nigeria 
Undernutrition is a problem that aggravates the spread of HIV in Nigeria (FMOH, 
2011). HIV prevalence in the country can be said to be stabilising but 
undernutrition is on the increase (FMOH, 2011). In 2008, the Nigeria 
Demographic and Health Survey (NDHS) showed that 41% of children aged less 
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than five years were stunted, 23% were underweight and 14% were wasted. The 
Nigeria Food Consumption and Nutrition Survey (2003) also reported that 11.6% 
of women of childbearing age were suffering from chronic undernutrition. 
Prevalence of micronutrient deficiencies was also high, for instance: Among 
children under five years old, 29.5% suffered from vitamin A deficiency. 27.5% 
were iron deficient and 27.5% suffered various degrees of iodine deficiency. 
Among women of childbearing age, 13.1% were vitamin A deficient (19.1% of 
pregnant women), 12.7% iron deficient and 15.3% iodine deficient (FMOH, 
2011). 
Research in HIV-positive children demonstrated that multiple large doses of 
vitamin A (50,000 IU at 1 and 3 months, 100,000 IU at 6 and 9 months, 200,000 
IU at 12 and 15 months) reduced diarrhea episodes (OR=0.51; 95% 
CI=0.27,0.99), increased CD4 cell counts, and reduced all-cause morbidity 
(OR=0.69; 95% CI=0.48, 0.99) (Coutsoudis et al., 1995).  Anaemia is a common 
problem affecting PLWH and may result from cytokine-induced suppression of 
red cells production; chronic inflammation; and/or reduction in dietary intake, 
absorption and retention of iron (Piwoz and Preble, 2000).  
Similar data on the prevalence of other micronutrient deficiencies like 
magnesium, selenium, and vitamin C are not available, but these nutrients, 
which are important for optimum immune functions, are also deficient among 
large sections of the population (Piwoz and Preble, 2000). It has long been 
established that undernutrition impacts negatively on optimal immune function 
(Figure 2.7), thus increasing susceptibility to morbidity and mortality among HIV 
positive patients. It is therefore important to include nutritional care and support 






Figure 2. 7: HIV/AIDS and under-nutrition form a symbiotic relationship (USAIDS, 2004) 
2.12 Potential role of Nutrition as modifiable risk factors to progression 
of HIV to AIDS 
Nutrition complications of HIV infection, including wasting syndrome, nutrient 
deficiencies, and metabolic complications, have been well documented over the 
last 25 years (Coyne-Meyers, 2004). Several studies observed that the level of 
HIV replication is closely associated with both the rate of growth and the quantity 
of lean tissue stores (Apardi, 2005). Thus, dietary intake varies inversely with 
level of virus, suggesting that viral replication directly or indirectly suppresses 
appetite. In many regions of sub-Saharan Africa, diarrheal diseases represent an 
important and potentially modifiable factor involved in growth disturbances in 
PLWHA. The benefit of providing adequate amounts of calories, protein, and 
micronutrients for persons with HIV is well accepted (Coyne-Meyers, 2004). For 
example, low serum carotene concentration is common in AIDS patients and 
predicts death but supplementation with micronutrients and natural mixed 
carotenoids improved survival by correction of a micronutrient deficiency (Austin 
et al., 2006). Therefore, low weight gain and growth failure, which are both 
severe manifestations of AIDS and related to high viral load and low CD4 count, 
are risk factors that raise the mortality rate among PLWHA.  
The correlation between clinical category and under-nutrition reinforces the 
concept of natural evolution that underlies the CDC classification of CD4 cell 
counts (Centeville, 2005). Thus the severity of AIDS manifestations is associated 
with nutritional status and with the age at onset of HIV disease symptoms. 
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2.13 Nutrient intakes of People Living With HIV/AIDS in Nigeria 
Dietary assessment for PLWH in Nigeria and the National Guideline shows that 
the mean daily energy intake for PLWHIV in Nigeria is 1725 kcal (male) and 
1885.85 kcal (female) (Table 2.2). The evidence on the low social economic 
status of PLWHA in Nigeria and the dietary assessment investigated by the 
FMOH on PLWH in Nigeria did not accentuate the need to examine the dietary 
assessment of the same group of patients in this research. Similar dietary 
assessment was investigated by Temitope et al. (2011) on PLWH (n=200). 
Hunger and undernutrition remain the most devastating problems that dominate 
the health of underprivileged Nigerians (Temitope et al., 2011). At the national 
level, there was evidence of high expenditure by the citizens on staples with 
cereals attracting the highest expenditure of about N643.97/week (approximately 
$4) compared to an average expenditure of N347.73 on roots and tubers.  
Results further revealed that some Nigerians spent more on sorghum (N228.3) 
than on either rice (N215.6) or maize (N127.2) (IITA, 2003). Nutrient intake is 
specific to a study population and depends on a variety of factors that are 
difficult to control. These factors include cultural, socioeconomic, environmental, 
and geographical determinants (Temitope et al., 2011). Carbonnel et al. 1997 
illustrated that body weight loss result mainly from decreased energy intake in 
HIV infected patients. They also found that HIV infected patients had lower 
levels of energy intake (1,725 kcal for male and 1,885.85 kcal for female) than 
the RDA (2,800 kcal for male and 2,500 kcal for female). This probably 
contributed to the lower body weight observed in HIV infected patients, since 
body weight and energy intake were correlated. HIV infection compromises the 
nutritional status of the infected individuals and, in turn, poor nutritional status 
which affects the progression of HIV infection. In Nigeria, the mean energy, and 
protein in PLWH are below the RDA (Table 2.2). This result was based on 24 
hours diet recall and dietary history, It showed that the mean daily energy intake 
of PLWHIV in Nigeria were below the recommended values by 38.4 per cent for 
male and 24.6 per cent for female (Temitope et al., 2011; FMOH, 2011). 
Although the data from the Federal Ministry of Health (2011) and Temitope et al. 
(2011) were generated from 24 hours diet recall and diet history; however Food 
Frequency Questionnaire method of dietary assessment would have been more 
appropriate because it is suitable for large scale surveys such as this 








The National Guidelines on Nutritional Care and Support for People Living with 
HIV in Nigeria specified 10% daily energy intake increase during asymptomatic 
phase of HIV infection and 20 – 30% daily energy intake increase during 
symptomatic phase. The meal should also provide multiple micronutrients. The 
most important nutrients are selenium, zinc, beta carotenes, and vitamins A, B, 
C and E. Selenium play an important role in metabolising reactive oxygen 
species and reducing oxidative stress. Selenium deficiency impairs the immune 
system and has been associated with faster HIV disease progression and 
reduced survival in adults (Piwoz and Preble, 2000; Kupka et al., 2004). Zinc is 
an essential component of the immune system and it is important for the 
development of non-specific and cell mediated immunity (particularly CD4 cells) 
(Piwoz and Preble, 2000; Kupka and Fawzi, 2002). Zinc supplementation 
(45.5mg/d orally) for one month plus AZT (Zidovudine) reduced the incidence of 
opportunistic infection, stabilised weight and improved CD4 count (p < 0.01) 
among adult with AIDS (Mocchegiani et al., 1995). Severe Zinc deficiency 
results in severe depression, frequent diarrhea and other infections (e.g. 
malaria) as well as mental disturbances (Piwoz and Preble, 2000; Kupka and 
Fawzi, 2002). Low beta-carotene concentration (>10mg/l) primarily reflect more 
active HIV-1 infection (Baeten et al., 2007). Vitamin A supplementation (50,000 
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IU at 1 and 3 months to 200,000 IU at 12 and 15 months) of HIV –infected 
children reduced diarrhea morbidity by 50 percent (Coutsoudis et.al., 1995; 
Piwoz and Preble, 2000; Mehta and Fawzi, 2007). Low serum B12 level (>180 
ng/L) is associated with neurological abnormalities (e.g peripheral neuropathy, 
myelopathy); impaired cognition (e.g information processing, problem solving); 
reduced CD4 T-cell count (Tang et al., 1997; Piwoz and Preble, 2000). Vitamin 
C (80-500mg) significantly (p < 0.05) reduced oxidative stress and HIV viral load 
(Piwoz and Preble, 2000; Isanaka et al., 2012). Vitamin E (15-30mg) increases 
humoral and cell-mediated immune response, including antibody production, 
phargocytic and lymphocytic responses, and resistance to viral and infectious 
diseases (Piwoz and Preble, 2000; Isanaka et al., 2012).  
The additional energy requirements as recommended by WHO (10 - 30% in 
addition to the daily energy intake) will provide more nutrients to compensate for 
nutrient losses and/or increased nutrient requirements, maintain body weight, 
manage specific symptoms (e.g. nausea, constipation and diarrhea and reduce 
the severity of symptoms by providing specific nutrient needs (Piwoz, 2004; 
FANTA, 2004; WHO, 2007).  
2.14 Additional energy requirements (Asymptomatic vs. symptomatic) 
Asymptomatic HIV-positive adults need 10% additional energy (per day) than 
HIV-negative individuals of the same sex. The additional energy requirement for 
symptomatic HIV positive adults is 20 to 30% (per day) than HIV-negative 
individual of the same sex while children with growth faltering require 50 to 100% 
additional energy (Table 2.3) (Piwoz, 2004; FANTA, 2004; WHO, 2007). 
Therefore, macro and micronutrients from naturally occurring (as opposed to 
synthetic with a less bioavailability) components tailored to meet the additional 
energy requirements of PLWHA will enhance well-being and health and/or 
reduce the risk of disease or provide health benefit so as to improve their quality 

















10% increase for asymptomatic 
20 – 30% increase for symptomatic 




12 – 15% of energy intake to maintain and/or 
recover lean body mass 
 
Micronutrients 
Essential micronutrients at RDA 
 
High energy, nutrient dense food is required to 
meet needs – not just more of the same!  
 
 
2.15 The European Perspectives of Functional Foods and the concept 
of a Tailored Food Recipe 
Because of increasing interest in the concept of "Functional Foods" and "Health 
Claims", the European Union set up a European Commission Concerted Action 
on Functional Food Science in Europe (FUFOSE). The report takes the position 
that functional foods should be in the form of normal foods and they must 
demonstrate their effects in amounts that can normally be expected to be 
consumed in the diet (EUFIC, 2006). 
Currently, health concerns of communicable and non-communicable diseases 
have necessitated investigating into options for dietary interventions including 
the role of tailored food recipes (e.g. Amtewa meal) in HIV/AIDS management. 
The outcome of the research will have direct effect on 90% of HIV infected 
subjects in West Africa vis-à-vis slowing down /eliminating the progression of 
HIV to AIDS (EUFIC, 2006). 
2.16 Justification for HIV nutrition intervention programme in Nigeria 
Antiretroviral (ARV) drugs have been shown to reverse under-nutrition in 
HIV/AIDS but are usually used at the later stages of the disease when the 
patients are moribund (Kumar and Clark, 2005; Boon and Walker, 2006). Thus, 
presently, 75% of Nigerians infected with HIV as recommended by WHO do not 
require ART (CD4 ≥ 350cells/mm3), but should receive nutritional assistance to 
maintain the immune system, sustain healthy levels of physical activity and for 
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optimal quality of life (WHO, 2010). Incidentally, in Nigeria all the HIV/AIDS 
programmes and interventions at the moment focus on the remaining 25% of 
HIV infected subjects that require ART (CD4<350cells/mm3) (UNAIDS, 2009). 
The implication of the reality on the ground is that all the interventions at the 
moment are grossly unable to cope with the treatment of those who require 
ARVs urgently. In essence, this study proposed a nutrition intervention 
programme which was designed to circumvent undernutrition of the 75% of 
PLWH who do not require ART (and sustain their CD4 count level ≥350 
cells/mm3 i.e. not require initiation of ART) and equally supporting and improving 
the anthropometric and biochemical indices of the remaining 25% who are 
receiving ART treatment (CD4 count ≥200 cells/mm3). See Figure 2.8. 
Therefore, the focus of this intervention was to develop an optimised tailored 
functional recipe – TFR (as defined in box 1.2) that is readily available and 
accessible at low cost to Nigerians. TFR is containing macro and micronutrients 
from natural food sources in Nigeria. Then the efficacy of the optimised TFR to 
strengthen the immune system of PLWH has been evaluated. The domestic 
production of the constituents of the optimised meal by household, individual and 
PLWH in sufficient quantities and quality will ensure access to the intervention 
meal. Availability and access dimension of food security will also guarantee the 
stability of this intervention programme. 
  
             
                 





Box 1.2: Definition of TFR 
*TFR:Food that is naturally occurring, accessible, affordable and perhaps consumed in 
unnatural concentrations as part of the usual diet and has demonstrated physiological 
and or biomedical benefits in reducing the risk of chronic disease beyond basic 
nutritional functions.. . 
2.17 Originality of the research 
Development of ‘Amtewa meal’ 
Under-nutrition and micronutrient deficiency remain significant contributors to 
morbidity and mortality in developing countries (FAO/WHO, 2002; Amuna et al., 
2004) and in economic terms, remain a major challenge. Food-based 
approaches need to be innovative, culturally acceptable, accessible, affordable, 
reliable and requiring low-tech approaches in order to assure compliance, 
sustainability and cost-effectiveness (Jiamto et al., 2003; Zotor et al., 2006). It is 
possible to improve the nutritive value of local foods through simple but scientific 
combinations of food ingredient in form of food multimixes (FMM) to develop 
Amtewa meal (Amuna et al., 2004). 
Nutrient deficiencies associated with HIV are: total calories, proteins, vitamin A, 
vitamin B6, vitaminB12, vitamin C, vitamin E, magnesium, selenium and zinc 
(Kotler, 1992; Beach et al., 1992; Baum et al., 1995; Cimoch, 1997; Van Staden 
et al., 1998; Kotler et al., 1999; Periquet et al., 1995; Vilaseca, 2003 and 
Oguntibeju, 2008). Development of a biochemical deficiency of vitamins A, B6 
and B12 is associated with faster disease progression. Normalisation of plasma 
vitamin A, B12 and zinc levels is linked to slower disease progression (Baum et 
al., 1995). Tang et al. (1997) confirmed that low serum (>180ng/L) vitamin B12 
precedes disease progression. Patients often have multiple nutrient deficiencies 
at once, and many of the nutrients likely to be deficient are directly or indirectly 
involved in maintaining normal immune system function (Tang and Smit, 1998). 
Amtewa meal is a combination of these macro and micro-nutrients carefully 
selected from locally available food in Nigeria (Table 2.4), analysed, optimised 
and formulated into a 100g pack for daily consumption and can contribute 
between 15 to 20% additional energy requirement by PLWH as recommended 
by WHO. This meal is a natural product that requires low-technology approaches 
in its development, has a greater bioavailability (The bioavailability of 
macronutrients – carbohydrates, proteins, fats – is usually very high at more 
than 90% of the amount ingested (EUFIC, 2010)) than synthetic nutritional 
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supplements. The nutritional content of the meal is tailored to: decrease 
functional impairment from under nutrition, improve immune function, preserve 
or increase fat-free mass, limit disease specific complications, improve tolerance 
to antiretroviral therapy (ART), provide relief from/prevent symptoms of HIV and 
improve quality of life of PLWH in Nigeria.(Kotler et al., 1999; Mahlungulu et al., 
2009; Ukibe et al., 2013). 
Bioavailability of natural food ingredients versus synthetic micronutrients 
Studies suggest that the bioavailability of natural food complex vitamins is better 
than that of most isolated United States Pharmacopeial vitamins that they may 
have better effects on maintaining aspects of human health beyond traditional 
vitamin deficiency syndromes and at least some seem to be preferentially 
retained by the human body (Thiel, 2000). The first step in making nutrients in 
Amtewa meal bioavailable is to liberate it from the food matrix and turn it into a 
chemical form that can bind to and enter the gut cells or pass between them. 
Collectively this is referred to as bioaccessibility (EUFIC, 2010). The Nutrients 
are rendered bioaccessible by the processes of chewing (mastication) and initial 
enzymatic digestion of the food in the mouth, mixing with acid and further 
enzymes in the gastric juice upon swallowing, and finally release into the small 
intestine, the major site of nutrient absorption. In addition to the bodily means of 
mastication and enzyme action, the digestibility of Amtewa meal is aided by 
cooking or pureeing the food. For example, whereas raw carrots, spinach and 
moringa are good sources of dietary fibre, cooking them allows the human body 




















Table 2. 4: Justification for the inclusion of some selected micronutrients in the optimised 
meal (Amtewa meal) and the sources of the nutrients from Nigerian foods 
 (Opoku et al., 1981; Adeyeye and Ajewole, 1992; Bijlsma, 2000; Zotor et al., 2000). 
Nutrient/100g Deficiency Sources Literature 
support   
Beta- carotene 
5.04mg 
Faster disease progression  
 
Dried moringa leaves, dried 
carrot roots 
Bijlsma, 2000; 









B1 0.4mg  
B2 3.08mg 
 B3 1.23mg 
 
Psychoneurological 
symptoms ranging from 
peripheral neuropathies to 




Dried moringa leaves 
 Vitamin C 
10.5mg 
Decreases resistance to 
infection 
Dried soya bean seeds, dried 




Reduced utilization of 
energy and metabolism by 
cells 
Dried soya bean seeds, dried 





Faster disease progression  Dried soya bean seeds, dried 
moringa leaves, dried carrot 
roots, dried millet seeds 
Copper 
0.33mg 
Increased incidence of 
infection and cell-mediated 
immunity 
 
Dried moringa leaves, dried 
carrot roots, dried millet seeds 
Iron 
18.4mg 
Anaemia Dried soya bean seeds, dried 
moringa leaves, dried carrot 





ability to reduce level of 
oxidative stress 
 








Dried soya bean seeds, dried 





Dried soya bean seeds, dried 
moringa leaves, dried carrot 






transmission of nerve 
impulse 
Dried soya bean seeds, dried 
moringa leaves, dried carrot 




Decreased normal heart and 
muscle functions, blood 
clothing and pressure, and 
immune defence 
Dried soya bean seeds, dried 
moringa leaves, dried carrot 
roots, dried millet seeds  
    
Selenium 
0.008mg 
Faster disease progression 
from oxidative damage 
Moringa leaves, whole grain  
The above Table 2.4 highlighted the richness of some Nigerian foods with 
micronutrients that may have therapeutic effect once optimised in an intervention 
meal. This warrants an investigation to assess their effect to attenuate the 














3.1 Subjects, Materials and Methods 
This chapter elucidates the various stages taken in the laboratory and the study 
site to establish the effect of the intervention meal. The chapter also set up steps 
to provide reliable evidence to assess the effectiveness of the intervention meal. 
These stages were summarised as follows:  
 
A. An overview of HIV in Nigeria  
     
 
 
















F. Sustainability plan  
 
 





3.1.1 Overview of HIV/AIDS in Nigeria  
In Nigeria, AIDS is one of the most challenging health problems of this era 
(FMOH, 2008; NACA, 2012). Since the first case report in 1986, the number of 
persons infected with the HIV has risen markedly, so that at present there are 
over 3.4 million Nigerians living with the virus, of which an estimated 750,000 
require medical care (FMOH, 2007). Youth and young adults (18 – 30 years)  
from the three main religions (Christianity, Islam and Traditional religion) in 
Nigeria are particularly vulnerable to HIV, with young women at higher risk than 
young men (UNAIDS, 2008).  
The care and support of people with HIV and AIDS presents special challenges 
for Nigerian health institutions unlike most other community encountered disease 
entities. HIV disease is multifaceted, and as such, the care provider is 
confronted with multiple manifestations of HIV associated disorders such as 
tuberculosis, undernutrition, depression etc (WHO, 2006; Pribram, 2011). 
The complex nature of HIV infection and disease management in Nigeria calls 
for a multidisciplinary approach to the care of PLWHA. HIV presents as a 
complex mix of many disease states. There is the physical illness requiring 
physical – medical care and there are sundry manifestations of psychosocial 
disorders. The later often the direct consequence of stigma, fear and neglect that 
is associated with a diagnosis of HIV infection in Nigeria (FMOH, 2007).  
To ensure that all persons living with HIV and AIDS have access to a 
comprehensive package of care and support, the Ministry of Health in Nigeria 
developed treatment guideline that anticipates and addresses the four 
components of HIV care in Nigeria. 
HIV Counselling and Testing, PMTCT, Adult and Paediatric ART Care are vital 
components of the strategies to expand access to comprehensive care for 
Nigerian population of PLWHA and they are universally acknowledged.  
Despite the care and support programmes adopted by the Ministry of Health in 
Nigeria, the high burden of HIV and AIDS calls for dedicated and sustained 
acceleration of prevention strategies against the transmission of the virus as well 
as affordable nutrition intervention to slow the progression of the disease in 
Nigeria. This study reviewed the existing epidemiologic evidences on the relation 
between nutrition and HIV disease and the basic principles of ethical practice in 
a nutrition intervention (see chapter 1 and 2). The study also has the potential to 
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provide a level of assurance about the role of locally formulated meal in HIV 
disease progression that is difficult to achieve with any observational design.   
This chapter (3) will illustrate the major steps of the planning phase and these 
include: 
Sampling methods 
Sample size calculation 
Inclusion,exclusion criteria and confounding factors 
Scientific approach to develop Tailored Food Recipe (Amtewa meal), etc. 
3.1.2 Sampling methods 
Randomised Control Trials (RCTs) was used to test the efficacy or effectiveness 
of Amtewa meal nutrition intervention.  
All patients who assess antiretroviral treatment at ARV treatment centres in 
Abuja, Nigeria between February 2002 and December 2010 were given 
opportunity to participate in the research. Demographic characteristics such as 
age, gender, occupation, marital status, number of spouses, past history of STIs, 
and blood transfusion were obtained from the patients‘ hospital record files.  
1000 participants were invited to participate in the research from all the HIV 
treatment centres in Abuja, Nigeria. These PLWH from the HIV treatment 
centres in Abuja, were assessed for eligibility (PLWH with a CD4 count of 
≥200cells/mm3, above 18years, not pregnant and without HIV/AIDS 
complications – for details see section 3.1.2.3 inclusion/exclusion criteria). The 
Study participants   were recruited based on the most recent CD4 count records 
obtained from the medical records department of the treatment centres.  
Based on the sample size calculation, inclusion and exclusion criteria,   
participants (Pilot N=100; Scale-up N=400), (adult, male and female from 
different religious background) were selected through simple randomisation 
(Figure 3.1). The selected participants were randomly allocated into one of four 
groups as illustrated in the study design (Figure 3.2 and 3.3) and given the right 
to decline participation without jeopardizing receipt of care at the State House 
Medical Centre, or other treatment centres in Abuja. They were also subjected to 
comprehensive assessment (appendix 3.8), which includes demographic, 
physical assessment (anthropometric measurements) and selected biomedical 
indices. The study participants continued standard treatment for PLWH by the 
SHMCA (nutritional Counselling, vitamin supplements for Pre-ART group and 
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HAART, nutritional Counselling, vitamin supplements for   the ART group). Half 
of each group (Pre-ART and ART) were dispensed Amtewa meal for daily 
consumption for six months. Prior intervention, project‘s information sheet and 
consent forms (appendix 3.3) were read /interpreted and signed by all the study 
participants. Pre and post intervention assessments were carried out as 
specified in the study design. 
Recruitment of study participants was done by the researcher while the sample 
collection, CD4 count and other laboratory investigations (Total protein, SGOT, 
RG, PCV) were performed by a trained laboratory scientist in SHMCA.  
One hundred enrolled participants from the four hundred eligible study 
participants were selected for the pilot study. Participants for the pilot 
intervention were randomly selected into the four study groups as illustrated in 
the pilot study design (Figure 3.2). Qualitative data were collected from the study 
participants through:  
 Informal individual interviews on life style, adherence to the meal and 
adverse reactions 
 Focus groups interview to get more objective and macro view of the 
intervention: Pre–ART and ART (Test versus control), 
 Continuous observation of participants‘ response to the intervention meal 
 Direct involvement of the researcher in ensuring that the study procedure 
is not compromised. 
3.1.2.1 Sampling framework   
Simple random sampling strategy was adopted in the selection of the different 
groups of the study participants according to the study design. In this type of 
probability sampling technique, there was an equal chance (probability) of 
selecting each group (Pre-ART and ART) from the PLWH being studied. This 
study was based primarily on the recognition that complete enumeration through 
census-based surveys imposes huge costs that are both unsustainable and 
unnecessary if the nature and methods of statistical sampling are properly 
considered. Such considerations in this research include understanding the: 
 Reasons for and objectives of sampling. 
 Relationship between accuracy and precision/reproducibility (pilot 
followed by scale-up intervention). 
 Determination of safe sample sizes for surveys for effective monitoring. 
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3.1.2.2 Sample size calculation  
This sample size calculation was used to determine the number of participants to 
be interviewed or assessed in order to obtain results that reflect the target 
population as precisely as needed. It also shows the level of precision in an 
existing sample (Creative Research System, 2012). 
The sample size was determined as follows (Bill Godden, 2004) 
Sample Size - Infinite Population (where the population is greater than 50,000)  
SS =  Z2 x (p) x (1 – p) 
      C2 
Z = Z-value (1.96 for a 95 percent confidence level) 
P = Percentage of population expressed as decimal, in the case of this study we 
are using 50% = 0.5 (this choice is used in this study since it is the safest when it 
is not possible to estimate ― anticipated population proportion‖) 
C = Confidence interval, expressed as decimal (0.05 = +/- 5 percentage points) 
Z-values (Cumulative normal probability table) represent the probability that a 
sample will fall within a certain distribution. 
The Z-values for confidence levels in this case is 1.96 (guided by the cumulative 
normal probability table). 
SS = 1.962 x 0.5 x 0.5              SS = 384        
                   0.52 
5% attrition was be added = (5/100 x 384) + 384 = 403 
For the pilot study, 25% of the SS was considered = 25/100 x 400  
New sample size (NSS) for pilot study = 100 
New sample size (NSS) for larger scale intervention = 400 
In the scale-up intervention Four Hundred (N=400) study participants were 
randomly selected for the six months intervention according to the study design. 
These 400 participants comprised of the 100 participants that overlapped from 
the pilot to the scale-up intervention.  However, due to fall outs and some 
incomplete results during follow up, the total number of research participants that 
completed the six months scale – up intervention was three hundred and 
eighty four (384).The justification of the sample size is based on the 95% 
confidence interval and a precision limit of 0.05 for the study. Also the Sentinel 
Survey in 1991 showed a prevalence of 1.8%. Subsequent sentinel surveys 
produced prevalence of 3.8% (1993), 4.5% (1996), 5.4% (1999), 5.8% (2001), 
5.0% (2003), 4.4% (2005), 4.6% (2008) and 4.1 % (2010), a trend signaling a 
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general reversal of the epidemic in the country (NACA, 2012). However, the 
prevalence of HIV in Abuja where this study was conducted showed 9.9% in 
2008 and 8.6% in 2010. The prevalence rate of HIV in Abuja is high compared to 
the National prevalence rate; hence the rationale for Bill Godden‘s formula to 




































Figure 3. 1: Flow Diagram for Amtewa meal nutrition intervention (pilot and scale up) 
 
Lost to follow-up (n=4) Reason: Absconded. 
Discontinued intervention (n= 2) Reason: 
Travelled out of the study centre 
Allocated to intervention (n= 200) 
 Received allocated intervention (n= 100) 
 Did not receive allocated intervention (give 
reasons) (n=100) Reason: Control 
Lost to follow-up (n=6) Reason: Absconded. 
Discontinued intervention (n= 2) Reason: 
Travelled out of the study centre 
 
Allocated to intervention (n= 200) 
 Received allocated intervention (n= 100) 
 Did not receive allocated intervention (give 
reasons) (n=100) Reason: Control 
Assessed for eligibility (n=1000) 
Excluded (n=600) 
 Not meeting inclusion criteria 
(n=350) 
 Declined to participate (n=50) 
 Other reasons (n=200): Distance 
study centre, access to other 
treatment protocol   
Analysed (n=192) 
 Excluded from analysis (n=6) Reason: 
incomplete data 
Lost to follow-up (n=3) Reason: 
Absconded 
Discontinued intervention (n=5): 
Travelled, Redeployed out of Abuja 
the Study site  
Allocated to intervention (n=200) 
 Received allocated intervention 
(n=100) 
 Did not receive allocated intervention 
(n=100) Reason: Control 
 
Analysed (n=192) 
 Excluded from analysis 






(After 6 months) 
Follow-Up  
(3 & 6 months) 








 Pilot  
Randomised (n= 100) 
 Participants in pilot 
progressed to scale-up 
intervention. This group 
of participants was 




3.1.2.3 Inclusion, exclusion criteria and confounding factors 
The study was conducted in two phases (pilot and scale-up) employing the 
following criteria: Prospective study participants were briefed and selected using 
the inclusion criteria listed below as a prerequisite. 
Inclusion Criteria 
 PLWHA with a CD4 count of ≥200cells/mm3. HIV infection documented by 
licensed ELISA test, confirmed by Western Blot or positive HIV blood 
culture or positive HIV serum antigen or second antibody test positive by 
a method other than ELISA or any two different rapid technique. 
 Male or Female, age 18years and above. 
 GIT – parasites free (e.g. de – wormed from GIT, worms, flukes etc). 
 Willingness and ability to provide a written consent to participate in the 
trial. 
 No life threatening opportunistic infections 
 No history of lymphoma  
 No pregnant women or nursing mothers 
 No severe kidney or and liver dysfunction  
 No HIV/AIDS complications 
Exclusion Criteria 
 AIDS patient with a CD4 count less than 200 cells/mm3 
 Life threatening opportunistic infections  
3.1.2.4 Randomisation of study participants 
Researchers in life science research demand randomisation (Suresh, 2011).  
Gray and John Hopkins University, (2006), defined a Randomised Controlled 
Trial (RCT) as a planned experiment designed to assess the efficacy of an 
intervention in human beings by comparing the intervention to a control 
condition. Random or probability sampling is recommended as a means of 
informant selection because Randomisation reduces biases and allows for the 
extension of results to the entire sampling population (Godambe 1982, Smith 
1983, Snedecor 1939, Topp et al., 2004). Specific plan to identify and enroll 
study participants involved screening and establishing criteria for number, 
location, and sampling method for the pilot and scale-up interventions. 
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In this study, randomisation of study participants was achieved by generating 
randomisation schedules, obtaining the random numbers and assigning random 
numbers to each subject Random numbers were generated by the computer 
from the attendance list of PLWH who attended the briefing and had all the 
requirements as enumerated in the inclusion criteria above. This randomisation 
ensures that each participant had an equal chance of receiving any of the 
treatments under study, generate comparable intervention groups, which are 
alike in all the important aspects except for the intervention each groups 
receives (Suresh, 2011). The major reason for randomisation in this study 
design was that it eliminates the selection bias, balances the groups (Pre-ART 
and ART) with respect to many known and unknown confounding or prognostic 
variables, and forms the basis for statistical tests, a basis for an assumption of 
free statistical test of the equality of treatments. 
The two groups (Pre-ART and ART) were randomly selected from the same 
population of PLWHA receiving treatment, care and support at the SHMCA and 
other treatment centres in Abuja. They were not only statistically equivalent to 
the larger group; they were also statistically equivalent to each other. The design 
of this simple randomised evaluation (with two groups) was that one group 
received the program that is being evaluated (Amtewa meal intervention) and 
the other did not. 
The study design ensured that the research assessment tools were feasible and 
the study answered questions with clear variables (Anthropometric and 
Biochemical indices) to determine the impact of the intervention on the study 
population. The essential inclusion and exclusion criteria for the study population 
were distinct, research hypothesis (appendix 3.0) was specified, method of 
enrollment, follow up and rigorous monitoring were not compromised hence 
findings were accurately generalised and specific results to the target group as 
illustrated in Chapters 4 and 5. 
Randomisation – Pilot Intervention 
This step involved the randomisation and grouping of the research participants 
into the following; ART (Asymptomatic) and Pre-ART (Symptomatic) as 




Pilot study (six month)
HAART: Highly Active Anti Retroviral Therapy  
 
Figure 3.2: Illustrating the two arms of study design (Symptomatic vs Asymptomatic) and 
showing the patients on Amtewa meal, Amtewa + HAART versus their controls. 
 
A. GROUP I : Pre-ART enrolment are People Living With HIV (PLWH) but are not on HAART yet because their 
CD4 count value is ≥ 350/mm
3 
according to WHO classification and HIV treatment guideline in Nigeria 
 
B. GROUP II : ART (Anti-Retroviral Therapy) enrolment are People Living With HIV (PLWH) and are on HAART 
with a CD4 count value of ≥ 200/mm3 according to WHO classificat ion and HIV treatment guideline in Nigeria. 
These patients are HIV patients but  not full blown AIDS patients 
 
C. Nutrition Counselling  is provided as a routine service to People Living With HIV/AIDS (PLWH) receiving care 
at the SHMCA 
 
D. Vitamin and minerals supplements (Box 3.1) are provided, prescribed and dispensed at a dose of one capsule 
daily or one capsule twice daily to PLWH receiving care at the SHMCA.  
 
E. HAART (Highly Active Anti-Retroviral Therapy) are HIV medicines provided, prescribed and dispensed 
(according to the clinical status of the patient) to PLWH receiving treatment at SHMCA 
 
F. Amtewa meal is a combination micro and macro-nutrients, carefully selected from locally available food in 
Abuja Nigeria, analysed and formulated into a 100g pack for daily consumption by study participants.  
 
 
Box 3.1: Vitamin and minerals supplements 
 
Vitamin and minerals supplements :The composition of the vitamin supplement is vitamin A 3333 IU, vitamin B1 
4.5mg, vitamin B2 5.1mg, vitamin B6 6mg, vitamin B12 6µg, vitamin C 180mg, vitamin D3 200 IU, vitamin E 10mg, 
Biotin 0.3mg, Pantothenic Acid 21mg, Folic Acid 0.2mg, Nicotinamide 57mg, Calcium 50mg, Magnesium 40mg, 
Phosphorus 50mg, Copper 0.4mg, Iron3.6mg, Manganese 0.5mg,Zinc 3mg, Chromium 10µg 
 
 
Randomisation – Scale up intervention (n=400) 
The sequence illustrated in the pilot intervention was adopted in the scale-up 













N = 100 participants 




N = 100 participants 
Nutrition counseling +
Vitamin supplement +
N = 100 participants 
Nutrition counseling + 
Vitamin supplement +
Amtewameal




Figure 3.3: The design for the scale up of public health-nutrition intervention programme 
(n=400). 
 
A. GROUP I: Pre-ART enrolment are People Living With HIV (PLWH) but are not on HAART yet because their 
CD4 count value is ≥ 350/mm
3 
according to WHO classification and HIV treatment guideline in Nigeria 
 
B. GROUP II: ART (Anti-Retroviral Therapy) enrolment are People Living With HIV (PLWH) and are on HAART 
with a CD4 count value of ≥ 200/mm3 according to WHO classification and HIV treatment guideline in Nigeria. 
These patients are HIV patients but  not full blown AIDS patients 
 
C. Nutrition Counselling  is provided as a routine service to People Living With HIV/AIDS (PLWH) receiving care 
at the SHMCA 
 
D. Vitamin supplements (Box 3.2) are provided, prescribed and dispensed at a dose of one capsule daily or one 
capsule twice daily to PLWH receiving care at the SHMCA.  
 
E. HAART (Highly Active Anti-Retroviral Therapy) are HIV medicines provided, prescribed and dispensed 
(according to the clinical status of the patient) to PLWH receiving treatment at SHMCA 
 
F. Amtewa meal is a combination micro and macro-nutrients, carefully selected from locally available food in 
Abuja Nigeria, analysed and formulated into a 100g pack for daily consumption by study participants. The 
composition of Amtewa meal is Soya beans (Glycine max), millet (Pennisetum typhoides), Carrot (Daucus 
carota), Moringa leaves (Moringa oleifera). 
 
 
Box 3.2: Vitamin supplements 
Vitamin supplements** :The composition of the vitamin supplement is vitamin A 3333 IU, vitamin B1 4.5mg, vitamin 
B2 5.1mg, vitamin B6 6mg, vitamin B12 6µg, vitamin C 180mg, vitamin D3 200 IU, vitamin E 10mg, Biotin 0.3mg, 
Pantothenic Acid 21mg, Folic Acid 0.2mg, Nicotinamide 57mg, Calcium 50mg, Magnesium 40mg, Phosphorus 
50mg, Copper 0.4mg, Iron3.6mg, Manganese 0.5mg,Zinc 3mg, Chromium 10µg 
3.1.2.5 Confounding factors 
Randomised trials are not affected by confounding by indication due to random 
assignment (Johnston, 2001). Confounding was less likely to occur in this study 
because baseline characteristics (inclusion criteria) for the different groups (Pre-
ART and ART) and subgroups (Test versus Control) were the same. A reduction 
in the potential for the occurrence and effect of confounding factors was also 
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obtained by increasing the types and numbers of comparisons performed in the 
analysis. 
Confounding variables may be categorised according to their source. The choice 
of measurement instrument (operational confound), situational characteristics 
(procedural confound), or inter-individual differences (person confound). A 
reduction in the potential for the occurrence and effect of operational 
confounding factors in this study was achieved by increasing the numbers of 
comparisons performed in the proximate analysis. Similarly, data from 
anthropometric measurements were repeated twice and witnessed by another 
medical personnel to ensure robustness of findings from the study and a 
reduction in the potential for operational confound. 
Peer review in the development of the conceptual framework and at the end of 
the pilot intervention assisted in reducing instances of confounding, either before 
study implementation or after analysis had occurred. Peer review also relied on 
collective expertise within medical colleagues in the care and support 
programme for HIV to identify potential weaknesses in the study design and 
analysis, including ways in which results may depend on confounding. This 
intervention research utilised the Randomised Control Trial (RCT) design where 
the study population was divided randomly after briefing (Figure 3.4) in order to 
mitigate the chances of self-selection by participants or bias by the study 
designer. The technique places participants in groups (Pre-ART and ART) and 
subgroups (Tests versus control) relevant to criteria that fit the research 
question. 
Briefing and recruiting participants
 
Figure 3. 4: Briefing of participants for the public health-nutrition intervention programme.  
3.1.3 Scientific approach to develop Tailored Food Recipe (Amtewa meal) 
The scientific approach involved the stepwise processes illustrated in Figure 3.5. 
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The Tailored Food Recipes blends were processed into powdered formulations 
which were also made into edible pudding by the study participants. The 
resulting optimised Amtewa meal is nutrient-dense, packaged and labeled 
appropriately for distribution according to the study design during the 
implementation phase. 
 
Figure 3. 5: A schematic diagram showing the stages and processes involved in the 
optimisation of Amtewa meal (Source: Amuna et al., 2004) 
3.1.3.1 Identification, harvesting and storage of basic traditional food 
ingredient 
Documented report on Nigeria Food Consumption and National Survey (IITA, 
2004) identified some frequently consumed Nigerian food that contains specific 
macro and micronutrients with potentials of boosting the immune system. The 
presence of these macro and micronutrients were confirmed in the proximate 
analysis of the food samples, hence the justification for inclusion in the 
formulation of the intervention meal (Amtewa). 
According to the IITA report (2004), the most available and frequently consumed 
foods/meals that are major source of energy (calories) in Nigeria were rice 
(14.8%), cassava (12.90%), maize (10.6%) and yam (10.1%). Cowpea, 
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groundnut and soya beans are major sources of plant protein (IITA, 2004). 
Furthermore, Nigerian‘s popular meals such as soyabean cake, moringa soup, 
millet tuwo, are also rich in both macro/micronutrients. Appraising the food 
composition databases enabled the selection of local, accessible, affordable, 
culturally accepted food ingredients. The nutritive values of each food ingredient 
were estimated to ascertain its inclusion in the formulation process of tailored 
food recipe (Amtewa meal).  Optimised TFR was then employed in the 
randomised control trial that aimed to slow the progression of HIV/AIDS in Abuja, 
Nigeria. See Table 3.1 for details.    
Staple and non-staple foods are available almost all the year round in Nigeria 
but are not affordable all the year round by the citizens. The availability – 
affordability gap is wider in meat and fish products. This has also affected the 
frequency of consumption of the staple and non-staple foods in Nigeria. 
Severe food insecurity was found in over 40% of all households in Nigeria (IITA, 
2004). The implication of this finding is that food security is not only in providing 
physical access but also economic access to food to increase food availability 
index of households (IITA, 2004). Judgments to identify, harvest and store food 
samples for analysis and the formulation of Amtewa meal were based on IITA 
(2004) reported and the following information on specific food sample. This 
information includes: 
 Macro and micronutrient composition of food samples 
 Sight-colour, size and shape  
 Touch-texture, hardness or softness  
 Smell-odour or aroma  
 Taste-sweetness, sourness, bitterness  
 Resonance-sound when tapped.  
Receptacles in vehicles and/or containers were not used for transporting 
anything other than the food samples during harvesting and transportation.   . 
Containers reserved for sample storage were marked clearly to show they are 
used only for the purpose of this research. 
From the survey found on IITA publication in (2004) and other literature sources 
listed in Table 2.4, foods samples in Nigeria were identified, selected, stored, 
transported to UoW/LMU and analysed to ascertain their macro and 
micronutrient compositions (Table 3.1). 
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Table 3. 1: Food sources in Nigeria identified and selected for analysis 
 








in Amtewa  








Soya meat etc. 
Vitamins A, B,  
C, D, E, 
 Iron, Phosphorus, 
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Millet Kunu drink 
Millet ogi 
Millet porridge 


































Iron, phosphorus,  
B. complex,  













salad, rice etc 
Vitamins A,B,C and D,  






















Iron, phosphorus,  
B. complex, potassium, 
magnesium, calcium,  
vitamin c, sodium  







Ugu leaves Telfaira 
occidentalis 
 Potassium, iron  
 


















Iron, calcium,  















(i) *Source of energy: (ii) † Nutraceutical boost to immune system: (iii) ‡
 




3.1.3.2 Estimation of Food Composition via Databases (COMA, 1991; IITA, 
2004; Anjorin et al., 2010; Omale and Ugwu, 2011; SACN, 2011) 
In this study, the macro and micronutrient values reported in the Dietary 
Reference Values for Food Energy and Nutrients for the United Kingdom 
database as recommended by the Committee on Medical Aspects of Food 
Policy (1991) and the Scientific Advisory Committee on Nutrition (2011) were the 
primary nutrient data sources referenced for safe intakes. To ensure that these 
values were appropriate for Nigeria, references were made to other sources 
such as the Guidelines on Nutritional Care and Support for People Living with 
HIV in Nigeria, International Scientific Publications on food composition tables in 
Nigeria and local food composition tables (IITA, 2004). To match the foods, 
consideration was given to total energy content and the following nutrients 
(macronutrients and minerals) for fruits and vegetables: energy, carbohydrates, 
calcium, phosphorous, sodium and potassium; dairy: energy, protein, fat, 
calcium, phosphorous; cereals: energy, carbohydrates, calcium, and 
phosphorous; and meats and eggs: energy, protein, fat, and iron, because these 
nutrients were likely to be present in those food groups. 
3.1.3.3 Proximate analysis (Pomeranz and Meloan, 1994; 2000) 
Proximates are used in the analysis of biological materials as a decomposition of 
a human-consumable good into its major constituents (Pomeranz and Meloan, 
1994; 2000; BradFord and Cook, 1997; Blamire, 2003). From an industry 
standard proximates used in the intervention study include five constituents:  
 Ash – ICP (Pomeranz and Meloan, 1994; 2000) 
 Moisture – Drying (Pomeranz and Meloan, 1994; 2000) 
 Proteins - Kjeldahl method (Pomeranz and Meloan, 1994; 2000) 
 Fat - Soxhlet method (Pomeranz and Meloan, 1994; 2000) 
 Carbohydrates (Calculation) 
Analytically, four of the five constituents were obtained via chemical reactions 
and experiments (appendixes 3.4 to 3.7). The fifth constituent, carbohydrates, 
was a calculation based on the determination of the four others. Proximates 
should nearly always add up to 100% (Pomeranz and Meloan, 1994).The 
proximate analysis employed in this intervention study is supported by Amuna, 
et al. (2004) in their study on human and economic development in developing 
countries: a public health dimension employing the food multimix concept. 
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Laboratory analyses of macronutrients (such as; Soxhlet method for fat 
extraction) were carried out in the laboratories of University of Westminster, 
London while other macro and micronutrient analyses (such as; Kjeldahl method 
for protein analysis; inductively coupled plasma method for analysis of minerals) 
were conducted at the Science Centre of the London Metropolitan University 
(appendixes 3.4, 3.5, 3.6 & 3.7).  
3.1.3.4 Food sampling and safety aspect of Amtewa meal  
The abundance of anti-nutritional factors and toxic influences in plants used as 
human foods and animal feeds certainly calls for concern (Omoruyi et al., 2007). 
Therefore, ways and means of eliminating or reducing their levels to the barest 
minimum was taken into consideration in this intervention. 
Seasonality and variability of the nutritional composition of single food items 
were taken into consideration in the collection of TFR ingredients.  
Representative samples (n=4) were subjected to proximal analysis.  Each 
sample was washed, irrelevant extraneous matter removed by sieving, 
sedimentation and flotation methods and then drained before drying in an oven 
heated at 780 C for 60 hours.  
The Soya Beans sample was fermented to reduce the phytic acid content. 
Appropriate facilities to maintain adequate personal hygiene was ensured where 
necessary; surfaces in contact with food were easy to clean. Utensils and 
equipment in contact with food were properly cleaned and disinfected where 
necessary. Dried samples were size reduced with an electric blender to fine, 
free-flowing powders (Figure 3.6).  
The dried ingredients enabled a longer shelf life of Amtewa meal package. 
Furthermore the food label of the package was designed in a way to address the 
safe food consumption of the meal as well as the mode of cooking and 
preparation. Consumers were advised to consume the meal once open and 
discard left over. This was part of the food safety briefing giving to all participants 
at the beginning of the intervention.  
Aeration of the samples during the blending process was avoided by allowing 60 
seconds of break from every 60 seconds of the blending process. Anyone known 
or suspected to be suffering from or to be carrier of a disease likely to be 
transmitted through food samples were not permitted to assist in the handling 
and formulation of Amtewa meal. 
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Additionally, study participants were strongly advise that all Amtewa meal 
preparations that is handled, stored, packaged, displayed or transported must be 
protected against any contamination likely to make it unfit for human 
consumption, dangerous to health, or contaminated in such a way that it would 
be unreasonable to expect it to be consumed in that state. 
3.1.3.5 Optimisation process of Amtewa meal 
The optimisation process involved the stepwise identification, combination and 
re-combination of macro and micronutrients obtained from the results of the 
proximate analysis from the local food sources in Nigeria (Section 4.6 for 
details). The resulting optimised macro and micronutrients were formulated 
(Section 3.1.3.5.1) and sensory evaluation test conducted (Section 3.1.3.5.2) to 
produce Amtewa meal. This meal is nutrient-dense, providing on average, 10% 
to 20% additional energy above of the Reference Nutrient Intakes (RNIs) per 
adult serving of 100 g of product. 
3.1.3.5.1 Formulation of Amtewa meal (the intervention meal) 
Based on WHO recommendations on additional energy requirements for 
asymptomatic (10%) and symptomatic (20–30%) PLWH and the EARs energy 
for male (2500 kcal/d) and female (2000 kcal/d), the average EARs was 
calculated as 2250 kcal/d.  
Three variations of Amtewa meal: Amtewa meal A (310 kcal/d), Amtewa meal B 
(354.92 kcal/d), Amtewa meal C (385.40 kcal/d) were formulated (Figure 3.7) to 
contain an average of 10–20% additional energy for both asymptomatic and 
symptomatic PLWH. These three formulations were subjected to sensory 
evaluation (Figure 3.8). The most suitable formulation from the sensory 
evaluation (Amtewa meal B 354.92kcal/d) was formulated and provided in a 
100g sealed pack of Amtewa meal. The 100g Amtewa meal containing 50g soya 
beans, 15g moringa leaves 15g of carrot roots and 20g of millet was dispensed 
to PLWH for daily consumption (up to 6 months) as illustrated in the study 
design. 
In similar studies, Amuna et al. (2004) proposed powdered blend in the 
development of FMM to which sugar, salt and milk could be added to increase 
the sensory characteristics of the product and for further energy and nutrient 
enrichment. Oldewage and Vaal University (2006) developed a culturally 
62 
 
acceptable and affordable food product using the FMM concept. The product 
was developed for specific target population and their nutritional need based on 
the staples use in the household. Also Amuna and Vaal University of Technology 
(2006) employed the concept in their research on the ―Industrial and Dietetic 
application of FMM concept in meeting the nutritional need of vulnerable group 
in South Africa. A food-to-food fortification approach assumes that there are 
locally available naturally rich food sources (Rajput, 2012). 
 
TFR Ingredients (all are locally produced and readily available) 
Moringa Soya bean Millet Carrot
Sundried, powdered ingredients   
Mixed percentage to produce the intervention meal
TFR = Amtewa (100gm)




Figure 3. 6: Mixed percentage of Amtewa meal 
 
Packed intervention meal; ‘Amtewa’
 
 
                      




3.1.3.5.2 Sensory Evaluation – Amtewa meal 
A descriptive sensory analysis test (Hedonic scale) was used to determine the 
preferred Amtewa meal formulation out of the three variations. In this method, a 
ranking or ordering scales was adopted e.g. preference between products A, B, 
C: 1 most preferred, 2 intermediate preferred; 3 least preferred. To ensure the 
quality of reporting by the panelist, they were instructed to please take a drink of 
water before tasting Amtewa samples and to please take a sip of water between 
samples. Also booths were used as the sensory panel room to prevent panelists 
from being distracted and interacting with other panelist – unbiased evaluation. 
The booths were computerised and the panelists entered the answers to the 
sensory assessment questions (preference in terms of colour, taste, smell and 
texture) electronically. The booths were also illuminated with white lights to 
ensure that features that change environmental conditions such as different 
colours of light to mask the samples were avoided Figure 3.8).       
The three variations of Amtewa meal: Amtewa meal A (310 kcal/d), Amtewa 
meal B (354.92 kcal/d, Amtewa meal C (385.40 kcal/d) were prepared according 
to the direction of use on the packaging. Seven participants in different booths 
were served with Amtewa meal A, B and C each in different containers for 
consumption to determine their preference in terms of colour, taste, smell and 
texture. Other questions that deal with quality of Amtewa meal were questions 
with the objective of describing liking or acceptability of Amtewa meal. These 
questions include: Do you like this product? How much do you like this product 
on a scale of 1 to 10, where 1 = dislike extremely, and 10 = like extremely? Is 
this product acceptable? What do you like most about this product? Is product A 
better than product B? Which of the three products A, B and C do you prefer? 
 Six of the panelists selected Amtewa meal B (354.92 kcal/d) as their preferred 
formula. This represents 85.71% preference compared to Amtewa meals A and 
C. Based on this result, Amtewa meal B (354.92 kcal/d) was formulated as the 







                              
                                        Figure 3. 8: Amtewa meal sensory evaluation test 
3.1.4 Intervention Setting, Assessment tools and Ethical consideration 
3.1.4.1 Intervention Setting 
The setting for the study was the State House Medical Centre Abuja (SHMCA), 
Nigeria. SHMCA is a secondary health institution recognised by the Federal 
Government of Nigeria for the care and management of PLWH. Presently, the 
institution is involved in intervention programmes such as Voluntary Counselling 
and Testing (VCT), Prevention of Mother to Child Transmission of HIV (PMTCT), 
Paediatric Antiretroviral Treatment (PAT) and Adult Antiretroviral Treatment 
(AAT). 
3.1.4.2 Measurements of research variables 
Biochemical, anthropometric measurements and the nutritional intervention 
clinical trial were undertaken at Department of laboratory medicine and the HIV 
clinic of State House Medical Centre Abuja (SHMCA) Nigeria, one of the centres 
in Nigeria recognised for the care and management of HIV/AIDS patients. 
3.1.4.3 Research assessment tool 
The assessment tool was designed with the aim of achieving a multi-dimensional 
concept of quality research. The various sections in the assessment tool include 
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items to assess quality according to several domains including quality of 
reporting, methodological rigor and conceptual depth. Critical appraisal of the 
assessment tool was ensured after the pilot study (n=100) to ensure adequacy 
of reporting detail on the data sampling, data collection and analysis in the scale- 
up (n=400). See appendix 3.8 
3.1.4.4 Study Variables/indicators (Nutritional assessment; biochemical 
indices; physical and anthropometric measurements) 
Specific research variables (biochemical, physical and anthropometric) were 
selected from the assessment tool to test the hypothesis. These variables (Table 
3.2) are conditions that are changeable during the course of the intervention. 
 











Normal values *Literature 
support (Box 
3.3) 
CD4 count Immune status 
 
500 – 1600 cells/mm
3
  
MUAC Nutritional status 
 



































60 – 85g/L 
 
 
5 – 35 IU/dL 
 
42 – 52% Male 
35 – 47% Female 
 
 
    
Box  3.3: Literature support 





3.1.4.5 Statistical analysis  
Anthropometric measurements (BMI, MUAC) and biochemical indices (RG, TP 
CD4 count, SGOT, PCV) were conducted at the commencement of the study 
and in the third and sixth months of the pilot interventions. This was replicated in 
the larger scale study. 
All collected assessment tools were revised for completeness and data analysed 
using SPSS Statistical Software. Simple frequencies were used for data 
checking. Also, simple descriptive statistics was used for summary of 
quantitative data and frequencies for qualitative data. Bivariate relationships 
were displayed in cross tabulations, i.e. the association of nutritional intervention 
on CD4 count and MUAC. Univariate group comparisons included Student‘s t- 
tests for continuous variables. 
3.1.4.6 Training of Trainers (TOT) and Quality control 
The TOT programme was designed for individuals with a strong skill and 
experimental background in HIV care and quality management. It provided                            
participants at the training (research team) basic knowledge on the research and 
exposure to some rigorous face-to-face challenges to be encountered with 
PLWHA. It was also designed with the demands of the HIV clinic in mind and 
significant portion of the TOT Program has been organised into ―pre-work,‖ a 
format that allows participants the flexibility to determine when they do the work 
(appendixes 3.9 & 3.10). 
3.1.4.7 Ethical consideration  
Research that involves human participants needs to go through a formal process 
of research ethics review (University of Leicester, 2006). Although this research 
required collection of in-depth high quality data from those most closely affected 
by HIV disease, however,  thoughts that may be tempting to consider unethical 
research practice in order to try to obtain and/or retain some of the data was 
avoided (Wellcome Trust, 2014; UKRIO, 2006 – 2014). 
The study design took responsibility in ensuring that: 
 the level of risk is justified by the importance and relevance of the 
research study; 
 the risk is unavoidable within the study‘s objectives; 
 in absolute terms, the level of risk is minimised; 
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 participants were fully aware of the level and nature of the risk before they 
agree, freely, to take part in the study; 
 precautions were in place to deal adequately with the effect of 
participation. 
Basic Principles of Ethical Practice 
1. Informed Consent  
Participants knew exactly what they were being asked to do, and what the risks 
were, before they agreed to take part. 
An Information Sheet was used to provide potential participants with information 
about the study (appendix 3.3) and was assured that the storage of data will 
comply with the Data Protection Act and the University of Westminster‘s Data 
Protection Code.  
2.  No Pressure on Individuals to Participate 
3. Respect Individual Autonomy 
4. Avoid Causing Harm 
5. Maintain Anonymity and Confidentiality 
Research ethics review forms were submitted at SHMCA and UoW and the 
ethical approvals from the two centres were received before commencement of 
the research (appendixes 3.1, & 3.2) (University of Westminster, 2013/14 v2; 
UKRIO, 2006 – 2014; Wellcome Trust, 2014). 
Risks and Discomforts 
Conventionally, HIV patients on management visit the hospital every three 
months for laboratory investigations such as CD4 cell count, viral load tests and 
other investigations (Hematology, blood chemistry and urinalysis). Naturally, the 
discomfort of the needle prick prior to sample collection may psychologically 
affect some participants that have phobia for injections.  
Furthermore, participants will be subjected to a research assessment tool and 
anthropometric measurements. These may constitute some stress to the 
participants. Administration of micro and macronutrient combination to 
participants for daily consumption is expected to have no side effects due to the 
fact that the quantities to be consumed were within the limit for recommended 
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intake for adult; however these products may constitute an additional stress as a 
result of adherence to the prescription on the product.  
Measures to reduce risks and Discomforts 
Participants were reassured of lesser needle prick pain. Trained laboratory 
scientists responsible for the sample collection implemented an improved 
technique (e.g. immersing participants‘ fingers in warm water before sample 
collection) of sample collection with minimal pain on study participants. 
Other methods adopted to reduce risks and discomforts were: 
1. Educate the participants on the benefits of adhering to the recommended 
micro and macronutrient combination on improving their quality of life  
2. Trained research team ensured compliance to assigned responsibilities in 
data collection with the assistant of a second member of the team to 
ensure accuracy. 
3.1.4.8 Legal Rights 
The research participants were assured that they were not waiving any of their 
legal rights by signing the informed consent document. 
3.1.5 Intervention strategy – Planning, Implementation and Evaluation 
phases (Figure 3.9) 
3.1.5.1 Planning Phase 
The planning phase focused principally on required project planning work. The 
purpose of this phase was to plan all project processes and activities 
enumerated below: 
Administrative procedures 
The following documents were developed and submitted to appropriate 
authorities for approval before the commencement of the research:  
 Registration at the University 
 Development of registration document 
 Ethical approvals in UK and Nigeria institutions (see appendixes 3.1 & 
3.2) 
 Identifying the necessary logistics before implementation – these include: 




Visit to collaborating institutions 
The institutions visited were London Metropolitan University, National Institute 
for Pharmaceutical Research and Development, Abuja – Nigeria and State 
House Medical Centre, Abuja laboratories.  
London Metropolitan University superlab offers unparallelled teaching and 
research in nutrition, dietetics and micronutrient analysis.  
National Institute for Pharmaceutical Research Development, Abuja provided 
training to how to undertake research and development work on, biological 
products including pharmaceutical raw materials from indigenous natural 
resources and by synthesis using appropriate science and technology 






 Figure 3. 9:Conceptual framework for public health nutrition intervention programmeto 
attenuate the progression of HIV to AIDS among PLWH in Abuja, Nigeria. Total Duration 42 
months (October 2010 – March 2014). 
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3.1.5.2 Intervention strategy – Implementation phase 
The implementation phase is associated with certain deliverables as described 
in sections on pilot and scale-up interventions described below: 
Pilot study (n=100) 
Pilot experiments are usually carried out before large-scale quantitative research 
in an attempt to monitor, safe time and avoid money being wasted on an 
inadequately designed project. This pilot study was carried out on PLWH 
(N=100) and most of them also progressed and formed part of the final sample 
size in the scale–up phase. It was a potentially valuable insight that ensured that 
anything missing in the pilot study was added to the scale-up intervention to 
improve the chances of a clear outcome. 
Pre - intervention assessment – Pilot study 
The following pre – intervention assessments were carried out. 
1. Assessment tool: A WHO approved questionnaire for public health 
nutrition intervention was reviewed and adapted for the purpose of this 
research and developed into an assessment tool (appendix 3.8). 
2. Physical assessments e.g. anthropometric measurements (MUAC, BMI, 
Weight, and Height) were recorded and filled on the appropriate column 
on assessment tool for all the study participants at the beginning of the 
study. 
3. Assessment of biochemical indices e.g. CD4 cell counts, RG, SGOT, 
PCV test were conducted by the trained Laboratory Scientist and also 
recorded in the appropriate column on the research assessment tool form 
at the beginning of the study.  
Intervention phase – (duration: six months) 
This phase involved the following steps: 
Step 1: Randomisation of research participants (Figure 3.2), administration of 
micro and macronutrients (Amtewa meal) to the various groups in the pilot study 




Step 2: Monitoring at zero, three and six months interval 
Effective monitoring to ensure that the research continues to conform to 
approved ethical standards and procedures. This was achieved through: 
 Standardised but adaptable approaches in the design of the intervention 
 Local feedback from the study participants to monitor adherence to 
HAART and Amtewa meal intervention e.g. checking left over Amtewa 
meal not consumed 
 Minimal data collection by the research team 
 Routine surveillance (health information system) to various units in the 
hospital during data collection  
 Community and household surveys to assess study participants‘ 
knowledge/adherence to the direction of use of Amtewa meal as indicated 
on the package   
 Support to the research participants in the form of stipend for 
transportation to assist and ensure uninterrupted hospital appointment 
during the research.  
Step 3: Post – intervention assessment – Pilot study 
Re-assessment of anthropometric (BMI, MUAC) and biomedical indices (CD4 
cell count, PCV, TP, RG, SGOT) for all the groups (ART & Pre- ART) at three (3) 
months and six (6) months interval. 
Step 4: Evaluation phase 
Project evaluation (process and outcomes): This phase involved the comparison 
of results obtained from pre–intervention assessment phase and the post– 
intervention assessment phase. Data entries and analysis were done after the 
sixth month of pilot intervention. 
 
Post Pilot to Scale up Evaluation phase 
On completion of the pilot intervention, the participants (n=100) progressed to 
form part of the scale-up intervention. This group of participants who overlapped 
from pilot to scale-up phase was monitored and evaluated for one year (six 
month pilot and six month scale-up) to ascertain the effectiveness of Amtewa 




Table 3. 3: Post Pilot to Scale up evaluation 
 
 Number 1-6 6-12 Duration 
(months) 
Pilot 100 100 100 12 
Scale-up 400 -  300 6 
Total  100 400  
Scale up intervention (N=400). 
The results of the pilot intervention are evidence-based and cost effective. This 
knowledge and innovative technology was demonstrated in a larger population 
(n=400) to ascertain the impact of the Amtewa meal in a larger sample size.  
Pre - intervention assessment – Scale up study 
The following pre–intervention assessments were carried out. 
1. Research assessment tool:  A WHO approved research assessment tool 
for public health nutrition intervention used for the pilot intervention was 
reviewed and adapted for the purpose of this research (appendix 3.8). No 
modification was made to the research assessment tool.  
2. The research team were re-trained to ensure strict compliance to the 
research procedure especially during data collection 
3. The use of xylocaine ointment was recommended to the Laboratory 
Scientist for application on the injection site during sample collection to 
reduce the pain for participants with phobia for injection.  
4. Physical assessments e.g. anthropometric measurements (MUAC, BMI, 
Weight, and Height) were recorded and filled on the appropriate column 
on assessment tool form for all the study participants at the beginning of 
the study. Each measurement was done twice and double- checks by an 
observer to ensure that correct data were entered into the assessment 
tool.   
5. Assessment of biomedical indices e.g. CD4 counts, RG, SGOT, PCV test 
were conducted by the trained Laboratory Scientist and also recorded in 
the appropriate column on the research assessment tool form at the 
beginning of the study.  
6. WHO prequalified the Laboratory Medicine Department of SHMC, Abuja 
as an accredited centre certified for laboratory investigations.    
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Intervention phase – six months 
This phase also involved the Randomisation of scale up research 
participants, administration of micro and macro – nutrients (Amtewa meal) to 
the various groups (n=400) and effective monitoring within the six months 
period of the intervention. 
3.1.5.3 Intervention strategy – Evaluation phase 
The evaluation phase was an ongoing phase from the commencement of the 
research to the completion.  The participants‘ hospital appointments were 
monitored to ensure compliance, Research Team was monitored to ensure that 
the quality data were not compromised. Data entries were double checked, 
Results were analysed, interpreted and report presented for the MPhil transfer 















3.1.6 Sustainability plan 
Planning for sustainability in this public health nutrition intervention was based 
on the results of the pilot intervention. A sustainability plan was proposed to 
integrate nutrition intervention in HIV care and support programme at the study 































Figure 3. 10: Proposed interaction between a Nutritionist and other Health care providers 
in an HIV treatment site with the introduction of ‘Amtewa meal’ 
 
The sustainability plan was proposed to ensure that PLWHA visiting the HIV 
clinic for their hospital appointments or referred from the voluntary Counselling 
and testing unit (VCT) would be assessed by the Nutritionist (nutritional 
assessment and Counselling) before referring them to the physician and other 
health care provider as illustrated in Figure 3.10 above.   
 
                            Amtewa meal nutrition intervention 





Amtewa meal formulation/ 
Production 


























 Food dispensary, 
 Inventory control 
 Record Keeping 
 Community Programs 
 Sustainability 
plan 
 Food Security  
















This pilot intervention was a rehearsal for subsequent full-scale intervention. It 
helped to fine-tune later larger study and also allow the researcher to experience 
the more practical aspects of implementing the study, such as determining the 
number of research team members needed to handle recruitment and data 
collection or identifying special requirements for participants‘ follow-up. 
4.2 Summary of Materials and Methods 
Enrolled participants were subjected to a comprehensive assessment (appendix 
3.8), which include variables such as anthropometric measurements and 
biomedical indices. These study participants continue standard treatment for 
PLWH by the SHMCA (nutritional Counselling, vitamin supplements) and half of 
each arm (Pre-ART and ART) were dispensed Amtewa meal for daily 
consumption for six months (Figure 3.2). 
Pre and post intervention assessments were carried out as specified in the study 
design (Chapter 3). 
4.3 Results (Pilot) – Proximate Analysis 
Tables 4.1, 4.2 and 4.3 demonstrate the macro and micronutrients contents in 
each sample employed in the optimisation and formulation of Ametwa meal.  
Table 4.1 shows the weight of CHO, protein and fat in a known weight of each 
food sample. It also shows the percentage total solid and the weight of crude 
fiber in the samples. Of the four samples analysed, 50g of soya bean seeds 
contain the highest amount of CHO (17.5g), protein (20g) and fat (10g) while 20g 
of the millet seeds contain 14.98g of CHO, 1.58g of protein and 0.64g of fat. 
These two samples formed the bulk of the macronutrient and therefore 70% of 
Amtewa meal.  
Table 4.2 shows the total weight of micronutrients in each of the analysed 
samples. The four samples contain micronutrients (vitamin A from carotene, 
vitamin B, vitamin C, Ca, Mg, K, Na, Mn, Fe, Cu, Zn and phosphorus) essential 
for immune boosting (Beach et al., 1992; Baum et al., 1995; WHO, 2005; Fawzi 
et al., 2003; 2004; 2005; Drain et al. 2007; Hurwitz et al., 2007). Soya bean seed 
and moringa leaves contain higher amounts of each micronutrient than carrot 
and millet as illustrated in the Table 4.2. However, carrot contains 2.2mg of 
carotene in 100g Amtewa meal and Moringa contains 2.84mg of carotene in 
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100g of Amtewa meal which were the natural sources of vitamin A in the 
formulation. The total weight of each sample was compared to the DRV and RNI 
for the United Kingdom (UK) for the macro and micronutrients (COMA, 1991) to 
ensure that the summation of each micronutrient does not exceed the DRV and 
RNI. UK values were used because the DRV for the Nigeria population has not 
yet been determined. According to DRV for UK, Table 4.3 shows the EARs 
energy per day for male is 2500 kcal/d and for female is 2000 kcal/d (average 
2250 kcal/d). The optimised 354.92 kcal/d of Amtewa meal which is 10% to 20% 
higher than the average daily energy requirements for healthy male and female 
adults was packaged and dispensed to PLWH to be consumed in addition to 
their normal daily nutritional intake.  
4.4 Information on the package: Direction of use 
Boil 0.5 litres of clean water in a pot. Gradually pour 100g of Amtewa meal into 
the boiling water, stir and maintain boiling for three to five minutes. Empty the 
boiled mixture in a container and allowed to cool to a temperature suitable for 
consumption.  
Recommendation: Consume the whole content. Addition of milk and sugar is 
optional to improve taste. Discard left over.    
4.5 Optimisation of macro and micronutrients (Amtewa meal) 
Reducing or eliminating undernutrition has the potential to significantly slow 
progression of HIV/AIDS disease and decrease its severity (ADA, 2010). Severe 
food insecurity was found in over 40% of all households in Nigeria (IITA, 2004), 
hence the need to optimise macro and micronutrients in HIV care (Table 4.1). 
Altered levels of plasma proteins, micronutrients, and other nutrition-related 
markers have been documented early in HIV disease process and have been 
associated with increased risk of mortality in HIV infection (ADA, 2010). Some of 
















Dietary Reference Value for Food Energy and Nutrients for the United Kingdom (COMA, 1991). 
 
Table 4.1 shows the macronutrient composition of optimise Amtewa meal (in 
100g product as additional consumed meal) compared to the Dietary Reference 
Values for adults as a percentage of daily total energy intakes (percentage of 
food energy). 
 
Table 4. 2: Micronutrients compositions in mg (see details of Table below) 
                  
SAMPLES Ca Mg K Na Mn Fe Cu Zn Se P Car B1 B2 B3 Vit. C 
SOYA 138.5 140 898.5 1 0 7.85 0 2.5 0.008 352 0 0 0 0 3 
MORINGA 300.4 55.2 198.6 0 0 4.23 0.09 0.5  30.6 2.84 0.4 3.08 1.23 2.60 
CARROT 0.48 0.12 1.34 0.17 0.3 0.13 0.12 0.5  0 2.2 0 0 0 4.9 
MILLET 12 23.1 90 5.4 0.3 6.18 0.12 0.5  59.4 0 0 0 0 0 
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Dietary Reference Value for Food Energy and Nutrients for the United Kingdom. RNI for Carotene is in mcg  
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Insufficient for women with high menstrual losses where the most practical way of meeting iron requirements is 
to take iron supplements 
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leaves 
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Carrot roots 
 
15 0 0 0.16 0.63 0 8.9  
Millet seeds 20 14.98 59.9 1.58 6.32 0.64 94.36 0.22 
         
TOTAL 100 38.21 153 25.80 103.21 10.99 224.99 7.75 
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Table 4.2 shows the micronutrient composition of optimise Amtewa meal (in 
100g product as additional consumed meal) compared to the Reference Nutrition 
intakes daily. 
 
Table 4. 3: Percentage composition of Carbohydrate, Protein and Fat contained in the 











354.92 38.21 25.80 10.99  25001  20001 
1
Dietary Reference Value for Food Energy and Nutrients for the United Kingdom 
 
Table 4.3 shows the daily total energy and percentage composition of Amtewa 
meal (in 100g product as additional consumed meal) compared to the Estimated 
Average Requirements for energy as recommended by Dietary Reference 




Table 4. 4: Anthropometric and biomedical indices (see details of table title below) 
MUAC (Mid upper arm circumference), PCV (Packed cell volume), TP (Total protein), RG (Random glucose), BMI (Body mass 
index)
Progression of participants’ anthropometric and biomedical indices from inclusion to six months for participants on Amtewa meal and those without the meal 
   Group (Pre-ART) Ia (Test) Group (Pre-ART) Ib (Control)  Group (ART)  IIa (Test)      Group (ART)  IIb (Control)  
             Time (month) N Min Max Median N Min Max Median             Time (month) N Min Max Median n Min Max Median  
 Group I : Weight(Kg)                 Group II : Weight(Kg)                  
 0 25 49 80 64.5 25 48 97 74 0 25 46 97 64 25 47 97 61.5  
 3 25 51 81 65 25 50 96.5 73.5 3 25 47 96 65 25 45 96 61  
 6 25 53 82 66 25 51 96 72.5 6 25 49 97 69.5 25 45 94 60  
 Group I : BMI(Kg/m
2
)                 Group II : BMI(Kg/m2)                  
 0 25 18.8 32 23.63 25 18.75 32.5 26.63 0 25 17.92 34.35 22.91 25 19.6 32.55 23.68  
 3 25 19.32 32 23.82 25 19.53 32.27 26.5 3 25 18.28 34.35 23.09 25 18.92 32.21 23.51  
 6 25 20.22 32.89 24.29 25 19.92 32.1 25.97 6 25 18.28 34.73 24.24 25 18.58 31.54 23.33  
 Group I : MUAC(cm)                 Group II : MUAC(cm)                  
 0 25 20 35 29 25 27 41 30 0 25 23 40 28.75 25 22 37 27  
 3 25 21 35 29.5 25 25 40 30 3 25 25 39 29.5 25 20 35 27  
 6 25 22 35 30 25 25 40 29.75 6 25 25 40 31 25 20 35 26  
 Group I: PCV (%)                 Group II: PCV (%)                  
 0 25 31 45 38 25 33 45 37 0 25 31 45 37 25 30 51 35.5  
 3 25 32 42 38 25 34 48 38 3 25 33 46 37.5 25 31 49 36  





                 GroupII CD4cells/mm
3
                  
 0 25 370 1105 573 25 340 1140 599 0 25 230 1029 399.5 25 205 820 313.5  
 3 25 320 1120 539.5 25 320 1282 595 3 25 190 1107 426 25 180 812 300  
 6 25 246 1122 560 25 325 1200 599 6 25 198 1110 442.5 25 195 800 292.5  
 Group I : TP(g/100ml)                 Group II : TP(g/100ml)                  
 0 25 57 112 72.5 25 62 89 77.5 0 25 52 95 69 25 55 95 71.5  
 3 25 59 112 79 25 65 89 77 3 25 59 98 73.5 25 57 98 72  
 6 25 60 108 79 25 65 88 76 6 25 61 93 71.5 25 59 96 75  
 Group I : RGmg/100ml                 Group II: RGmg/100ml                  
 0 25 70 176 109.5 25 73 211 88 0 25 69 169 107 25 68 207 98  
 3 25 72 140 104.5 25 72 180 95 3 25 74 136 104 25 70 200 103.5  
 6 25 78 140 112.5 25 70 124 94 6 25 79 125 108.5 25 71 190 95  
 Group I : SGOT (I.U/L)                 
 Group II : SGOT 
(I.U/L)                  
 0 25 7 41 13.5 25 7 26 12 0 25 7 20 11 25 6.5 27 11  
 3 25 7 25 12 25 7 24 10.5 3 25 7 17 9.5 25 6 24 10  
 6 25 8 29 12.25 25 7.2 21 10 6 25 7 23 10 25 6 25 9  
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4.6 Participants’ characteristics at baseline, three months and six 
months follow up 
4.6.1 Anthropometric measurements 
Median increase in MUAC of participants in the Pre-ART group (with Amtewa) 
was 3.4% while for the ART group (with Amtewa), it was 7.8%. On the other 
hand, control groups (without Amtewa) for both Pre-ART group and ART group 
had a decrease in their median MUAC by 0.8% and 3.7% respectively as 
illustrated in Table 4.4.  
Similarly, Figure 4.1 shows that the mean MUAC for Pre-ART (with Amtewa) 
group increased by 3.25% while mean MUAC of ART (with Amtewa) group, 
increased by 5.58% after six months. This is statistically significant (P = 0.05). 
 
Impact of Amtewa meal on mean MUAC  
 
Figure 4. 1: Bar graph showing the impact of Amtewa meal on Mean MUAC (cm) of study 
participants 
4.6.2 Immune status of study participants (pilot) 
The variations of CD4 lymphocytes count for all the groups (Table 4.4) shows 
that the median CD4 count of participants on Pre-ART with Amtewa meal group 
decreased by 13cells/mm3 (statistically significant) while that of ART with Amtewa 
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meal group increased by 43cells/mm3. Also, participants in Pre-ART without 
Amtewa meal group maintained a median CD4 count (599cells/mm3) while CD4 
count for ART without Amtewa meal group decreased by 11cell/mm3. Similarly, 
mean CD4 count for Pre-ART with Amtewa meal group increased by 0.69% and 
ART with Amtewa meal group increased by 9% (Figure 4.2). This indicated 
clinical and statistically significant differences between the two groups of 
participants on the meal and those without the meal. 
 
Impact of Amtewa meal on Mean CD4 count. 
 
 
Figure 4. 2: Bar graph showing the impact of Amtewa meal on Mean CD4 (cells/mm3) cell 
counts of study participants (n=100) 
4.6.3 Clinical end points 
Table 4.4 shows the result of other biomedical indices (Random glucose, packed 
cell volume, total protein and serum glutamic oxaloacetic transaminase). The 
median random glucose (normal range=140-200mg/100ml), packed cell volume 
(normal value=40% female, 45% male), total protein (normal range=60-
83g/100ml) and SGOT (normal range=0-12 I.U/L) were within the normal range.  
 
4.7 Discussion (pilot intervention) 
This study describes participants in the pilot intervention (n=100) that were 
divided into four groups of 25 participants in each group (Figure 3.2). Fifty PLWH 
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were monitored for adherence to Amtewa meal nutrition intervention (354.92 kcal 
per day) whiles the other fifty were control groups (without the meal) for six 
months according to the study design. 
Comparison of before and after the pilot trial suggest that in two groups on the 
meal,  there were mean increases in the CD4 lymphocyte count of the Pre–ART  
Test (with Amtewa meal) group and CD4 count of ART Test (with Amtewa meal) 
group. This increases are statistically significant (p=0.05) compared to the control 
groups without Amtewa meal with a median decrease in Pre–ART control group, 
mean decreases in Pre-ART control and ART control groups respectively. The 
effect of Amtewa meal was more pronounced in participants on HAART than 
those not on HAART.  CD4 count increases with Amtewa meal is supported by 
Paton et al. (2006) in his study on the impact of malnutrition on the survival and 
the CD4 count response in HIV-infected patient starting ART (N=394).  According 
to Parton et al. (2006) those on HAART showed a significantly (P=0.03) greater 
increase in CD4 count than those not on HAART. 
Also, median BMI increase (Table 3.4), median MUAC increase (Table 4.4) and 
mean MUAC increase (3.25% in Pre-ART with Amtewa meal group and 5.58% in 
ART with Amtewa group see Fig. 4.1). This is supported by Chlebowski et al. 
(1993), Chlebowski et al. (1995), Suttmann et al. (1993) and Suttmann et al. 
(1995), who demonstrated a 4 and 3kg gain in body weight in their HIV studies 
on nutritional support (Pichard et al., 1998). Also in another randomised double-
blind controlled study on HIV-infected patients (N=55) on oral nutritional 
supplementation enriched with fish oil and fish oil-arginine for 6 months, gain of 
body weight and fat mass were approximately 2 and 1kg respectively for patients 
on the nutritional support. Furthermore, in the study participants‘, median random 
glucose (normal range = 140-200mg/100ml), PCV (normal value=40% female, 
45% male) total protein (normal range=60-83g/100ml), and SGOT (normal 
range=0-12 I.U/L) were within the normal range. Protein and energy 
improvement by Amtewa meal suggests that nutritional supplements in clinically 
stable patients are selectively efficient to increase nitrogen intake and stimulate 
protein tissue deposition (Pichard et al., 1998).  
On the other hand, decreases in the mean CD4 cell count of pre ART and ART 
groups that were not on the meal (Fig.4.2) and decrease in median CD4 count in 
ART group (control) are supported by Kaiser et al. (2006) who demonstrated a 
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mean absolute CD4 count increase by an average of 65 cells in the micronutrient 
group versus a 6-cell decline in the placebo group at 12 weeks.  
Although in both Pre-ART (control) and ART (control) groups, there was a 
decline in the median BMI (normal BMI=18.5-25kg/m2) and mean MUAC from 
28.52 to 27.36cm (normal ≥23cm for male and ≥22cm for female) at the sixth 
month of the study (Table 4.4, Figure 4.1), however, the mean and median 
values were not suggestive of underweight or undernutrition. This could be 
attributed to the fact that in the study design, all the groups were given nutritional 
counselling (Chapter 3) in addition to the multivitamin supplementation dispensed 
to PLWHA receiving care and support at the study centre (SHMCA). Tabi (2006) 
investigated the effectiveness of nutritional Counselling as an intervention to 
improve health outcomes for HIV positive patients in Ghana. The result shows a 
mean increase (from 43.86kg to 46.57kg for females and from 51.86kg to 
55.23kg for males)  in the body weight of the study participants (p=0.001). 
Nutrition counselling and intervention programmes must be sustained to maintain 
anthropometric parameters (BMI, MUAC) within normal values to decrease 
mortality. This is evident in the study (n=1657), Body mass index at time of HIV 
diagnosis: A strong and independent predictor of survival Van der Sande et al. 
(2004) states that a one unit decrease of BMI resulted in 21% increase in 
mortality rate (p<0.001) after controlling baseline immune status (CD4 count).     
Participants‘ compliance was also impressive with over 95% completing the 6 
months trial. This might be explained by (1) the selection of participants willing to 
undertake proactively a prolong action that they believed potentially able to 
improve the course of their infection. (2) PLWHA attend their hospital 
appointment every month or once in two months for prescription refill and other 
investigations. Hence, the intervention programme with Amtewa meal was run 
concurrently with the HIV clinic. 
Finally, daily micronutrient (antioxidant) supplementation improved body weight 
and body cell mass, reduced HIV RNA level, improved CD4 cell counts and 
reduced the incidence of opportunistic infections in small studies of adults with 
AIDS, including those on antiretroviral therapy (USAID, 2004). Larger clinical 
trials (Fawzi, et al., 2004; Hurwitz, et al., 2007) demonstrated that daily 
micronutrient supplementation increased survival in adults with low CD4 cell 
counts. The optimal formulation of a daily multiple macro and micronutrient 
supplement for HIV positive individuals is evident in the innovation of Amtewa 
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meal. These positive outcomes qualified Amtewa meal to the next scale-up 
intervention phase (n=400 participants) to ascertain its effectiveness on health 
status of HIV infected subjects and appraise its position within the National 
Health Services framework as innovative approach to attenuate the progression 
of HIV to AIDS in Nigeria. 
Consequently, the model of Amtewa meal nutrition intervention was envisage on 
a Nigeria population and the recipe of macro and micro–nutrients cautiously 
selected from locally available and accessible food in Abuja, Nigeria. The meal is 
a natural product that requires low technology in the formulation and with 
affordable training workshop to consumer could be sustainable. Unlike most 
intervention programmes referenced above, the authors researched on synthetic 
macro and micronutrients (e.g. Kupka and Fawzi, (2002) study on zinc nutrition 
and HIV infection; Coutsoudis et al., (1995) investigated the effects of vitamin A 
supplementation on the morbidity of children born to HIV‐infected women). 
The study design was scientific and the variables (e.g. CD4 T-cell count, MUAC, 
PCV, SGOT) were standardised. The inclusion and exclusion criteria were strictly 
followed to ensure that the positive outcome could be attributed to the additional 
100g (400 kcal) of the Amtewa meal which was consumed on daily basis by each 
participant in the Test group. 
4.8 Planning the Scale-up intervention  
4.8.1 Quality control measures and good practices to be adhered to in the 
larger scale intervention (N=400) 
 The research assessment tool was refined to fulfill the study objectives 
and fit the study population. Subsequent monitoring plan (input, 
modifications, and revisions) were developed adopted through pilot 
testing. 
 At the study site, research team was re-trained to ensure the flow of the 
study and assure quality of collected data. 
 Revision of data forms (checking for completeness, logical response, etc) 
was performed at the study site at the end of each visit of the participant 
by the researcher. 
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 Regular visits and meetings were held for the research team to monitor 
field progress and the need to address any potential problems arising in 
the field. 
 Ascertain the key role of Amtewa meal in increasing the CD4 count, BMI 
and MUAC of HIV infected subjects. 
 Sustainability plan (from outcome of conclusion and discussion) and 
technology transfer for delivering the package of nutrition services 
(assessment, Counselling and Amtewa meal support) in SHMCA and 

























Results: Scale-up intervention 
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5.1 Introduction 
This presented Larger Scale Intervention (n=400) results consist of one hundred 
study participants in the pilot study that overlapped into the scale-up phase and 
additional three hundred study participants recruited based on the sample size 
calculation and the sampling strategy. This implied that the study participants in 
the pilot study were monitored over a period of one year (12-month period). This 
larger scale intervention was an approach for organising sustainable changes 
with active involvement of the researcher, the research team and the study 
participants throughout the six months period of data collection. 
5.2 Objectives 
The specific objectives of the scale-up intervention study are: 
1. To appraise the outcomes of Amtewa meal on health status of HIV 
infected subjects (with CD4values above 200/mm3) at baseline and 
compare these at post- scale up intervention. 
2. To evaluate the effectiveness of macro and micronutrient (Amtewa meal) 
intervention as possible measure to attenuate the progression of HIV to 
AIDS. 
3. Draw up a sustainability plan for outcome of discussion and conclusion.   
5.3 Summary of method 
Enrolled participants (1000) were invited to participate in the research from all the 
HIV treatment centres in Abuja, Nigeria. Based on the sample size calculation, 
inclusion and exclusion criteria, 400 participants were selected through simple 
Randomisation (Figure 3.1). The selected participants were subjected to an 
―assessment tool‘‘ (appendix 3.8), which includes demographic, anthropometric 
and biomedical indices. These study participants continued standard treatment 
for PLWH by the SHMCA (nutritional Counselling, vitamin supplements for Pre-
ART, nutritional Counselling, and vitamin supplements for the ART group). Half 
of each group (Pre-ART and ART) were dispensed Amtewa meal for daily 
consumption for six months. 
Pre and post intervention assessments were carried out as specified in the study 
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5.4 Results 
This result section in the scale-up intervention was divided into results obtained 
from the demographic characteristics, anthropometric and biochemical indices of 
study participants. 
5.4.1 Demographic Characteristics of the study participants 
Sample size 
Table 5.1 shows four hundred (400) PLWH were recruited for the intervention 
programme, however sixteen participants could not complete the six months 
duration of the research. All the research participants were above 18 years of 
age. Gender, age range and marital status of the various groups of the study 
participants are illustrated in the sections below. 
 
Table 5. 1: Demographic characteristics of study participants (n=400) 
           
 
GENDER AGE (years) 
AGE RANGE 
(years) MARITAL STATUS 
GROUPS MALE FEMALE MEAN MEDIAN 
STD 






51 DIV M S WID WIDR 
PRE ART 
TEST 36 60 45.57 45 9.965 20 65 8 56 32 0 68 26 2 0 
PRE ART 
CONTROL 33 63 41.89 41.5 8.763 25 64 10 70 16 0 46 43 5 2 
ART TEST 40 56 45.22 45 9.784 26 67 7 61 28 1 72 20 3 0 
ART 
CONTROL 40 56 40.61 40 9.535 25 66 14 66 16 0 40 53 3 0 
TOTAL 149 235 NA NA NA NA NA 39 253 92 1 226 142 13 2 
 
Key: STD DEV: STANDARD DEVIATION; MIN: MINIMUM; MAX: MAXIMUM;  
DIV: DIVORCED; M: MARRIED; S: SINGLE; WID: WIDOW; WIDR: WIDOWER;  
NA: NOT APPLICABLE 
 
Marital status frequency distribution of study participants  
Figure 5.1 shows the marital status frequency distribution. It shows that 0.26% of 
the participants were divorced, 36.98% were single, 58.85% were married, 
3.39% were widow and 0.52% was widower. The percentage of married 
participants may be a factor to explain the degree of adherence why most of the 
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participants completed the six months or one year intervention program. All 
marital status were represented with the highest representation from the married 
(n=226) and the lowest representation from the divorced (n=1). The cumulative 
frequency was 100%.   
 
         Figure 5. 1: Bar graph showing the marital status distribution of participants 
 
The Bar graph above shows that 95.83% of participants were either married or 
single. The remaining 4.17% participants were the Divorced, Widow and 
Widower. This result reflects the inclusion criteria that excluded participants with 
a CD4 count less than 200cells/mm3 (PLWAIDS) who may have lost either of 
their spouses from the complications of HIV which is often the case when the 
CD4 count is less than 200cells/mm3.  
Sex distribution of study participants in the scale-up intervention 
Figure 5.2 shows the sex distribution of the study participants in the scale up 
intervention. 61.2% were female while 38.8% were male. This shows that more 
women are receiving treatment care and support in Abuja, Nigeria or women are 
interested in intervention programmes that will slow the progression of their 
disease condition (HIV) than men.  
 
Figure 5. 2: Bar graph showing sex distribution of study participants in the scale-up 
intervention 
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The greater percentage of 22.4% of women more than men in the research as 
shown on the bar graph above was also an indication that a positive outcome in 
the research is likely to be sustained because they have the skill to educate their 
spouses. Also women are more likely to adhere to the intervention approach than 
men. Therefore, positive outcome in the nutrition intervention programme. 
Age distribution of study participants in the scale-up intervention 
Figure 5.3 shows that 10.1% of the participants were less than 30 years, 65.9% 
of the participants were between ages 31 to 50 years and 24% were greater than 
50 years. Mean age (n=400) was 43.32 years, median age (n=400) was 43years 
and the standard deviation (SD) was 9.721. 
 
 
Figure 5. 3: Bar graph showing the percentage age range in years of study participants in 
the scale-up intervention 
 
The bar graph above shows 89.9% of participants were above 30 years of age. 
This was an indication that participants above 30 years of age were more 
interested in the intervention approach and are less likely to be affected by 
stigma associated with HIV intervention programmes. The 10.1% of participants 
less than 30 years of age compared to the 89.9% (30 years above) were the 
group that was most likely affected by stigma. Therefore, intervention 
programmes to alleviate stigmatization in PLWH/AIDS is more likely to impact 
more on PLWHIV/AIDS that are less than 30 years of age than those above 30 
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5.4.2 Anthropometric parameters and Biochemical indices 
Table 5. 2: Results showing Biochemical indices and Anthropometric parameters 
 
Anthropometric and Biochemical indices of study participants from inclusion to 6 months of the Amtewa 
meal nutrition intervention n=400 
 
 
    
Test 




(months)   N Mean N 
      
Mean 
Time 
(months)   N Mean N Mean 
 
 
Pre ART Weight 
(Kg)         ART Weight (Kg)         
 
 
0   96 68.20 96 69.73 0   96 66.27 96 65.24 
 
 
3   96 68.81 96 68.59 3   96 67.47 96 64.80 
 
 
6   96 70.83 96 67.39 6   96 69.15 96 63.76 
 
 
Pre ART Height 
(m)         ART Height (m)         
 
 
0   96 1.66 96 1.65 0   96 1.64 96 1.63 
 
 
3   96 1.66 96 1.65 3   96 1.64 96 1.63 
 
 
6   96 1.66 96 1.65 6   96 1.64 96 1.63 
 
 
Pre ART BMI 
(kg/m
2
)         ART BMI (kg/m
2
)         
 
 
0   96 24.75 96 25.54 0   96 24.64 96 24.55 
 
 
3   96 24.97 96 25.12 3   96 25.08 96 24.39 
 
 
6   96 25.70 96 24.68 6   96 25.71 96 24.00 
 
 
Pre ART MUAC 
(cm)         ART MUAC (cm)         
 
 
0   96 31.23 96 30.61 0   96 31.00 96 29.67 
 
 
3   96 31.35 96 30.55 3   96 31.10 96 29.42 
 
 
6   96 32.08 96 30.01 6   96 31.78 96 29.01 
 
 
Pre ART PCV (%)         ART PCV (%)         
 
 
0   96 39.81 96 37.73 0   96 38.74 96 37.54 
 
 
3   96 39.74 96 37.82 3   96 40.39 96 37.84 
 
 
6   96 43.18 96 37.71 6   96 41.84 96 37.57 
 
 
Pre ART CD4 
(cells/mm
3




)         
 
 
0   96 621.09 96 600.34 0   96 418.53 96 351.81 
 
 
3   96 635.36 96 559.79 3   96 443.93 96 322.65 
 
 
6   96 660.26 96 536.01 6   96 469.26 96 306.07 
 
 
Pre ART TP 
(g/100ml)          ART TP (g/100ml)         
 
 
0   96 73.23 96 72.48 0   96 70.44 96 67.93 
 
 
3   96 74.56 96 74.15 3   96 71.98 96 68.06 
 
 
6   96 76.10 96 74.89 6   96 72.85 96 71.18 
 
 
Pre ART RG 
(mg/100ml)         
 ART RG 
(mg/100ml)         
 
 
0   96 131.61 96 125.44 0   96 123.14 96 117.13 
 
 
3   96 143.46 96 136.66 3   96 134.21 96 127.08 
 
 
6   96 147.31 96 138.09 6   96 133.28 96 131.41 
 
 
Pre ART SGOT 
(I.U/L)          ART SGOT (I.U/L)         
 
 
0   96 9.08 96 8.87 0   96 9.21 96 9.10 
 
 
3   96 8.24 96 8.84 3   96 8.51 96 8.67 
 
 
6   96 8.76 96 9.48 6   96 9.52 96 9.44 
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Table 5.2 above shows the mean values of the variables at baseline to the sixth 
month of the nutrition intervention for all the groups (Pre-ART and ART) and 
subgroups (Test versus control) of participants. The sample size (n=400) 
represents the number of participants enrolled into the intervention research. 
However 384 participants completed the intervention programme for six months. 
16 participants had incomplete data, hence incomplete data were not analysed.  
In the analysis of the results, emphasis was placed on MUAC as a tool to assess 
the nutritional status and CD4 cell counts as a tool to assess the immune status. 
The t-test analysis was used to compare the difference between two means (Test 
versus Control groups) in relation to the variation in the data. 
Mid Upper Arm Circumference (MUAC) 
Figure 5.4 shows significant increase in the MUAC from inclusion into the study 
(0 month) to the sixth month of the intervention. Mean MUAC in the Pre-ART 
Test group increased by 0.38% at the third month and 2.72% at the sixth month. 
Similarly, mean MUAC in the ART Test group increased by 0.33% at the third 
month and 2.52% at the sixth month. Conversely, in the control group, mean 
MUAC in the Pre-ART Control decreased by 2% while a similar decrease of 
2.28% was recorded for the mean ART Control group at the sixth month of the 
study. The increase in mean MUAC in the scale–up intervention (n=400) is 
comparable to the increase in mean MUAC in the pilot intervention (n=100). As 
illustrated in Figure 4.1 (pilot result), mean MUAC for Pre-ART Test (Amtewa 
meal) group increased by 3.25%and ART Test (Amtewa meal) group, mean 
MUAC increased by 5.58% after six months. This is statistically significant 
(p=0.05). 
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Key: Ia = Pre-ART Test, Ib = Pre-ART Control, IIa = ART Test, IIb = ART Control 
 
Figure 5. 4: The impact of Amtewa meal on Mean MUAC (cm) at zero, three and six months 
intervals of the scale-up intervention (n=400) 
5.4.3 Biochemical indices 
Regular biochemical assessments are good markers to assess the progression 
of HIV to AIDS. Potential deficit in micronutrients were also assessed by specific 
biochemical markers during routine blood tests as specified in the study design. 
These biochemical markers include the following as illustrated in the Table 5.2 
and include the following: 
Packed cell volume (PCV) 
Table 5.2 shows the results of the PCV for the Pre-ART and ART groups. In both 
groups (Test and Control), the mean range in PCV from inclusion to the sixth 
month of the intervention was between 37. 54% to 43.18%.  Reference values 
are 42-52% for males and 35-47% for females (Encyclopedia of Surgery). The 
hematocrit is usually about 3 times the hemoglobin value (assuming there is no 
marked hypochromia). The average error in hematocrit is about 1-2%. The 
hematocrit may be changed by altitude, position, and heavy smoking, in the 
same manner as the hemoglobin may be changed. The results obtained were 
within the normal range for all the groups (Test and Control).  
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Random plasma glucose (RPG) 
From the results on Table 5.2, the mean random plasma glucose (RPG) in all the 
groups range between 117.13 to 147.31mg/100ml from inclusion to six months of 
the intervention. This shows that the participants RPG were within the normal 
range. The range in the mean RPG can also be explained by the fact that the 
RPG test were usually done in the morning between 7am to 8am local time to 
enable the participants on routine HIV clinic appointment see the physician with 
the results. Most individuals may not have taken their breakfast within this period. 
Hence what was considered RPG may be fasting plasma glucose in reality.  
Total protein 
The result in Table 5.2 shows that the mean Total protein range for all the groups 
was between 67.93 to 76.10g/dl from their inclusion to the sixth month of the 
intervention. The reference range for total protein is typically 60-85g/L (It is also 
sometimes reported as 6.0-8.5g/dl) (McAuley, 2012). Concentration below the 
reference range usually reflect low albumin concentration, for instance in liver 
disease, poor nutrition, malabsorption, diarrhea, or severe burns and sometimes 
immunodeficiency. Similarly, concentrations above the reference range are found 
in paraproteinaemia, Hodgkins‘s lymphoma, leukemia, liver disease, chronic 
infections, alcoholism, tuberculosis or any condition causing increase in 
immunoglobulins.   
Serum glutamic oxaloacetic transaminase 
The SGOT result in Table 5.2 shows results within normal range of SGOT 
(Normal range of SGOT is 5-35 IU/dL) in all the group of participants. This again 
could be attributed to the inclusion and exclusion criteria. PLWH with any HIV 
complication according to WHO clinical staging of HIV disease were excluded. 
The normal SGOT value also indicates that Amtewa meal may not be toxic to the 
liver.   
CD4 Count 
Figures 5.5 shows increase in mean CD4 count of the Test groups (Amtewa 
meal intervention groups) of participants in the scale–up intervention. In the Pre–
ART group, the percentage increase in the mean CD4 count at three and six 
months were 2.3% and 6.31% respectively. Similarly, in the ART Test group 
percentage increase at three and six months were 6.07% and 12.12%. In the 
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control groups, mean CD4 count decreased by 64.33cells/mm3 in the Pre–ART 
group and 45.74cells/mm3 in the ART group. This result was a further 
confirmation of the result obtained in the pilot intervention. 
 
 
Key: Ia = Pre-ART Test, Ib = Pre-ART Control, IIa = ART Test, IIb = ART Control 
 
Figure 5. 5: The impact of Amtewa meal on Mean CD4 counts (cells/mm3) at zero, three 
and six months intervals of the scale-up intervention (n=400) 
 
Percentage increase in Mean MUAC (cm) and Mean CD4 counts (cells/mm
3




Figure 5. 6: Percentage increase in participants’ CD4 Count and MUAC over six (6) months 
period (n=400) 
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Table 5. 3: Variance on percentage increase 
 
 







count cells  
ART CD4 count 
cells 
0 - 3 0.38 0.32 2.30 6.07 
     6 2.72 2.52 6.31 12.12 
 
The graph (Figure 5.6) and Table 5.3 shows steady increases in the mean CD4 
counts (Pre-ART and ART Test groups) in the third and sixth months respectively 
when compared to the mean CD4 count at baseline (0 month). Pre–ART Test 
group increased by 6.31% while the ART Test group increased by 12.12%. Mean 
MUAC increased by 2.72% and 2.52% for both groups (Pre–ART and ART Test 
groups) within the same period.  
5.5 Qualitative assessment 
Qualitative data were collected through direct encounter (interview) with the 
study participants. Specific interview questions were focused on participants‘ 
opinion, feelings and experience as illustrated in Table 5.4.  
 
Table 5. 4: Qualitative assessment (interview) of study participants 
           
 
Finished their 
Amtewa meal before 
the next Hospital 
appointment date ® 
Difficult to 
prepare the meal 
Shared intervention meal 




































12 7 0 0 6 10 0 1 
 
Keys : ® = Not more than 2 appointments, © =Not more than 2 occasions   
 
The Table 5.4 above shows 9.5% of participants (N=400, male =6%, female 
=3.5%) in the Test group at some point within the six month duration of the 
intervention but not more than two occasions, finished their meal before the next 
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hospital appointment date. The direction of use of the meal was quite explicit; 
hence there was no record of any participant who did not understand the method 
of preparation of the meal. The method of preparation is similar to the method of 
preparation of some local meals such as ―Akamu‖ (a traditional oatmeal made 
from cereals) in Nigeria. Therefore the participants understood the concept.  
Similarly, 8% of the participants (male=3%, female=5%) shared their intervention 
meal with others (spouses, participants in Control groups etc) probably due to the 
positive effect of the meal while 0.5% of the participants reacted (nausea and 
vomiting) to the meal and discontinued the intervention programme.   
5.6 One year follow up from Pilot to Scale–up (12 months) intervention 
Fifty (50) Test (Pre-ART and ART) participants out of the one hundred sample 
size in the pilot intervention (n=100) were followed up for another six months in 
the scale-up intervention to establish the impact of Amtewa meal on PLWH over 
a period of twelve (12) months. The results of the overlapped participants 
(n=100) illustrated in Tables 5.5 further confirmed the independent results 
obtained from the pilot and scale-up interventions. The major indicators assessed 
in the one year follow-up were the CD4 cell counts for immune status and the 
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Table 5. 5: X2 T Test analysis: One year follow-up for study participants (pilot to scale-up 




Table 5.5 shows a 12 month follow up on participants (n=100) that participated in 
the pilot intervention and overlapped into the scale-up intervention. The result 
above shows that the longer the duration of the intervention meal the more the 
improvement in the anthropometric and biochemical indices.  
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Figure 5. 7: Percentage increase in participants’ CD4 Count and MUAC over twelve (12) 
months period (n=100) 
 
 
Table 5. 6: Variance on percentage increase for twelve (12) months 
 
 
                      Percentage (%) increase/decrease  
 
Months Pre-ART 
MUAC ART MUAC 
Pre-ART CD4 
count cells 
ART CD4 count 
cells 
0 - 3 1.59 1.97 -0.23 6.11 
    6 3.25 5.58 0.69 9.10 
    9 0.69 4.02 -1.70 8.43 
  12 2.08 3.95 2.21 12.14 
 
Figure 5.7 and Table 5.6 shows the significant increases (p=0.05) in CD4 count 
and MUAC at twelve month duration from baseline to 12 months of the research. 
The increase in the mean CD4 count in the ART Test group was 54.40cells/mm3 
(over twelve-month period). Mean MUAC decreased from 29.82cm at the sixth 
month to 29.48cm at the 12 month. Pribram, (2011) classification of MUAC 
values (MUAC > 32cm, BMI > 30kg/m2 =obesity; MUAC < 23.5cm, BMI < 
20kg/m2 =underweight) shows that these participants were neither obese nor 
underweight. However, the 0.24cm drop in the MUAC may be due to general 
information on healthy life style to all patients assessing treatment in State House 
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6.1 Author’s Critical view on the different phases of the Intervention 
In the planning phase of this research, vegetables and grains rich in 
carbohydrates, protein and mineral elements needed for normal body function, 
maintenance and reproduction were selected and analysed. In the analysis of 
these grains and vegetables, some contained high amount of carbohydrates, 
protein, vitamins and minerals while some had low amount of these nutrients. It 
was obvious from the results obtained in this investigation that intakes of these 
nutrients in different combination is essential for the maintenance of healthy life 
and normal body functioning of PLWH as recommended by WHO. In the article 
on comparative studies on the protein and mineral composition of some selected 
Nigerian vegetables, the authors Omale and Ugwu (2011) recommended further 
investigations to determine the effects of cooking and storage conditions on the 
valuable nutrients in the vegetables studied. The nutrients in Amtewa meal is 
neither affected by cooking nor storage conditions because the formulation 
processes took the necessary precautionary measures as explained in chapter 3 
to ensure that the product was sterile and safe for human consumption. 
Scientific advances have allowed researchers to better characterise the 
biological basis of disease states, understand the metabolism of food at the 
cellular level, and identify the role of bioactive components in food and assess 
their impact on metabolic processes. The tenet ―Let food be thy medicine and 
medicine be thy food‖ espoused by Hippocrates nearly 2,500 years ago is 
receiving renewed interest under the term ‗nutrition sensitive food sciences‘. 
Avorn et al. (1994) published a randomised, double-blind, placebo-controlled 
clinical trial. The positive outcome of their publication measured a baseline and 
one month intervals data that investigated the effect of regular intake of cranberry 
juice beverage on bacteriuria and pyuria in elderly women. McClements and 
Decker (2009) advanced in research method to study food sensory perception, 
digestion and absorption. They reported that the breakdown of food structures in 
the gastrointestinal tract has a major impact on the sensory properties and 
nutritional quality of foods. Amuna et al. (2004) demonstrated the processes 
involved in the development of a suitable foodmultimix - FMM and how such 
products can provide sufficient nutrients in the daily composite diets of 
underprivileged, food-insecure impoverished communities as a short-term 
nutrient intervention. Amtewa meal nutrition intervention adapted the theoretical 
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approaches of these and other scientists, improved on their scopes by designing 
and implementing the intervention program in a Randomised Control Trial (i.e. 
putting theory into practice). The Amtewa-RCT was designed to compare study 
participants (allocated to treatment/intervention or control/placebo groups) using 
a random mechanism. Furthermore, Amtewa-RCT was best for studying the 
effect of an intervention, unbiased distribution of confounders, blinding more 
likely and randomisation facilitates statistical analysis. Cohort study, cross over, 
cross sectional or other forms of study designs were not used in Amtewa meal 
nutrition intervention to avoid wash-out period, unequal distribution of 
confounders and potential bias associated with these study designs.  
Adherence to ART by PLWH is an essential component of programmatic 
treatment success.  Adherence to ART is required to achieve adequate and 
sustained viral suppression and prevent the emergence of drug-resistant viral 
strains. Adherence rates exceeding 95% are necessary in order to maximize the 
benefits of ART. Even with adequate regimen adherence, there is a significant 
risk of ART-induced toxic effects and metabolic dysfunction. Thus, complete 
control of HIV over time using ART is unlikely and pharmacotherapeutic 
limitations leave a significant void in the treatment of HIV. Despite promising 
findings in the pilot study that Amtewa meal may improve nutritional status and 
immune functioning, definitive evidence of its impact in the scale–up intervention 
suggests this meal as an adjunct treatment in the care and support treatment of 
PLWH in Nigeria. The success of the Amtewa meal nutrition intervention 
depended on the education of research participants before the initiation of the 
meal, an assessment of their understanding of the intervention meal and their 
readiness to participate in the intervention programme. 
6.2 Author’s critical view on the other published intervention in relation 
to employed intervention. 
The article, randomised trial of multivitamin supplements and HIV disease 
progression and mortality, the authors: Fawzi et al. (2004) proposed 
micronutrient supplements as low-cost immunomodulating interventions that may 
slow the progression of HIV disease. In this study, the progression of the disease 
was related to the WHO disease staging of HIV and the study participants‘ CD4 
cell count was not a criterion for inclusion in the research. The authors‘ data 
suggests that multivitamins delay the onset of disease progression and thus the 
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time to the initiation of antiretroviral therapy may be delayed. This study provided 
information on the number of enrolled pregnant women of which by WHO 
recommendations all pregnant women must be on HAART to prevent mother to 
child transmission of HIV. Fawzi et al. (2004) study did not provide information on 
the group of participants who were Pre-ART hence their conclusion that 
multivitamin supplements are a means of delaying the initiation of antiretroviral 
therapy in HIV-infected women may not be justified.  
In the Amtewa meal nutrition intervention, similar results to Fawzi et al. (2004) 
were obtained but the PLWHA with CD4 cell counts of >200cells/mm3 were 
excluded from the research according to the inclusion and exclusion criteria of 
the research. Also the study design identified the Pre–ART group to justify the 
findings that Amtewa meal nutrition intervention was a means of delaying the 
initiation of ART. Hence, the originality of this reported data. 
In Baum et al. (1995), deficiencies of vitamin A or vitamin B12 was associated 
with a decline in CD4 cell count (P =0.0255 and 0.0377, respectively), while 
normalization of vitamin A, vitamin B12 and zinc was associated with higher CD4 
cell counts (P =0.0492, 0.0061 and 0.0112, respectively). Baum et al.‘s results 
were based on vitamins A, vitamin B12 and zinc only. Amtewa meal contains 
varieties of macro and micronutrients with proven efficacy to improve nutritional 
status and immune function of PLWH in Nigeria.    
6.3 Author’s critical view on the employed meal (Amtewa) compared to 
other employed meal or nutritional fact on Nutrition in support of HIV in 
the existing body of knowledge 
The World Health Organization (2005) reported HIV infection and undernutrition 
rates are raising to alarming levels in sub-Saharan Africa. There are complex 
interactions between nutrition and HIV/AIDS; lack of nutrition weakens the 
immune systems of people living with HIV/AIDS, increasing their susceptibility to 
other infections and worsening weight loss. To address these issues, the World 
Health Organization convened a Consultation on Nutrition and HIV/AIDS in 
Africa. The goal of the consultation was to: 
 Develop strategies that were both evidence-based and feasible to help 
improve the health status of people living with HIV/AIDS in southern and 
eastern African countries. 
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 Review and disseminate the latest evidence on nutrition and HIV/AIDS, 
and thereby help ensure nutrition is integrated as part of a comprehensive 
response to HIV/AIDS. 
Amtewa meal as a competent tool in nutrition intervention programme may be 
suggested as the latest evidence on the clinical nutrition - HIV interplay.  
In the book, Nutrition and HIV, the author Pribram (2011) provided health 
professionals with a source of comprehensive information on the nutritional care 
and treatment of people living with HIV. This includes people of different age 
groups and varying states of health in a wide range of settings. The author gave 
excellent evidence to support other Nutritional experts who now see HIV patients 
with conditions as diverse as advanced wasting, obesity, cancers, renal failure, 
metabolic disorders, and many other illnesses. In support of Pribram and other 
related articles, nutrition has always been an important aspect of HIV care. In the 
early days of the pandemic, clinical nutrition was of necessity, experimental and 
required urgent responses to extreme and often fatal weight loss and wasting, 
associated with HIV disease progression. HIV has become a long-term chronic 
condition and the knowledge and skills required to manage this have changed 
rapidly and profoundly. 
In the UNAIDS (2008) global report on HIV, regions of the world mostly affected 
by HIV infection simultaneously are affected by undernutrition. In Schaible and 
Kaufmann article on undernutrition and infection: complex mechanisms and 
global impacts, the author‘s reported that undernutrition is responsible, directly or 
indirectly, for 54% of the 10.8 million deaths per year in children under 5 and 
contributes to every second death (53%) associated with infectious diseases 
among children   under 5 years of age in developing countries.  While severe 
undernutrition resulting from acute, life threatening complications is still a major 
problem in sub-Saharan Africa, undernutrition in HIV may cause changes in 
immune function and have negative effect on each other. This provides a 
baseline setting on which the HIV pandemic has been imposed in many areas of 
sub-Saharan Africa. In regions with good access to ARVs, undernutrition and 
wasting associated with HIV disease are still highly prevalent and various forms 
of nutrition support are routinely required. Resource constraints often exist in 
these regions at household level where PLWH are often affected by unstable 
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immigration and poor socio-economic status like Nigeria. Nutritional care in HIV 
infection involves more than treatment of disease states. It has become 
increasingly apparent that optimum nutrition and healthy lifestyle interventions 
are essential to help enable people with HIV to lead long and healthy lives. 
Amtewa is not only accessible but also convenient and affordable by low socio-
economic people in the Nigerian community. 
Interestingly, in the article macronutrients and HIV/AIDS: a review, the authors; 
Hsu et al. (2005) reported a WHO working group recommended intake above 
10% of expected energy for asymptomatic HIV infection. The authors also 
reported that in a recovery phase after opportunistic infections, nutritional 
requirements may be increased by 20 to 50% in both children and adults. Hsu 
JW.C et al. supports WHO (2003) and FANTA/USAID (2007) report on additional 
nutrient intake for asymptomatic and symptomatic PLWH. Although Ockenga et 
al. (2006) reported that the role of nutrition support in HIV infection has been 
poorly investigated, so is a paucity of evidence to demonstrate improved clinical 
outcomes through dietary interventions, however scientific evidence by WHO, 
UNAIDS, Mahlungulu et al. (2007), Fawzi et al. (2004), Fawzi et al. (2005) and 
other scientists suggests that dietary support may improve clinical outcomes in 
individuals with HIV infection by reducing the incidence of HIV–associated 
complications and attenuating progression of HIV disease, thereby improving 
quality of life and ultimately reducing disease–related mortality. The WHO report 
on additional nutrient intake for PLWH formed the baseline evidence for the 
calculation and formulation of Amtewa meal nutrition intervention.   
Furthermore, in the article nutrients intake and health status of HIV/AIDS 
patients, the authors; Temitope et al. (2011) reported that nutrient intake is 
specific to a study population and depends on a variety of factors that are difficult 
to control. These factors include cultural, socioeconomic, environmental and 
geographical determinants. Therefore, the concept of Amtewa meal nutrition 
intervention was envisaged on a Nigeria population and the combination of 
macro and micronutrients carefully selected from locally available food in Abuja, 
Nigeria. The meal is a natural product that requires low technology in the 
formulation and with affordable training workshop to consumer could be 
sustainable. 
Kupka and Fawzi (2002) reported low plasma zinc values in up to 26% of HIV-
infected asymptomatic subjects without clinical evidence of nutritional 
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deficiencies; low plasma zinc was seen in up to 96% of AIDS/AIDS-related 
complex patients. Some investigators also reported a significant association 
between plasma zinc levels and immune parameters such as CD4 cell counts 
and HIV-RNA levels when data from HIV-positive subjects were evaluated cross-
sectionally. Although Kupka and Fawzi‘s observational epidemiologic studies 
have provided conflicting results on the role of zinc status in HIV disease 
progression. However, they recommended that randomised, placebo-controlled 
trials are needed to resolve this controversy. Amtewa meal nutrition intervention 
is RCT to support other authors on the role of zinc in the progression of HIV. Zinc 
is a constituent of Amtewa meal (3.88mg in Amtewa meal) and the RNI for zinc is 
9.5mg (male) and 7.0mg (female).  
Kotler (1992), Van Standen et al. (1998), Piwoz (2004), FANTA (2004), WHO 
(2010) and other authors also supported the evidence that nutrient deficiencies 
associated with HIV are: total calories, proteins, vitamin A,B,C,E, selenium , iron,  
and zinc, however most of the nutrition intervention studies proposed the use of 
synthetic macro and micronutrients for example, micronutrient supplementation 
increases CD4 cell count in HIV–infected individual on HAART (Kaiser et al., 
2006). 
Contrary to Kaiser et al. (2006), Amtewa meal nutrition intervention supports 
Thiel (2000) article on natural vitamins that may be superior to synthetic ones. In 
this article, the author reported that vitamins originate primarily in plant tissues. In 
the United States Pharmacopoeia (USP) synthetic vitamin isolates are not 
naturally included in the diet, they do not necessarily originate primarily in plant 
tissues, nor have all of them been proven to safely and fully replace all natural 
vitamin activities. USP vitamins are not food, even though they are often called 
‗natural‘ and are sometimes added to foods. USP vitamins are synthesised, 
standardised chemical isolates. Also, in Thiel (2000) report, an animal study 
found synthetic vitamin A in the form of retinyl acetate significantly reduced 
vitamin E utilization. Another animal study found that natural food complex 
vitamin B6 was absorbed 2.54 times more into the blood and was retained 1.56 
times more in the liver than an isolated USP form. Thiel‘s conclusion suggests 
that the bioavailability of natural food complex vitamins is better than most 
isolated USP vitamins. Amuna et al. (2004) took the view, whereas food 
fortification and food supplementation may be important alternatives that 
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complement food-based approaches to satisfy nutritional needs in poor 
communities in developing countries, the bioavailability of some synthetic 
supplements and fortificants may be limited. They are also expensive, may be 
unaffordable and may, thus, be less cost-effective as a long-term strategy. This 
formed the basis for the macro and micronutrients in Amtewa meal which 
originate primarily in plant tissues, is affordable and the bioavailability of this 
natural food complex (Amtewa meal) is better than the synthetic supplements. 
Additionally, in the article on Food insecurity and HIV/AIDS: Current knowledge, 
gaps and research priorities; the authors, Anema et al. reported that food 
insecurity is associated with decreased ART adherence, reduced baseline CD4 
cell count, incomplete virologic suppression, and decreased survival. Integration 
of food security interventions into HIV/AIDS treatment programs is essential to 
curtail the HIV/AIDS epidemic and improve health and quality of life among those 
infected. Hence, the selection of Amtewa meal constituents was based on: 
1. Literature sources and sound scientific researches on Nigeria indigenous plant 
with known macro and micronutrient compositions. 
2. Plant based food sources in Nigeria that are readily available and affordable to 
ensure sustainability of the intervention program. 
Food security with Amtewa meal nutrition intervention is a strategy to build the 
capacity of households and communities affected by HIV and AIDS to cope with 
the disease. Many other services and intervention programs exist, which are 
relevant but not primarily designed to address nutrient deficiencies HIV/AIDS with 
natural food sources available in Nigerian community. 
Ten (10) indigenous food samples from Nigeria were selected and analysed 
based on their macro and micronutrient compositions and other reasons 
mentioned above. However, only four (4) of the samples constitutes the 
composition of the Amtewa meal formulation. The justification for this selection 
was based on the macro and micronutrient strengths, stability of the formulation 
and the sensory evaluation. Although proximate analysis of some of the samples 
such as Corchorus walcottii (Ewedu leave) and Telfairaocci dentalis (Ugu leaves) 
show that these samples contain iron (Iron deficiency anaemia is the most 
widespread nutritional problem in the world and it is the main cause of anaemia) 
and antioxidants which are essential micronutrients to slow the progression of 
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HIV disease, but were excluded in the formulation to avoid stability and sensory 
evaluation challenges.    
6.4 Author’s critical view on Amtewa meal and HAART interactions 
Food and drug interactions are an important issue for effectiveness and 
tolerability of HAART regimens. Thus, in the Amtewa meal nutrition intervention, 
HAART regimens with documented evidence of interaction with food were 
monitored and the study participants on such regimen were counsel to use their 
medication 2-3hrs before or after the intervention meal. The presence of Amtewa 
meal in the gastrointestinal tract can influence the absorption of several HIV 
medications such as didanosine, indinavir, saquinavir, and nelfinavir. Drug-food 
interactions can influence serum drug concentrations, thus increasing the 
likelihood of side effects of the ART when serum concentrations are too high and 
increasing the risk for viral resistance and loss of durable viral suppression when 
serum concentrations are too low. 
In summary, the National Guidelines for HIV and AIDS treatment and Care in 
Adolescents and Adults, the Federal Ministry of Health, Nigeria recommended 
strategies for improving and monitoring nutritional status. These 
recommendations include:  
 Close weight monitoring 
 Nutrition education and Counselling 
 Prompt treatment of opportunistic infections (mouth disorders, diarrhea) 
 Nutritional Support (macro and micronutrient) 
 Economic empowerment 
Although the guidelines recommended nutritional support with macro and 
micronutrients but no evidence of any intervention meal in all the treatment 
centres in Abuja, Nigeria to ensure that the nutrient requirements for PLWH as 
recommended by WHO is achieved. Thus, Amtewa meal nutrition intervention if 
embedded into the guidelines on nutritional care and support for PLWH in Nigeria 
may suppress the progression of HIV and provide indirect improvement of CD4 
count. The results support the use of Amtewa meal as a tailored functional recipe 
that is simple, inexpensive, and safe adjunct therapy in HIV disease 
management. 
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7.1 Introduction to the Discussion of results 
The findings from this Amtewa meal nutrition intervention confirm that the 75% of 
Nigerians infected with HIV who does not require ART, but nutritional assistance 
to maintain their immune system. This group of PLWH is guaranteed decrease in 
progression of their HIV status to AIDS.  Similarly, the remaining 25% of HIV 
infected subjects in Nigeria who are currently on the HIV care and support 
programmes can be sustained by obviating their progression to AIDS. This 
discussion will be addressed under the following: 
7.2 Sample size 
 According to Cochran (1997) our knowledge, our attitudes and our actions are 
based to a very large extent on samples. Sample surveys can be classified 
broadly into two types – descriptive and analytical (Cochran, 1997). This 
research was an analytical survey where comparisons were made between 
different sub-groups of a population in order to discover whether difference exist 
among sub-groups (Test group versus control) to verify the hypothesis (appendix 
3.0). Larger sample size (n=400) compared to the sample size in the pilot 
intervention (n=100) generally led to increased precision (Bartlett et al., 2001). 
Also the sample size was based on the quality of the resulting estimates to have 
95% confidence interval.  In Abbie Griffin and John Hauser article, the 
importance of a quality sample report 20-30 in-depth interviews are necessary to 
uncover 90-95% of all customer needs for the product categories studied (Unite 
for Sight, 2013). This number is corroborated by a clinical research that identified 
sample size larger than 30 and less than 500 as appropriate for most research, 
(Unite for Sight, 2013). Also, Sandelowski (2007) reported that adequate sample 
size in qualitative research is ultimately a matter of judgment and experience in 
evaluating the quality of the information collected against the uses to which it will 
be put, the particular research method and purposive sampling strategy 
employed, and the research product intended. This research employed the RCT 
strategy for the calculated sample size of 400 study participants recruited for the 
study. 
  113 
7.3 Marital status frequency distribution of study participants – Social 
dimension. 
Having a main partner has been associated with better HIV outcomes in some 
studies, including higher HIV survival rates. This was evident in Amtewa meal 
nutrition intervention results (58.9% of the participants were married). 
Relationships characterised by mutual exchange, or reciprocity, of support are 
associated with positive appraisals of support, and with better mental and 
physical health outcomes (Knowlton et al., 2011). Also, Roach et al., (1981) 
reported marital satisfaction scale: Development of a measure for intervention 
research. They defined marital satisfaction as an attitude of greater or larger 
favorability towards one‘s own marital relationship. Couples on this intervention 
study encouraged one another to ensure adherence to the meal. In Knowlton et 
al. (2011) investigation, spouses or boy/girlfriends are often important sources of 
informal care and social support to the chronically ill, supports the outcome of 
this research. This study encouraged the monthly support group meetings which 
was an avenue for social interactions between PLWHA. Main partner support 
and care–giving may be especially important to the health of individuals 
vulnerable to family alienation and failed HAART.  
7.4 Sex distribution of study participants in the scale-up intervention 
The findings of this study suggest the merit of interventions targeting men and 
their informal caregivers, particularly main partners, and gender-specific, 
contextually tailored strategies to promote HAART adherence (Knowlton et al., 
2011). The findings also complement findings from a prior study of HAART 
adherence among women in the study community, and suggest that gender 
differences in support exchange in this community affect their HAART 
adherence. This study means to encourage clinicians to plan specific, gender-
focused support for enhancing adherence as supported by Ubbiali et al. (2008). 
The result suggests that more women were interested in HIV nutrition 
intervention than men in Abuja, Nigeria.   
7.5 Age distribution of study participants in the scale-up intervention 
In Rosenberg et al. (1994) age-specific data on the seroincidence of the human 
immunodeficiency virus (HIV) are difficult to obtain, however in this intervention 
research the age distribution results ascertained the response of specific age 
group to the intervention. In Detels et al. (1998) cohort studies that followed up 
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persons with human immunodeficiency virus (HIV) infection in periods 
characterised by different therapies, offered the opportunity to estimate therapy 
effectiveness at the population level. Similarly, in the calendar period when 
Amtewa meal was introduced with or without (Pre-ART and ART groups) 
antiretroviral therapy, the time to development of AIDS and time to death were 
extended and rate of CD4 cell count increase was more beneficial to the age 
group 31 – 50 years which constituted 65.9% of the study population. The SD of 
9.721 indicates that over 97% of the values lie in the symmetric intervals as 
stated by Chebyshev‘s inequality from Weisstein (2014) that the minimum 
population Number of standard deviation from mean is  six (6) for a 97% 
Confidence Interval. 
7.6 Biochemical Indices of the study participants in the scale–up 
intervention 
PCV results within normal range (Reference values: 42-52% for males and 35-
47% for females) could be as a result of the exclusion criteria in the intervention. 
Although anaemia is more common and more severe with advanced HIV disease 
progression however, several longitudinal studies have reported either a 
significant increase in haemoglobin concentration or a significant decrease in 
clinical anaemia one year after HIV-positive persons began ART (Pribram, 2011). 
Participants monitored for one year did not show any clinical sign of anaemia. 
Pribram (2011) reported a multivariate analysis in which BMI, opportunistic 
infections and sex were adjusted for, mean heamoglobin concentrations 
increased significantly by 0.223g/L per month in HIV-positive person receiving 
ART. This may explain the significant increase in Pre-ART Test group from 
39.81% to 43.18% within six months. Although some data reported that 
increased iron intake may be detrimental in HIV infection but conclusive evidence 
is lacking (Pribram, 2011).  In Fawzi, et al. (2007) children born to mothers who 
received multivitamins had a 63% reduced risk of anemia (RR=0,37, 95% CI: 
0,18, 0,79, p=0.01) compared to the placebo group. Therefore, multivitamin 
supplementation provided significant improvements in hemoglobin status among 
HIV-infected women and their children (Fawzi, et al., 2007). Amtewa meal 
nutrition intervention provided significant improvement in hemoglobin status of 
the study participants.   
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Furthermore, diagnostic criteria for diabetes are defined as: The presence of 
classical diabetes symptoms plus either a random venous plasma glucose 
concentration >11.1 mmol/L (>200g/dl) or a fasting venous plasma glucose 
concentration >7.0 mmol/L or >11.1 mmol/L as part of an oral glucose tolerance 
test (OGTT) (WHO, 1999; Pribram, 2011; NIH and NIDDK, 2012). Any test used 
to diagnose diabetes requires confirmation with a second measurement unless 
clear symptoms of diabetes exist (NIH and NIDDK, 2012). In this intervention, the 
random plasma glucose (RPG) test was used because it is sometimes used to 
diagnose diabetes during a regular health checkup (Pribram, 2011; NIH and 
NIDDK, 2012). If the RPG measures 200 micrograms per deciliter or above and 
the individual also shows symptoms of diabetes, then a health care provider may 
diagnose diabetes (NIH and NIDDK, 2012). Any test used to diagnose diabetes 
requires confirmation with a second measurement unless clear symptoms of 
diabetes exist. However, in the HIV population, the prevalence of diabetes is 
estimated at between 8 and 10% and results from decompensated insulin 
resistance (Pribram, 2011). Participants with history of diabetes mellitus were 
strongly advised to adhere to their medications. In this study, RPG was 
monitored and there was no need for further confirmation with a second 
measurement in all the participants. 
Immune dysregulation in terms of hyper and hypo-gammaglobulinaemia was part 
of definition of immunodeficiency that characterised AIDS. This results in either 
raised level of total plasma/serum protein or low level of plasma/serum protein 
depending on which component of immune dysregulation predominates (Audu, et 
al., 2004). Sarro (2010) reported hypo-albuminemia and hyperproteinemia to be 
associated with a polyclonal ã-globulinemia in HIV seropositive patients as 
compared to HIV seronegative patients. Total protein test measures the total 
amount of two kinds of protein in the body: albumin and globulin. It was used as 
part of the investigations in this research. Study participants were recommended 
to repeat this test when experiencing unexpected weight loss, fatigue, or have 
symptoms of a kidney or liver disease but there was no need for such since their 
results was within the normal range. These symptoms are frequently experienced 
in HIV disease progression to AIDS. 
Also, in HIV low serum albumin which is a component of TP remains a marker for 
mortality (Pribram, 2011). A serum albumin of level of less than 35g/l, along with 
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a history of prolong inadequate nutritional intake and other physical signs of 
undernutrition indicates severe undernutrition (Pribram, 2011). 
The most widely used liver enzymes that are sensitive to abnormalities in liver 
and most commonly measured are the aminotransferases. The two 
aminotransferases are the alanine aminotransferase (ALT or SGPT) and 
aspartate aminotransferase (AST or SGOT). In this study, only the SGOT was 
checked. SGOT is normally present in a number of tissues such as heart, liver, 
muscle, brain and kidney. It is released into the blood stream whenever any of 
these tissues gets damaged. Normal range of SGOT is 5-35 IU/dL (McAuley, 
2012). Results on SGOT obtained in this study shows that they were within 
normal range.  
7.7 Multidimensional advantages of Amtewa meal nutrition intervention 
The combination of Amtewa meal consumption in addition to the daily nutrient 
intake (DNI) has significantly improved the overall nutritional status of PLWH. 
This multi-levels improvement can be summarised as follows: 
 Meeting the daily requirements of some essential minerals and vitamins 
(selenium, zinc, iron etc and vitamins - A, B, C, D, and E). 
 Preserving or increasing fat-free mass 
 Achieving and maintaining an ideal body weight 
 Decreasing functional impairment from under-nutrition (muscular fatigue, 
bedridden state and work incapacity). 
 Improving immune function. 
 Improved quality of life 
Additionally, Amtewa meal may also assist in limiting disease-specific 
complications, improving tolerance to antiretroviral treatment, provide 
symptomatic relief and alleviating gastrointestinal symptoms of HIV illness 
(nausea, diarrhea and bloating) and improving quality of life and survival of 
PLWH in Nigeria. 
The mechanism of improved immune and nutritional status achieved by Amtewa 
meal nutrition intervention has qualified Amtewa meal to assist in 
multidimensional facet as illustrated in Figure 7.1 below: 
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Figure 7. 1: The Multi-dimensional advantages of Tailored Functional Meal - AMETWA 
 
 
7.7.1 Health Dimension 
The Amtewa meal nutrition intervention increased CD4 cell counts and MUAC of 
PLWH. This supports other trials that have shown positive effect of vitamins B, C 
and E supplements on the immune status of HIV-infected persons and the 
relationships between micronutrients status and HIV disease progression among 
adults and children (Fawzi, 2003).  The finding of this study was similar to Kupka 
et al.  (2004) report on increased plasma selenium levels. It shows that selenium 
in Amtewa meal may be related to a decreased risk of mortality. Although plasma 
selenium levels was not associated with time to progression to CD4 cell count < 
200 cells/mm, but were weakly and positively related to CD4 cell count in the one 
year of follow up. Selenium (present in moringa leaves) status is important for 
clinical outcomes related to HIV disease in sub-Saharan Africa (Kupka et al., 
2004). 
Also, Diplock et al. (1998) identified human diet to contain an array of different 
compounds that possess antioxidant activities or have been suggested to 
scavenge reactive oxygen species (ROS). This ROS is responsible for the 
oxidative damage of biological macromolecules such as DNA, carbohydrates and 
proteins. These processes are discussed as pathobiochemical mechanism 
involved in the initiation or progression phase of various diseases including 
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HIV/AIDS. Antioxidants such as selenium, zinc and vitamin C in Amtewa meal 
may be responsible for scavenging this ROS.  
According to Fridovich (1986) and Halliwell (1996), there are various sources of 
specific ROS in the human organism. However, the superoxide radical anion 
appears to play central role, since other reactive intermediates are formed in 
reaction sequences starting with O2
-. It is generated by enzymic one–electron 
reduction of oxygen from xanthine oxidase (EC 1.2.3.2), NADPH oxidase, or by 
leakage of the respiratory chain. It has been estimated that 1-3% of the O2 we 
utilize is converted to O2
-. To counteract the prooxidant load, a diversity of 
antioxidant defence systems is operative in biological systems including enzymic 
and non-enzymic antioxidants (Diplock et al., 1998). This antioxidants (present in 
Amtewa meal) are substances when present in low concentration compared to 
that of an oxidizable substrate significantly delays or inhibits the oxidation of that 
substrate (Halliwell and Gutteridge, 1989). 
Vitamin C (present in carrot, moringa and soyabeans) is the most powerful, least 
toxic natural antioxidant (Bendich and Langseth, 1995). It is a water-soluble 
vitamin and is found in high concentration in many tissues. Vitamin E a generic 
description for all tocols and tocotrienol derivatives exhibits the biological activity 
of alpha tocopherol (Diplock et al., 1998).The richest sources of vitamin E in the 
diet are vegetables oils such as soyabean, maize, cottonseed and safflower seed 
(Diplock et al., 1998).   
Carotenoids (present in Amtewa meal) are lipophilic antioxidants present in 
lipoproteins such as LDL and HDL. Some of the major sources are carrots (alpha 
carotene and beta carotene), tomatoes, citrus fruits, spinach. Flavonoids are 
considered polyphenolic antioxidants that occur in several fruits, vegetables and 
beverages. Enzymes such as glutathione peroxidase and superoxide dismutase, 
which require a dietary supply selenium, copper and zinc respectively, 
contributed to the overall oxidative defence mechanism (Diplock et al., 1998) 
achieved by the intervention meal. 
Local food substances in Nigeria (soyabean, millet, carrot and moringa) that 
contain vitamin C, vitamin E, carotenoids and flavonoids provided antioxidant 
effect in the formulation of Amtewa meal. Therefore, the first strategy to balance 
oxidative damage and antioxidant defence of human cells and tissues in PLWH 
was to enhance the antioxidant capacity by carefully selecting and optimising the 
dietary intake (macro and micronutrients) of antioxidants. 
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Furthermore, micronutrients (zinc, copper, selenium) and vitamins (A, C, E, B6 
and B12) contained in Amtewa meal are essential for maintaining proper 
immunological function and they perform very important roles in the body‘s 
physiological and psychological (fear of death, anger, anxiety etc) processes and 
the regulation of energy metabolism (Williams, 1999; Drain et al., 2007; Pribram, 
2011).Deficiencies of these micronutrients in HIV disease have been associated 
with higher risks of HIV disease progression and mortality. Studies have shown 
low or deficient serum concentration of several micronutrients, including 
thiamine, selenium, zinc and vitamins A, B3, B6, B12, C, D and E to be 
individually associated with either low CD4 cell counts, advance HIV-related 
diseases. Also, faster disease progression or HIV-related mortality among HIV-
positive persons not receiving ART was observed (Drain et al., 2007; Pribram, 
2011). 
Some morbidity characteristics, such as diarrhea, nausea or vomiting, lower 
respiratory tract infections, oral ulcers; thrush, severe anemia, and low CD4+ are 
related to a higher risk of wasting. Paton et al. (2006) reported moderate to 
severe undernutrition was present among 16% of patient at the time of starting 
ART, and was a significant predictor of death. Villamor et al. (2005) indentified 
vitamin B and vitamins C and E (contained in Amtewa meal) as essential 
vitamins that can reduce the risk of wasting. Jones et al. (2006) also reported 
increased serum zinc levels (as optimised in Amtewa meal) are associated with 
improved virologic control. 
Interestingly, Austin et al. (2006) investigated a prospective double blind placebo 
controlled trial on the impact of carotenoids (which is a constituent of Amtewa 
meal) supplements on survival and health of AIDS patients. Their result shows 
mortality was increased in participants who did not receive carotenoids treatment 
compared to those who did. In the multivariate analysis survival was significantly 
and independently improved in those with higher baseline serum carotene 
concentration (p=.04) or higher baseline CD4 T lymphocyte counts (p=.005). It 
shows that low serum carotene concentration is common in AIDS patients and 
can predict death among advanced AIDS patients. The presence of carotenoids 
in Amtewa meal may account for the delay in the progression of HIV to AIDS in 
this study as justified by Austin et al. (2006).  Supplementation as used in this 
intervention can correct micronutrient deficiency, improve survival and the study 
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participants were less likely to have progression to advanced stages of HIV 
disease with a better preservation of CD4+ (Fawzi et al., 2004; Austin et al., 
2006). 
In Kaiser et al. (2006)  investigation on absolute CD4 count increase by an 
average of 24% in the micronutrient group versus no change in the control group 
(p=.01), serum parameters were not different among both groups but 
micronutrients supply as proposed in the study improved  CD4 cells count 
reconstitution in HIV-infected person taking HAART. Similarly, a synergistic effect 
in Amtewa meal nutrition intervention with PLWH already on HAART was 
documented (12.12% increase in the CD4 count of the ART Test group (group on 
HAART) compared to the 6.31% increase in the Pre–ART Test group (not on 
HAART). 
The finding of Amtewa meal nutrition intervention was further supported by the 
following authors: Kruzich et al. (2004) reported that the effect of inadequate 
intake of vitamin A and E and zinc is related to impaired immune function and 
metabolic complications of the disease in the population. O‘Brien et al. (2005) 
analysis using adjusted models also showed an association between anemia and 
an increased risk of all cause mortality and AIDS-related mortality, independent 
of CD4 cell count, WHO clinical stage, age, pregnancy, vitamin supplementation, 
and BMI. Papathakis et al. (2007) identified micronutrients deficiencies are 
associated with disease progression, reduced CD4 cell counts, and increased 
morbidity and mortality in HIV-positive persons. 
According to Pribram (2011) the choice of MUAC in the assessment of the 
nutritional status in this intervention was based on the fact that MUAC is simple 
and minimally invasive and is rarely affected by oedema than other 
anthropometric measurements. Bishop et al. (1981) classification of mean MUAC 
(cm) according to age groups confirmed that the mean MUAC for men within the 
age group 18-74 years is 31.8cm while that of women within the same age group 
(18–74 years) is 29.4cm. Although the MUAC results (Test versus control) in the 
scale-up intervention indicated that both groups are within the normal range as 
specified by Bishop et al. (1981)  however there was a consistent decrease in 
MUAC in the control (Pre-ART and ART) groups. 
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Although Pribram (2011) identified time constraints and lack of practitioner 
training, along with inter and intra operator variation and inaccuracies that 
informed practice in paediatric units within the UK, to not routinely include this as 
an assessment tool, however this intervention research excluded paediatric 
participants, the research team were periodically trained and measurements 
monitored by a second observer to ensure accurate readings. The MUAC results 
provided a measure of acute nutrition status in adults (USAID and Measure 
Evaluating PRH) and this indicator is part of the linked set of ‗Harmonised 
indicators for Nutrition and HIV Care‘ which track and provide comparative and 
trend data on the number and proportion of undernourished individuals receiving 
various program services (FANTA, 2009). The percentage increase in the pilot 
and scale–up interventions was used to tract the improvement in the nutritional 
status of the study participants. The validity of this indicator is also supported by 
USAID and Measure Evaluating PRH who states that this indicator can be used 
by donors and international organizations to track the extent to which nutrition 
interventions are improving client status and to identify countries or regions 
where more focused efforts may be required. 
In support of our findings, Arpadi (2005) reported that lean body mass is lower in 
HIV-infected children than in HIV-negative control children when assessed by 
arm muscle circumference. Grinspoon et al. (2003) reported that HIV infection 
lead to wasting, particularly loss of metabolically active lean tissue, even in the 
era of highly active antiretroviral therapy. Similarly, Berhane et al. (1997) 
identified HIV-infected Ghanaian children with poor weight gain in infancy have a 
fivefold increase in the risk for death by age 2 years. Fontana et al. (1999) 
estimated that the relative risk of death was increased fivefold in HIV-infected 
children with the lowest quantities of fat-free mass. This implies that there is a 
strong association between poor growth and mortality in HIV which may further 
be investigated in future work with Amtewa meal. In Berhane et al. (1997) they 
proposed a possibility that poor nutritional status accelerates the progression 
from asymptomatic HIV infection to AIDS. Likewise, Centeville et al. (2005) 
reinforced the link between nutritional status and clinical progression of 
HIV/AIDS. Villamor et al. (2005) reported that multivitamins alone significantly 
reduced the risk of a first episode of a low mid-upper arm circumference. 
Therefore, Amtewa meal which is a natural source of macro and micronutrients 
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may give better outcome in future comparative studies with studies done with 
synthetic multivitamins.   
From the results of 12 months follow-up (pilot to scale-up), the CD4 count in the 
Pre-ART Test group increased by 2.16% over a period of 12 months. Similarly, in 
the ART Test group the CD4 count increased by 10.8% over the same period. 
This increase is statistically significant (p=0.05). The result suggests that ART 
Test participants had 5 folds increase more than the Pre-ART Test group. 
Additionally, the result obtained in the 12 months follow up is comparable to pilot 
intervention that reported a 0.69% increase in the Pre-ART Test group and a 9% 
increase in the ART Test group. Although Paton et al. (2006) justified these 
results (pilot and scale-up intervention) however, Fawzi et al. (2005) caution the 
use of micronutrient supplementation as an alternative treatment, instead 
recommend micronutrient supplementation as a complementary intervention to 
antiretroviral therapy (ART). Therefore, Amtewa meal nutrition intervention is not 
a substitute to ART for PLWH who are eligible for HAART but complimentary in 
HIV care and support. 
Similarly, the 12 months pilot to scale-up intervention results also shows the 
results of the MUAC increased by 2.04% in the Pre-ART Test group from 
inclusion to the study to 12 months. Also, in the ART Test group, MUAC 
increased by 3.8% within the same period. Tang (2003) reported body weight, fat 
free mass and body mass index improved in patient receiving nutritional 
intervention compared with the patient receiving placebo.  
The Malnutrition Universal Screening Tool (MUST) developed by the British 
Association of Parenteral and Enteral Nutrition (BAPEN) and supported by many 
professional bodies, including the British Dietetic Association, Royal College of 
Physicians and National Institute for Health and Clinical Excellence (NICE) 
(Pribram, 2011) classified MUAC values using the following reference tool: 
 If MUAC < 23.5cm, BMI < 20 kg/m2 (underweight) 
 If MUAC > 32cm, BMI > 30 kg/m2 (obese)  
From the above reference tool, the MUAC intervention results reveals that the 
participants monitored over a period of 12 and 6 months were not underweight 
but the controls consistently losing weight calls for an urgent intervention 
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(Amtewa meal intervention) because Tang et al. (2005) studies have shown that 
among HIV-positive persons 5% weight loss in 6 months is markedly associated 
with an increased risk of death. 
7.7.2 Economic and Social dimensions 
The traditional diets of most societies in developing countries (like Nigeria) are 
good (FAO, 2014). Scientific approach in the development of a functional meal 
like Amtewa will help to protect, support and help preserve the many excellent 
existing local food sources nutritionally valuable in the management of some 
disease conditions like HIV. Although synthetic multivitamins are present in the 
Nigerian market, however, functional food such as Amtewa meal constituents 
(soya beans, millet, carrot and moringa leaves) are readily available, accessible, 
affordable and more bio-available than the synthetic products. Synthetic 
multivitamins are very expensive food supplements which are not affordable by 
an average Nigerian, and if the country continues to import them, then foreign 
exchange is unnecessarily spent. The production of food comes mainly from 
agriculture. Nigeria has the human and material resources for the cultivation and 
production of the constituents of Amtewa meal. High-yielding varieties of the 
important cereals in Amtewa meal (soyabeans, millet) have been successfully 
developed, and much progress has been made in increasing food yields per 
hectare of land. 
The suggested association on prolong use of Amtewa meal over 12 months 
period may slow down the progression of HIV to AIDS thereby improving the 
economic and social status of PLWH by: 
 Improving the high manpower-intensive sectors of the economy that are 
most affected by HIV disease in Nigeria. This includes the agricultural, 
educational and health sectors as well as the rural economy. 
  Decreasing the number of orphans and decreasing the cost of achieving 
set developmental goals by increasing the size of the workforce. 
  Improving the quality of life of Nigerians thereby contributing positively to 
the economic development. 
  Decreasing cumulative deaths which represent an incalculable loss of 
human potential associated with enduring trauma in households and 
communities. 
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 PLWHIV with a CD4 count above 200 cells/mm3 can be continually 
productive in their community economy and sustain a little disrupted family 
life. 
7.7.3 Food security 
Household food security depends on a nutritionally adequate and safe food 
supply in Nigeria, at the household level and for each individual; a fair degree of 
stability in the food availability to the household both during the year and from 
year to year; and access of each family member to sufficient food to meet 
nutritional requirements (FAO, 2014). This last criterion includes not only physical 
access but also economic and social access to foods that are culturally 
acceptable (Amtewa meal). Incomes received from cash crops or wage earnings 
and prices paid for purchased items influence a rural population's food security 
(FAO, 2014). However, IITA (2004) reported that average household expenditure 
on non-staples in Nigeria was highest on fish (N140.84 approximately $1) 
followed by meat products (N81.54 approximately half a dollar). Here, the least 
weekly expenditure was on fruit (N13.62), followed by weekly expenditure on the 
leafy vegetables (N20.88). This suggests that most Nigerians have vegetable 
gardens in their neighborhood were these vegetables such as moringa leaves 
are easily accessed and may not need to purchase from the market. Food 
security can be threatened by increased prices, job loss, income reduction, rent 
increases, larger numbers of dependent persons (more children, or relatives 
moving into the household) and other factors (FAO, 2014; Ivers, 2009). 
Nonetheless, IITA (2004) report on frequently consumed staple and non-staple 
foods in Nigeria suggests that the constituents of Amtewa meal (soyabeans, 
millet, carrot and moringa leaves) are available and affordable.  
The concept of food security in this intervention research is to ensure both 
physical and economic access to food that meets dietary needs (in the form of a 
functional meal - Amtewa) of PLWH. Wang et al. (2011) reported that food 
insecurity associated with unsuppressed viral load and may render treatment 
less effective among HIV-infected participants receiving antiretroviral 
medications.  
Similarly, Palar (2012) reported improvements in work and mental health status 
were identified as potential pathways through which ART may improve food 
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security. Therefore, Amtewa meal nutrition intervention may guarantee food 
security due to the fact that the intervention meal meets the three pillars on which 
food security is built. These are: 
 Amtewa meal constituents are readily available: sufficient quantities of 
soyabeans, moringa leaves, carrot and millet are available on a consistent 
basis (IITA, 2004 report on Nigeria Food Survey). 
 Amtewa meal constituents are accessible: having sufficient resources to 
obtain /afford the constituents for a nutrition intervention (FAO, 2014; IITA, 
2004). 
 Amtewa meal formulation requires low technology: appropriate use based 
on knowledge of basic HIV nutrition and care, as well as adequate training 
on TFR concept (Amuna et al., 2004). 
7.7.4 Sustainability and health promotion 
The relationship between undernutrition and infection has been extensively 
studied and documented. There is no doubt that common infections such as 
diarrhoea, respiratory disease, intestinal worms, measles and HIV/AIDS are 
important causes of undernutrition (FAO, 2014). However, the need to sustain 
the gain of Amtewa meal nutrition intervention in slowing down the progression of 
HIV to AIDS is imperative. 
Planning for sustainability in this public health nutrition intervention required a 
clear understanding of the concept of sustainability and operational indicators 
that may be used in monitoring sustainability over time within State House 
Medical Centre, Abuja and the community. In addition, it also required the use of 
programmatic approaches and strategies that favored long-term program 
maintenance in a resource limited setting. The current HIV clinic structure in 
SHMCA, identifies some key personnel (Health professionals), management staff 
of SHMCA, the monthly support group meeting of the PLWH and the HIV 
programme implementing partners. Sustainability will be assured if these groups 
of people are incorporated into the intervention programme. Broad-based support 
from this cross-section of service providers is necessary to overcome reasons 
related to limited financial resources, territoriality concern, local politics, limited 
time and lack of hospital management interest. Quality control procedures and 
HIV treatment protocols implemented in HIV care and support programmes will 
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incorporate Amtewa meal nutrition intervention. However, the sustainability and 
health promotion approach focused primarily on the following:  
 Three training-workshops to empower (capacity building) the PLWH 
community: Topics covered in these workshops were: Basic health 
education on HIV/AIDS; Nutrition education on the macro/micronutrient 
contents of local fruit and vegetables; formulation/preparation of Amtewa 
meal at home standardised but adaptable approaches in the design of the 
intervention. 
 maintenance of research outcome (pilot and scale-up) health benefits 
achieved through the intervention program.  
 Presentation of research outcome at the Federal Ministry of Health 
Nigeria, National Agency for the Control of AIDS Nigeria, and publication 
in international journals. 
 Level of institutionalization of a program within the health settings by 
incorporating Amtewa meal nutrition intervention in the HIV care program 
as a policy framework. 
 Replication of Amtewa meal nutrition intervention in other HIV treatment 
centre in collaboration with the National Agency for the Control of AIDS 
(NACA) in Nigeria. 
In summary, the multi-faceted dimensional benefits of amtewa meal nutritional 
intervention is justifiable and should be an integral part of HIV care and support 













Limitations, Conclusion and 
Future work
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8.1 Limitations to the study 
This presented research is an implementation of previous research papers on the 
subject with a view of developing a culturally acceptable, affordable and 
accessible nutrition intervention meal (Amtewa) to slow the progression of HIV to 
AID amongst PLWHIV in Nigeria. However, some limitations include: 
 The shortage of trained research active/oriented staff was challenging in 
the health setting particularly nutrition and dietician trained staff.   
 Risk of sample contamination (Un-intentional collusion between the 
control and Test group while on HIV care hospital appointments). 
 The undivided attention of the Principal investigator (researcher) to 
manage a large sample size (logistics and funding) in the scale-up 
intervention. 
 Financial support: Lack of funds stalled the inclusion of viral load test as 
an assessment tool in the study design. Viral load test is very expensive.  
 Time period: The time period from the points of participants‘ assessment, 
data collection, blood sample collection and collection of the Amtewa meal 
was a challenge to some participants who were in a hurry to report in their 
respective work places. 
 Large population (sample size): Recruiting and monitoring participants in 
the ART group was not challenging compared to the Pre–ART group. 
Participants in the Pre–ART group are not on HAART according to WHO 
recommendations; hence they are not mandated to the monthly or 
bimonthly hospital appointment prescribed for ART group of participants. 
The Pre–ART irregular hospital appointment was a challenge in tracking 
this group of participants. 
  
8.2 Conclusions  
The success of recent nutrition interventions in HIV demonstrate the progress 
made in HIV care and support. The idea to adapt principles and technologies 
from the TFR concept to the development of a functional recipe to slow the 
progression of HIV to AIDS proves to be meaningful and realisable in Amtewa 
meal nutrition intervention approach. 
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Although the achieved results take the form of specific technology, it suggests 
that a prolong consumption of the intervention meal (Amtewa) will be suitable to 
sustain the gained improvements in the anthropometric and biochemical indices. 
The research highlighted crucial issues and identified key design parameters that 
require further attention and research in developing countries like Nigerian 
context.   
Overall, it underpins the synergistic relationship between nutrition and HIV 
infection, the nutritional requirement and nutritional care and support for PLWH in 
Nigeria. While the nutrition intervention demonstrated a positive effect, the study 
also suggests that the initial visit of a newly diagnosed HIV-positive patient 
should include screening for nutritional status, identify risks and offer appropriate 
nutrition Counselling which was not in existence but currently has been 
imbedded as ―Nutritional Framework‖ within the HIV care and support 
programme in SHMCA, Nigeria. This drafted Nutritional Framework has provided 
information to PLWH on their HIV medication and food interactions and about 
nutritional screening tools available in the health setting. 
Finally, the research provides evidence which may be used as a basis for policy 
makers to incorporate Amtewa meal nutrition intervention in HIV care and 
support programme in other HIV treatment centres in Nigeria with a view of 
attenuating the progression of HIV to AIDS amongst PLWH in Nigeria.   
8.3 Future work 
The conducted intervention identified areas for further research that may 
significantly support the government initiative to combat HIV in Nigeria. Future 
researches are necessary and must expand upon past programmes and this 
presented intervention. The following intervention programmes warrant clinical 
investigation. These can be summarised as:  
   
 Amtewa meal nutrition intervention approach in the management of adult 
patients with AIDS (CD4 <200cells/mm3). 
 Amtewa meal nutrition intervention approach in the management of 
paediatric patients living with HIV. 
 Amtewa meal nutrition intervention approach in management of pregnant 
women living with HIV. 
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Appendix 3.0 
Research Hypothesis 
Daily intake of optimised Amtewa meal which contains immune-boosting macro 
and micronutrients from indigenous food sources in Nigeria delays progression of 
HIV to AIDS by ameliorating and sustaining the nutritional status (BMI, MUAC) as 
well as improving the biochemical indices (CD4 count, PCV, RG, SGOT, and TP) 
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I am advised by the Committee to remind you of the following points: 
 
1.    Your responsibility to notify the Research Ethics sub Committee immediately of any 
information received by you, or of which you become aware, which would cast doubt upon, or 
alter, any information contained in the original application, or a later amendment, submitted to the 
Research Ethics sub Committee and/or which would raise questions about the safety and/or 
continued conduct of the research. 
2.    The need to comply with the Data Protection Act 1998 
3.    The need to comply, throughout the conduct of the study, with good research practice 
standards 
4.    The need to refer proposed amendments to the protocol to the Research Ethics sub 
Committee for further review and to obtain Research Ethics sub Committee approval thereto prior 
to implementation (except only in cases of emergency when the welfare of the subject is 
paramount). 
5.    You are authorised to present this University of Westminster Ethics Committee letter of 
approval to outside bodies, e.g. NHS Research Ethics Committees, in support of any application 
for further research clearance.   
6.    The requirement to furnish the Research Ethics sub Committee with details of the conclusion 
and outcome of the project, and to inform the Research Ethics sub Committee should the 
research be discontinued.  The Committee would prefer a concise summary of the conclusion 
and outcome of the project, which would fit no more than one side of A4 paper, please. 
7.    The desirability of including full details of the consent form in an appendix to your research, 
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TITLE OF RESEARCH: ‘Assessing the effectiveness of public health-
nutrition intervention programme to attenuate the progression of human 
immuno-deficiency virus (HIV) to AIDS (acquired immuno-deficiency 
disease syndrome) among People Living with HIV (PLWH) in Abuja, Nigeria’ 
 
NAME(S) AND AFFILIATIONS OF RESEARCHER(S): UNIVERSITY 
OF WESTMINSTER 
 
PRINCIPAL INVESTIGATOR(S): AMLOGU MAINAJI ABRAHAM 
 
SPONSOR(S) OF RESEARCH: AMLOGU MAINAJI ABRAHAM 
 
PURPOSE(S) OF RESEARCH: INTERVENTION ON PATIENT 
MANAGEMENT 
 
PROCEDURE OF THE RESEARCH: 
 
Eligible People Living with HIV (PLWH) will be recruited, and given the right to 
decline participation without jeopardizing receipt of care at the State House 
Medical Centre, Abuja. Prior intervention, ‗consent form‘ will be signed and 
‗project information‘ sheet will be given and explained to all participants.  
 
Once enrolled, participants will be subjected to a research assessment tool, 
which include some variables; demographic information, specific questions on 
lifestyle, health habits and nutritional practices. 
Furthermore, participants shall be grouped into four groups according to the 
study design. Nutrition Counselling, Highly Active Antiretroviral Therapy 
(provided as standard mode of treatment for PLWH by the State House Medical 
Centre), vitamin supplements, specific micro and macro-nutrient combination will 
be administered to the groups‘ accordingly. 
At the onset of the research, one hundred (100) participants will be recruited for 
the pilot study. Thereafter, a larger scale intervention that will recruit four hundred 
(400) participants will follow to determine the impact of the research on a larger 
population.  
 
Anthropometric measurements(e.g. body mass index, skin fold measurement, 
waist circumference), clinical assessments (e.g. review of dietary history, blood 
pressure measurement) and laboratory investigations (e.g. blood glucose level, 
lipid profile,CD4 count ) will be conducted at the commencement of the study, 
third and sixth months of the pilot and larger scale studies respectively. 
 




Risks and Discomforts 
Conventionally, HIV clients on management visit the hospital every three months 
for laboratory investigations such as CD4 count and viral load tests. Naturally, 
the discomfort of the needle prick prior to sample collection may psychologically 
affect some participants that have phobia for injections.  
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Furthermore, participants will be subjected to a research assessment tool and 
anthropometric measurements. These may constitute some stress to the 
participants. 
 
Administration of micro and macro-nutrient combination to participants for daily 
consumption is expected to have no side effects due to the fact that the 
quantities to be consumed will be within the limit for recommended intake for 
adult; however these products may constitute an additional stress as a result of 
adherence to the prescription on the product.  
 
Measures to reduce risks and Discomforts 
 
Participants will be reassured of lesser needle prick pain. 
To discuss with the trained laboratory scientists responsible for the sample 
collection on an improve technique (e.g. immersing participants fingers in warm 
water before sample collection) that will not inflict much pain on study 
participants. 
3. Educate the participants on the benefits of adhering to the recommended 
micro and macro-nutrient combination on improving their quality of life  
4. Trained interviewers will be assisting in filling the research assessment 




The research participant is not waiving any of his/her legal rights by signing this 
informed consent document. 
Please initial your choice(s) below:  
___ I agree to allow my samples to be kept and used for future research 
___ I do not agree to allow my samples to be kept and used for future research 
___ I wish to be notified if my samples are going to be used for future research. 
 
Signatures 
Your signature below indicates that you agree to participate in this study. You will 
receive a copy of this signed document. 
 
Signature of Participant        Date 
 
Signature of investigator or other person obtaining consent   Date 
 
Signature of Witness        Date 
 
The consent process must include a witness unless the PI requests and justifies, 
and the SHMC REC approves a waiver of the requirement. 
The person administering the consent (e.g., study coordinator) cannot sign as the 
witness. 
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  STATE HOUSE MEDICAL CENTRE, ABUJA 
                     RESEARCH AND ETHICS COMMITTEE (REC) 
 
AUTHORIZATION FOR USE/DISCLOSURE OF HEALTH INFORMATION AND 
PARTICIPANT INFORMATION SHEET FOR RESEARCH 
 
 
What is the purpose of this form?  You are being asked to sign this form so that 
SHMC may use and release your health information for research.  Participation in 
research is voluntary.  If you choose to participate in the research, you must sign this 
form so that your health information may be used for the research. 
 








What health information do the researchers want to use? All medical information 
and personal identifiers include past, present, and future history, examinations, 
laboratory results, imaging studies and reports and treatments of whatever kind 
related to or collected for use in the research protocol. 
 
Why do the researchers want my health information? The researchers want to use 
your health information as part of the research protocol listed above and described to 
you in the Informed Consent document. 
 
Who will disclose, use and/or receive my health information? The physicians, 
pharmacists, nurses, laboratory scientists and staff working on the research protocol 
(whether at SHMC, University of Westminster, London or elsewhere). 
 
How will my health information be protected once it is given to others? Your health 
information that is given to the researcher will coded and remain private to the extent 
possible, even though the researcher is not required to follow the federal privacy laws. 
However, once your information is given to other organizations that are not required to 
follow federal privacy laws, we cannot assure that the information will remain protected. 
 
How long will this Authorization last? Your authorization for the uses and disclosures 
described in this Authorization does not have an expiration date. 
Can I cancel the Authorization? You may cancel this Authorization at any time by 
notifying the Principal investigator in writing, referencing your Research Protocol 
Number. If you cancel this Authorization, the researcher will not use any new health 
information for the research. However, researchers may continue to use the health 
information that was provided before you cancelled your authorization. 
Can I see my health information? You have a right to request to see your health 
information. However, to ensure the scientific integrity of the research, you will not be 
able to review the research information until after the research protocol has been 
completed. 
 
Signature of participant     
Date: 
Or participant's legally authorised representative: Date: 
Printed Name of participant‘s representative: 
Relationship to the participant: 
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Appendix 3.4 
 
Determining Moisture Content in Food Samples (Pomeranz and Meloan,  
1994) 
Oven Drying Methods 
Materials: Food samples, analytical balance, Mortar and pestles, Petri dishes, 
Blender, Spatula, Oven   
Method: With oven drying, a known weight of each sample was heated at 780C 
for 60hrs.The loss of weight was used to calculate the moisture content of the 
samples. 
Moisture Content Calculations: For oven-drying methodologies 
% Moisture = 
(wt/wt)  
(wt of wet sample - wt of dry sample) 
x 100  























  157 
Appendix 3.5 
 
Fat (Soxhlet extraction of Fat from Food Samples) (Pomeranz and Meloan, 
1994) 
Purpose 
This experiment involves the extraction of fat from food samples in Nigeria by an 
exhaustive extraction with solvent using a Soxhlet extractor apparatus as shown 
below 
Materials 
• Organic solvent 
• Sodium sulfate 
• Thimble (cellulose or slitted glass) 
• Food samples from Nigeria 
• Teflon® boiling chips or glass beads  
• Glass wool 
• Nitrogen gas 
• Mortar and pestle 
• Micro-Soxhlet glassware with 25-mL round-bottomed flask 
• Heating mantle 
• Concentrator (evaporation) apparatus 
• Rubber tubing 
• Analytical balance 
Handling and Disposal 
Specifically the University of Westminster Standard Operating Procedures 
(SOPs) and guidelines on safe handling and storage of all chemicals and 
equipment were strictly followed in these activities. This includes determining and 
using the appropriate personal protective equipment (e.g., goggles, gloves, and 
apron).  
This experiment uses hazardous solvents that were disposed of in appropriate 
waste containers. Organic solvents tend to be highly flammable. Appropriate 
precautions (Extraction and post extraction evaporation steps)were performed in 
a vented hood. 
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Method 
Glasswares were cleaned with petroleum spirit, drained, and dried in an oven at 
102 º C for 30 minutes and cooled in desiccators. A piece of cotton wool was 
placed in the bottom of a 100ml beaker and also a plug of cotton wool was 
placed in the bottom of an extraction thimble. The thimble was made to stand in 
the beaker. 
 5 g of sample was accurately weighed into the thimble. 1 - 1.5 g of sand was 
added and mixed with the sample with a glass rod. Dried sample was allowed to 
cool in desiccators. The thimble was inserted into in a Soxhlet liquid/solid 










Soxhlet extraction of fat 
 
A clean dried 150ml round bottom flask was accurately weighed and 90ml of 
petroleum ether was poured into the flask. The extraction unit was assembled 
over either an electric heating a water bath. The solvent in the flask was heated 
until it boils. The heat source was adjusted at intervals to avoid solvent drips from 
the condenser into the sample chamber at the rate of about 6 drops per second. 
The extraction process continued for 6 hours. After 6hrsthe heat source was 
removed the solvent drained from the extractor in the flask. The thimble was 
removed from the extractor and the sample transferred to a 100ml beaker. With 
the aid of a glass rod, the sample was broken, returned to the thimble and 
replaced in the extractor. The beaker with the petroleum ether was rinsed and 
poured into the extract. Extraction continued for a further two hours. After 2hrs of 
further extraction, the heat source was removed and the extraction unit and 
condenser were detached. 
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The flask was replaced on the heat source to evaporate off the solvent. (The 
solvent may be distilled and recovered). The flask was placed in an oven at 
102ºC to dry the contents until a constant weight was reached (1-2 hours). The 
flask with the content was cooled in desiccators and weighed. 
 
Weight of empty flask (g) = W1 
 
Weight of flask and extracted fat (g) = W2 
 
Weight of sample = S 
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Appendix 3.6 
 
Protein (Kjeldahl extraction) (Blamire, 2003)  
The Kjeldahl method consists of three steps, which were carefully carried out in 
sequence: 
1. The sample was first digested in strong sulfuric acid in the presence of a 
catalyst, which helps in the conversion of the amine nitrogen to 
ammonium ions, 
2. The ammonium ions were then converted into ammonia gas, heated and 
distilled. The ammonia gas was led into a trapping solution where it 
dissolved and became an ammonium ion once again, 
3. Finally, the amount of the ammonia that was been trapped was 
determined by titration with a standard solution, and a calculation made. 
 
 
Step 1: Digestion 
Approximately 1gm of sample containing protein was weighed, placed into a 
digestion flask, containing 12-15 ml of concentrated sulfuric acid (H2SO4). 
Seven grams of potassium sulfate and a copper catalyst were added. The 
mixtures in the flask were heated (about 370oC to 400oC) using a heating a 
block until white fumes were seen, and then the heating continued for about 
60-90 minutes. The flask was cooled cautiously by adding 250ml of water. 
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Step 2: Distillation 
The pH of the mixture was raised using sodium hydroxide (45% NaOH 
solution). This has the effect of changing the ammonium (NH4
+) ions (which 
were dissolved in the liquid) to ammonia (NH3), which is a gas. The nitrogen 
was separated away from the digestion mixture by distilling the ammonia 
(converting it to a volatile gas, by raising the temperature to boiling point) and 
then trapping the distilled vapors in a special trapping solution of about 15 ml 
HCl (hydrochloric acid) in 70 ml of water. The trapping flask was removed and 
the condenser rinsed with water to ensure that all the ammonia has been 
dissolved. 
Step 3: Titration 
An indicator dye was added to the acid/ammonia trapping solution. This dye 
turned a strong color, indicating that a significant amount of the original 
trapping acid was still present. A standard solution of NaOH (sodium 
hydroxide) was poured into the burette (a long tube with a tap at the end), and 
slowly, slowly adding small amounts of the sodium hydroxide solution to the 
acid solution with the dye. This process continued to the point at which the 
dye turned orange, indicating that the "endpoint" has been reached and that 
all the acid has been neutralised by the base. 
The volume of the neutralizing base(sodium hydroxide solution) that was 
necessary to reach the endpoint was recorded.Amount of ammonia, and thus 
nitrogen that came from the original sample was calculated. 
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Calculations: 
 
 moles of acid = molarity of acid x volume used in flask (moles A = M x V)  
 moles of base = molarity of base x volume added from the burette (molesB = 
M x V)  
 gms nitrogen = moles nitrogen x atomic mass (gN = molesN x 14.0067)  
 %nitrogen = (gms nitrogen / gms sample) x 100 %N = (gN / gS) x 100 
 Amount of crude protein in the sample (CP) can be found by multiplying the 
percent Nitrogen by a factor (usually 6.25). 
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Appendix 3.7 
 
Minerals (Inductively coupled plasma analysis of micronutrients) 
(Pomeranz and Meloan, 1994; Brad & Cook, 1997; Xiandeng and Bradley, 
2000) 
 
An ICP typically includes the following components: 
 sample introduction system (nebulizer)  
 ICP torch  
 High frequency generator  
 Transfer optics and spectrometer  






Schematic of an ICP system 
 
Aqueous or organic solutions of samples were obtained and injected into the 
ICP. The nebulizer transformed the aqueous solution into an aerosol. The light 
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emitted by the atoms of an element in the ICP was converted to an electrical 
signal that was measured quantitatively. This was accomplished by resolving the 
light into its component radiation (nearly always by means of a diffraction 
grating). The light intensity was measured with a photomultiplier tube at the 
specific wavelength for each element line. The light emitted by the atoms or ions 
in the ICP was converted to electrical signals by the photomultiplier in the 
spectrometer. The intensity of the electron signal was compared to previous 
measured intensities of known concentration of the element and a concentration 
was computed. Each element had many specific wavelengths in the spectrum 
which could be used for analysis. However, the best line with the assistance from 
an experience technician with considerable experience of ICP wavelengths was 
obtained. 
 
Recommended wavelengths and estimated instrumental detection limits 
 




Aluminum 308.215 45 
Antimony 206.833  32 
Arsenic 193.696 53 
Barium 455.403 2 
Beryllium 313.042 0.3 
Boron  249.773 5 
Cadmium  226.502 4 
Calcium  317.933 10 
Chromium  267.716 7 
Cobalt  228.616 7 
Copper 324.754 6 
Iron  259.940 7 
Lead  220.353 42 
Magnesium 279.079 30 
Manganese  257.610 2 
Molybdenum  202.030 8 
Nickel  231.604 15 
Potassium  766.491 See note c 
Selenium 196.026 75 
Silicon 288.158 58 
Silver 328.068 7 
Sodium  588.995 29 
Thallium 190.864 40 
Vanadium 292.402 8 
Zinc 213.856 2 
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Appendix 3.8: Public Health Nutrition intervention Assessment Tool 
 
Cxc ANNEX I:      DEMOGRAPHY        INITIALS OF PATIENTS 
 
HOSPITAL NUMBER : _____________________ 
 
Date of visit    dd   mm    yy   
 
IMPORTANT:  
1) Make sure that written informed consent has been obtained at this point before 
Proceeding. 
 
2) This screening assessment should take place within 7 days (1 week) before the 
Baseline 
     (day 0) visits. 
 
   
 
Weight, kg Height,cm Temperature, degrees Celsius 
 
   Body Mass Index, kg  
   
Date of birth dd      mm yy   
  Male      Status  single 
Sex 
  Female     married divorced 
 
Risk factors (more than one box may be ticked)  widow 
    Heterosexual contact 
    Homosexual contact 
Blood product or transfusion recipient 
I.V. drug use 
Females   post-menopause 
Sterile 
Pre-menarche 
Potentially able to bear children (determine serum β-HCG) 
Not applicable 
For females of childbearing potential, please tick the type of birth control used 
oral contraceptive 
intra-uterine contraceptive device 
depot contraceptive (implants/injectables) 
 





    None
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Tuberculosis screening 
Chest X-ray date  dd       mm    yy 
     
Are there radio-diagnostic indications that pulmonary tuberculosis may be present? 
    Yes 
    No 
PPD skin test date 
             dd           mm         yy   
PPD skin test positive? 
    Yes 
    No 
If PPD skin test is positive, the patient may only be included if the following conditions 
are met: 
1:  no signs of systemic or pulmonary tuberculosis; 
2: the patient is willing to take INH secondary prophylaxis according to protocol 
guidelines (section 3.3) 
 
 
Peripheral neuropathy screening 
 
Does the patient have symptoms indicating peripheral neuropathy > grade 1? 
(See Adverse Events section for Grading Scale) 
 
  Yes (=exclusion criteria) 
  No 
 
For females of child-bearing potential only: 
Date of pregnancy test      pregnancy test 
outcome  positive 
(serum or urine β-HCG)        dd  mm          yy    (=exclusion criteria) 
           
 Negative 
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ANNEX II:  HIV-RELATED ILLNESSES INITIALS OF PARTICIPANT 
 
HOSPITAL NUMBER:________________________________________ 
Please indicate if the patient has experienced any of the following HIV-related illnesses 
at any time, whether the diagnosis was definitive (Def) or presumptive (Pres) and if the 









     Yes           
No 
B1 Bacillary angiomatosis      
B2 Candidiasis oropharyngeal      
B3 
Candidiasis vulvovaginal (persistent, 
Recurrent, or unresponsive to therapy) 
     
B4 
Cervical dysplasia (moderate or severe) / 
Cervical carcinoma in situ 
     
B5 
Herpes zoster (shingles), involving at 
least two distinct episodes or more than 
one dermatome 
     
B6 Idiopathic thrombocytopenia purpura      
B7 Listeriosis      
B8 Oral hairy leukoplakia      
B9 Pelvic inflammatory disease      
B10 Peripheral neuropathy      
B11 Persistent fever (> 1 month  duration)      
B12 Persistent diarrhoea (>1 month duration)      
B13 Pruritic papular eruptions      









     Yes           
No 
C1 Candidiasis of bronchi, traches, or lungs      
C2 Cervical cancer, invasive      
C3 
Coccidioidomycosis, disseminated or 
extrapulmonary 
     
C4 Cryptococcosis, extrapulmonary      
C5 
Cryptosporidiosis, chronic intestinal 
(> 1 month duration) 
two distinct episodes or more than one 
dermatone 
     
C6 
Cytormegalovirus disease 
(other than liver, speen or nodes). 
     
C7 
Cytomegalovirus retinitis (with loss of 
vision) 
     
C8 
Herpes simplex : chronic ulcer(s) (> 1 
month duration) ; or  bronchitis, 
pneumonitis, or oesophagitis 
     
C9 Histoplasmosis, disseminated or      









     Yes           
No 
C10 HIV-related encephalopathy      
C11 
HIV wasting syndrome (more than 
10% bodyweight loss with chronic 
diarrhea and/or fever, otherwise 
unexplained) 
     
C12 
Isosporiasis, chronic intestinal 
(>1month duration) 
     
C13 Kaposi’s sarcoma      
C14 
Lymphoma, Burkitt’s (or equivalent 
term) 
     
C15 
Lymphoma, immunoblastic (or 
equivalent term) 
     
C16 Lymphoma, primary, of the brain      
C17 
M.avium complex or M.Kansasii, 
disseminated or extrapulmonary 
     
C18 
M.tuberculosis, any site  
( pulmonary or extrapulomonary) 
     
C19 
Mycobacterium, other or unidentified 
species, disseminated or 
extrapulmonary 
     
C20 Oesophageal candidiasis      
C21 Pneumocystis carinii pneumonia      
C22 
Pneumonia, recurrent ( 2 distinct 
episodes) 




     
C24 Salmonella septicemia, recurrent      
C25 Toxoplasmosis of the brain      
 
 
The  following additional events, although not currently part  of the CDC Classification 
System, will be 
Reported as HIV-related illnesses: 
 





     Yes           
No 
D1 Aspergillosis      
D2 Isosporiasis      
D3 Leishmaniasis      
D4 Microsporidiosis      
D5 Nocardiasis      
D6 Penicillium marneffei, disseminated      
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ANNEX III:    LABORATORY INVESTIGATIONS   INITIALS OF 
PARTICIPANT 
 
HOSPITAL  NUMBER :___________________________ 
 
Storage samples  Date of collection      
              dd          mm         yy  
Have the following blood samples been collected for serum and plasma storage? 
I large serum tube   and 2 large EDTA tubes 
   yes no     yes no  
 
Hematology      Date of collection 
                            dd           mm         
yy  
Hemoglobin g/dl                            Neutrophile   % 
Hematocrit       %                                      Lymphocytes   % 
WBCcells/µl                                        Monocytes.      % 
Platelets       10
9
/l                           Eosinophils  % 
Basophils   % 
 
 
Immunology      Date of collection 




   CD4+cells %   .  % 
CD8+cells /mm
3
   CD8+cells %   .  % 
 
HIV Virology      Date of collection 
                             dd      mm         
yy  
HIV RNA           copies/ml 
EKG   pass    Date of collection 
                              dd        mm         
yy  
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Laboratory Investigations (Continues) 
  
Storage samples    Date of collection 
                     dd           mm         
yy 
Have the following blood samples been collected for serum and plasma storage? 
I large serum tube   and 2 large EDTA tubes 
   yes   no      yes  no  
 
Biochemistry     Date of collection 
         dd           mm         yy 
SGOT    U/l 
SGPT    U/l 
Bilirubin   mg/dl 
Albumin    mg/dl 
Globulin    mg/dl 
FBS    mg/dl 
BUN    mg/dl 
Creatinine   mg/dl 
Sodium    mmol/l 
Potassium   mmol/l 
Carbonate ion   mmol/l 
Chloride ion   mmol/l          
Amylase          U/l 
Protein electrophoresis 
Total Protein
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ANNEX IV: 
OTHER MEDICATIONS DURING STUDY/DIETARY SUPPLEMENT/ 
HIVMEAL NUTRITION  
INITIALS OF PARTICIPANT___________________ 
HOSPITALNUMBER : _____________________________ 
Date Items Dose 
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ANNEX V:  
FOLLOW UP VISITS      INITIALS OF PARTICIPANT 
 
HOSPITAL NUMBER: _________________________________________________________ 
 
 
Please report all relevant medical history, all abnormalities found 
Upon physical examination at screening, and all lab-abnormalities grade 3 or 4, that 
havenot been listed in the “HIV Related Illnesses” section. In each column record Grading scale of each symptom 
 
       VISITS 
     














































































Yes   
No 
E1 Fever                       
E2 Sore throat                       
E3 Diarrhea                       
E4 Anorexia                       
E5 Weight loss                       
E6 Candidiasis                       
E7 Skin rash                       
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E12 Headache                       
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ANNEX VI:   KARNOFSKY PERFORMANCE SCALE 
 
 






          SECOND VISIT 
___100 Normal, no complaints, no evidence of disease 
___90 Able to carry on normal activity : minor symptoms of disease 
___80 Normal activity with effort: some symptoms of disease 
___70 Cares for self: unable to carry on normal activity or active work 
___60 Requires occasional assistance but is able to care for needs 
___50 Requires considerable assistance and frequent medical care 
___40 Disabled: require special care and assistance 
___30 Severely disabled: hospitalizations indicated, death not imminent 
___20 Very sick, hospitalization necessary: active treatment necessary 
___10 Moribund, fatal process progressing rapidly 
 
 
          THIRD VISIT 
___100 Normal, no complaints, no evidence of disease 
___90 Able to carry on normal activity : minor symptoms of disease 
___80 Normal activity with effort: some symptoms of disease 
___70 Cares for self: unable to carry on normal activity or active work 
___60 Requires occasional assistance but is able to care for needs 
___50 Requires considerable assistance and frequent medical care 
___40 Disabled: require special care and assistance 
___30 Severely disabled: hospitalizations indicated, death not imminent 
___20 Very sick, hospitalization necessary: active treatment necessary 
___10 Moribund, fatal process progressing rapidly 
___100 Normal, no complaints, no evidence of disease 
___90 Able to carry on normal activity : minor symptoms of disease 
___80 Normal activity with effort: some symptoms of disease 
___70 Cares for self: unable to carry on normal activity or active work 
___60 Requires occasional assistance but is able to care for needs 
___50 Requires considerable assistance and frequent medical care 
___40 Disabled: require special care and assistance 
___30 Severely disabled: hospitalizations indicated, death not imminent 
___20 Very sick, hospitalization necessary: active treatment necessary 
___10 Moribund, fatal process progressing rapidly 
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ANNEX VII: 
 
WHO CLINICAL STAGING SYSTEM FOR HIV INFECTION AND DISEASE 
 
 The WHO Global Program on AIDS has issued the following proposed clinical staging 
system for HIV infection and disease. Based primarily on clinical criteria, the system is organised 
into four prognostic categories. It also incorporates a performance scale based on the Eastern 
Cooperative Oncology Group score. 
 




Persistent generalised lymphadenopathy (PGL) 
Performance scale 1:  asymptotic, normal activity 
 
Clinical stage 2: 
 
Weight loss of <10 % of body weight 
 
Minor mucocutaneous manifestation (seborrhoeic dermatitis, prurigo, fungal nail infections, current 
oral ulcerations, angular shelties). 
 
Herpes zoster, within the last 5 years 
 
Recurrent upper respiratory tract infection (i.e., bacterial sinusitis) and/or Performance scale 2: 
symptomatic, normal activity 
 
Clinical stage 3: 
 
Weight loss of > 10 % of body weight 
 
Unexplained chronic diarrhoea, < 1 month 
 
Unexplained prolonged fever (intermittent or constant), < 1 month 
 
Oral hairy candidiasis (thrush) 
 
Oral hairy leukoplakia 
 
Pulmonary tuberculosis, within the pass year 
 
Severe bacterial infections (i.e., pneumonia, pyomyositis) and/or Performance scale 3: bed-ridden 
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Clinical stage 4: 
 




Pneumocystis carinii pneumonia 
 
Toxoplasmosis of the brain 
 




Cytomegalovirus (CMV) disease of an organ other than liver, spleen, or lymph nodes 
 
Herpes simplex virus (HSV) infection, mucocutaneous (> 1 month) or visceral (any duration) 
 
Progressive multifocal leukoencephalopathy (PML) 
 
Any disseminated endemic mycosis (i.e., histoplasmosis, coccidioidomycosis) 
 
Candidiasis of the oesophagus, trachea, bronchi, or lungs 
 
Atypical mycobacteriosis, disseminated 
 






Karposis sarcoma (KS) 
 
HIV encephalopathy, as defined by CDC
1
 
and/or Performance scale 4: bedridden 50 % of the day during the last month. 
 






                                               
2 HIV wasting syndrome : Weight loss of 10 % of body weight, plus either unexplained chronic diarrhoea (1 month) 
or chornic waekness and unexplained prolonged fever (1 month). 
1 HIV encephalopathy: Clinical findings of disabling cognitive and/or motor dysfunction interfering with activities of daily living, 
progressing over weeks to months, in the absence of a current illness or condition other than HIV infection that could explain the 
findings. 
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ANNEX VIII:  TOXICITY GRADING SCALE







Mild tolerable symptoms, 












permanently, results in 
congenital abnormalities, 
cancer, overdose 
TREATMENT Not required Not required except when 
noted 
Required, responds to Rx No response to Rx, 
hospitalisation required 
 
ALLERGY GRADE 1 GRADE 2 GRADE 3 GRADE 4 
ALLERGIC 
REACTION 
Transient URTICARIA, DRUG 







FEVER WITH DRUG 
(Absence of infection) 
37.1-38ºC, 98.7-100ºF 38.1-40ºC, 100.5-104ºF >40ºc, >104ºF FOR 
>24 hours despite 
antipyretic Rx 
>40.ºC, >104ºF despite 
Rx for >24 hours, or any 
fever associated with 
hypotension  
     
CARDIOVASCULAR GRADE 1 GRADE 2 GRADE 3 GRADE 4 
CARDIAC 
SYMPTOMS 
Mild or transient Symptoms on exertion, 
recurrent or persistent, no 
Rx required 
Symptoms at rest, 
requires Rx 
Severe symptoms, 
unresponsive to Rx 
ARRHYTHMIA Asymptomatic, transient, 
no Rx required 
Recurrent or persistent, 
no Rx required 
Requires Rx Requires monitoring; or 
hypertension, or 




0.5 1.0 1.5 >1.5 
CARDIAC FUNCTION Asynptomatic, decreased 
ejection fraction by  20% 
of baseline 
Asymptomatic decreased 
ejection fraction by 
>20% of baseline 
Mild CHF, responsive to 
Rx 
Severe refractory CHF 
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CARDIOVACULAIRE cont. GRADE 1 GRADE 2 GRADE 3 GRADE4 
 
OEDEMA (e.g. Peripheral 
capillary leak syndrome) 
also see Pulmonary 
 
Minimal ankle pitting 
oedema 
 
Ankle pitting oedema and 
weight gain 5kg 
 
Peripheral oedema, weight 
gain 5-10kg, pleural 
effusion with no pulmonary 
function deficit 
 
Anascara, severe pleural 
effusion with pulmonary 
function deficit, ascities, 
pulmonary oedema, weight 
gain>8kg.   
HYPERTENSION Asymptomatic, transient 
increases 20mm Hg or 
150/100 if previously WNL. 
No Rx required 
Recurrent or persistent  (>1 
hr) 20mm Hg or 150/100 if 
previously WNL. No Rx 
required 
Persistent increase >20mm 
Hg  
or>150/100 if previously 
WNL. Rx required 
Hypertension crisis 
HYPERTENSION 10-20% decrease, systolic, 
no Rx required (includes 
transient orthostactic 
21-50% decrease systolic, 
requiring fluids or other Rx 
but no hospitalisation 
21-50% decrease systolic, 
requires pressors and 
hospitalisation, resolves 
within 48 hours 
>50% decrease systolic, 
requiring hospitalisation, 
unresponsive to pressors, 
requires >48 hours to 
resolve after stopping agent 
ISCHAEMIA Non-specific T-wave 
flattening; stable EKG 
Asymptomatic, EKG 
change; ST and T-wave 
change suggests ischaemia 
New onset angina without 
evidence of infraction; 
clinical signification EKG 
Acute EKG change 
diagnostic for myocardial 
infraction 
PERICARDIAL EFFUSION Asymptomatic, No Rx 
required 
Pericarditis (rub, chest  
pain, EKG changes) 
Symptomatic; large 
effusion, drainage required, 
no tamponade, responsive 
to drainage 
Large effusion, temponade, 
drainage urgently required 
CNS GRADE 1 GRAGE 2 GRADE 3 GRADE 4 









Unreason to Rx; Suicidal 
ideation 
ATAXIA 9Cerebellar) Mild/transient gait or limb 




Moderate gait or limb ataxia Disabling ataxia, cerebella 
necrosis   
AUTOMATIC 
DYSFUNCTION 
Abnormal sweating Impotence Asymptomatic arrhythmia, 
orthostatic hypertension 
Symptomatic arrhythmia, 
orthostate hypertension  





permanent catheter  
COGNITIVE DEFFECT Slow, accurate Impaired memory or new 
learning 
Global deficiency Unresponsive  
CONSTIPATION 
AUTOMATIC 





vomiting;  Ileum>96 
hours  
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Moderate somnolence  or 
agitation ; responds to 






hallucinations ; responds 
to pain only 
 
Coma, grand male 
seizures (current), toxic 
psychosis 
FOCAL SEIZURES Isolated 2 per day 3 per day Status epileptics 
GENERALISED 
SEIZURES 
Isolated 2 per day 3 per day Epilepsy partials  
continua  
HEADACHE Mild Moderate or severe but 
transient 
Unrelenting and severe  
HEARING LOSS Transient decrease, loss 
by audiometer only 
Tinnitus, moderate loss Interferes with functions, 
correctable  
Deaf, despite hearing aid 
LANGUAGE 
ABNORMALITY 
Inattentivness, slurring Motor or communicative 
aphasia 2 hours 
Motor or communicative 
aphasia hours 
Global aphasia 













Severe and reversible 
parkinsonism, dystonia or 
tremor 
Permanent parkinsonism 
dystonia or tremor 
SENSORY DEFICIT Mild parenthesis, 
decreased DTR’s 
Mild to moderate 
objective sensory loss; 
absent DTR’s moderate 
Severe paresthesia, 
severe objective sensory 
loss; interferes with 
function 




Mild slurring Moderate slurring Unintelligible Mute 
VERTIGO Mild, transient Moderate, nausea Associates with nausea 
and vomiting 
Disabling intractable  
VISION 
ABNORMALITY 
Slightly reduces  acuity Symptomatic, correctable Symptomatic, unable to 
correct 
Blind 
     
DERMATOLOGIC GRADE 1 GRADE 2 GRADE 3 GRADE 4 
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ALOPECIA Partial loss Complete loss  Non-reversible  
CHEILITIS Chapping Fissures Bleeding Necrosis 
SKIN REACTION Dry skin, mild or 
transient rash, scattered 
asymptomatic macular or 
papular eruption or 
erythema  
Dry desquamation, 
scattered macular or 
papular eruption or 
erythema with pruritius 





macular, papular or 
vesicular eruption 
Exfoliate dermatitis; 
requires surgical Rx 
GASTROINTESTINA
L 
GRADE 1 GRADE 2 GRADE 3 GRADE 4 
DIARRHOEA Transient, 2-3 stools per 
day over baseline 
Tolerable, 4-6 stools per 
day over baseline, or 
nocturnal stools, 
moderate cramping 
Intolerable, 7-9 stools 
per day over baseline, or 
incontinence, severe 
cramping 
Haemorrhagic,  10 
stools per day over 
baseline, dehydration, 
requires parenteral Rx. 
NAUSEA Able to eat, reasonable 
intake 
Able to eat, decreased 
intake 
No significant intake  
VOMITING 1 x in 24 hours 2-5 x in 24 hours 6-10 x in 24 hours 10 x in 24 hours, or 
requires parenteral 
support  
STOMATITIS                       Milk soreness, erythema, 
painless ulcers 
Painful erythema, patchy 
oedema or ulcers, but can 
eat 
Confluent ulcers, painful 
erythema, necrosis, 




parenteral or entereal  
support 
     
GENERAL GRADE 1 GRADE 2 GRADE 3 GRADE 4 
MYALGIA Myalgia Myalgia requiring 
treatment 
Severe, CK 2.0-5,0 X 
ULN 
Intractable, CK 5 x 
ULN 
CHILLS Mild Moderate   
LOCAL Pain Pain and swelling, 
inflammation or phlebitis 
Ulceration Plastic surgery indicated 
     
HAEMATOLOGICAL GRADE 1 GRADE 2 GRADE 3 GRADE 4 
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Anaemia (gHgb) 10 – normal 8,0 - 10 6,5 – 7,9 6.5 
GRANULOCYTOPENI
A (X 10 L) 
1-5.9 and  20% 
decrease from baseline 
1.0- 1.4and 35% 
decrease from baseline 
0.5 – 0.9 and 50% 
decrease from baseline 
0.5 and 75% decrease 
from baseline 
LEUKOPOENIA  (X10  
l) 
3.0 – 3.9 and 20% 
decrease from baseline 
2.0 – 2.9 and  35% 
decrease from baseline 
1.0 – 1.9 and 50% 
decrease form baseline 
1.0 and  75% decrease 
from baseline 
THROMBOCYTOPOEN
IA (X10  L) 
75-99 and 20% decrease 
from baseline 
50-74 and  35% 
decrease from baseline 
25-49 and  50% 
decrease from baseline 
25 and  75% decrease 
from baseline 
HAEMORRHAGE  Petechiae, minimal blood 
loss, no transfusion 
required, mild 
Gross, transfusion 
required, 1-2 U 
Gross, transfusion 
required  




     
     




1.5 –2.5 X ULN1 1.5 – 2.5 X  ULN1 5.0 – 10.0 X ULN1 10.0 X ULN1 
BILIRUBIN INCREASE  1.3 – 1.5 X ULN1 1.5 – 3.0 X ULN1 3.0 X ULN1 
HEPATIC SYMPTOMS   Pre-coma Hepatic Coma 
TRANSMINASE 
INCREASE 
1.5 – 2.5 X ULN1 2.5 – 5.0 X ULN1 5.0 – 20 X ULN1 20 X ULN1 
     
INFECTION GRADE 1 GRADE 2 GRADE 3 GRADE 4 
INFECTION Mild Infection, Unknown 
origin 
Moderate infection Major organ infection Disseminated infection, 
multi-lobar pneumonia; 
life-threatening sepsis 
FEVER 37.1-38C 38.1-40C 40C, 104F for 24 
hours despite antipyretic 
Rx 
40C, 104F for 
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FVC 70-80% of 
predicted FEV, or DLCO 
60-80% of predicted; 15-
25% decrease from 
abnormal baseline 
FVC 50-69%  of 
predicted FEV, or DLCO 
40-59% or predicted; 
50% decrease from 
abnormal baseline 
FVC 50% of predicted 
FEV, or DLCO 40% of 
predicted; 50% decrease 
from abnormal baseline 
Unable to perform test 
due to respiratory distress 
RESPIRATORY 
SYMPTOMS 
Mild or transient, 
asymptomatic with PFT 
(Pulmonary Function 
Tests) abnormal 
Dyspnea on significant 
exertion 
Symptoms during normal 
activity; persistent 
Dyspnea 
Severe symptoms a1 rest, 
non-responsive to Rx 
CHEST X-RAY 10% lung fields show 
infiltrate or effusion 
10-20% lung fields show 
infiltrate or effusion 
21-50% lung fields show 
infiltrate or effusion 
50% lung fields show 
infiltrate or effusion 
ABG PAO2 95 on room air PAO2 80 on room air PAO2 60 on room air PAO2 60 on 
supplemental  oxygen 
     
RENAL GRADE 1 GRADE2 GRADE 3 GRADE 4 
CREATININE 
INCREASE (mg/dL) 
1.25-2.5 X ULN1 2.5-5.0 X ULN1 5.0-10.0 X ULN1 10 X ULN1; requiring 
dialysis )8.0), 




70-80% of baseline 50-69% of baseline 30-49% of baseline 30% of baseline 
DYSURIA Mild Moderate Severe  
HAEMATURIA 6-10 RBC/HPF2 11-50 RBC/HPF2 50 RBC/HPF2 Requires transfusion 
PROTEINURIA 1; 3.0g%, 3g/l 2-3; 0.3-1, 0g%, 3-10gl 4; 1.0G%, 10g/l Nephritic syndrome 
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METABOLIC GRADE 1 GRADE 2 GRADE 3 GRADE 4 
HYPERGLYCAEMIA 140-160MG/dL 161-250MG/dL 251-500mg/dL 500MG/dL; ketoacidosis 
HYPOGLYCAEMIA 
(Random) 
55-64ML/dL 40-54mg-dL 30-39MG/Dl 30MG/dL 
MYLASE 1.5 XUNL1 1.5-2.0 XUNL1 2.1 –5.0 XULN1 5.0 XULN1 
HUPERCALCAEMIA 10.6-11.5MG/dL 11.6-125MG/dL 12.6-13.5MG/dL 13.5MG/dL 
HYPOCLACAEMIA 8.4-7.8mg/dL 7.7-7.0MG/dL 6.9-6.81MG/dL 6.1MG/dL 
HYPOMAGNESEMIA 1.4-1.2mg/dL 1.1-0.9mg/dL 08-06mg/Dl 0.5mg/Dl 
HYPOALBUMINEMIA 2.8mg/dL 2.4-2.7mg/dL 2.0-2.3mg/Dl 2.0mg/Dl 
     
COAGULATION GRADE 1 GRADE 2 GRADE 3 GRADE 4 
FIBRINOGEN 0.99-0.75 XUNL1 0.74-0.5 XUNL1 049-0.25 XUNL1 0.24 XUNL1 




1.1 – 1.66 X UNL1 1.67-2.33 XULN1 2.34.3.0 XULN1 3.0 X ULN1 
KEY: 
 
ULN – Upper Limit of Normal 
RBC/HPF – Red Blood Cells/High Power Field 
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Appendix 3.9 
 





Study Personnel Profession/Designation & Role in the Project Remarks 
1.  
 
Dr. Abraham Amlogu 
(Principal Investigator) 
Consultant Clinical Pharmacist: Recruiting 
patients, general supervision and monitoring 
laboratory investigations; writing and 
submitting reports as required. 
 
2.  




Pharmacist: Co-ordination of product supply 






Senior Registrar (Medicine): Recruiting 
patients & coordinating clinic activities, 




Dr. T. Acho 
Physician: Recruiting patients & assisting 





Nurse & Counsellor: Counselling, nursing 










Mr. Evaristus Ibekwe 
Med. Lab. Scientist: CD4 count, and 




Mr Ifeanyi Ikete 
Med. Lab. Scientist: CD4 count, and 




Mrs. Ibilanke Yomi 







Medical Records officer: Collate participants‘ 
case files for routine assessment, 




Mr. Henry Ukachi 
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Appendix 3.10 
 
Programme of Events for the TOT Training 
 
Time Activity Facilitator 
8.00am Registration Research Assistant 
8:35am Welcome address, 
Introduction of the 
research aim, objectives 
and expected outcome 
Principal Investigator 
8:45am Introduction, ground rules 
and appointment of a 
rapporteur 
Research Assistant 
9:00am General research data 
collection 
Medical Records Officer 
9:30am Nursing HIV care and the 
significance of patient 
follow up in a research 
setting 
Nurse & Counsellor 
10:00am Nutritional status and 
anthropometric 
measurements in HIV 
care 
Nutritionist 
10:30am HIV & Nutrition – Gaps Physician 
11:00am Laboratory investigations 
in HIV care and support 
Laboratory Scientist 
11:30am Adherence to HAART and 
Amtewa meal in HIV care  
Pharmacist 
12:00pm Statistical analysis of 
variables in the research 
Statistician 
12:30pm Review of the research 
assessment tool 
Principal investigator 
1:00pm Interactive session ALL 
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Appendix 3.11 
 
List of Publications based on this study 
 
1. Amlogu, M. A., Tewfik, S., Wambebe, C., Godden, K. and Tewfik, I. (2011) 
Conceptual framework of public health-nutrition intervention programme to 
attenuate the progression of HIV to AIDS among People Living with HIV (PLWH) 
in Abuja, Nigeria. In Sharing Knowledge Making a Difference: The Role of 
International Scientific Cooperation, World Sustainable Development Outlook 
2011. ISBN 978-1-907106-12-5, 11-20. 
 
2. Amlogu, A.M., Godden, K., Tewfik, S., Wambebe, C. & Tewfik, I. (2012). 
Tailored Food Recipe – TFR: Employing the European perspective on functional 
food science (FUFOSE) to promote effective dietary intervention in Africa. 
International Journal of Food, Nutrition & Public Health, 5 (1/2/3), 1-10. 
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Conceptual Framework. International Journal of Food, Nutrition & Public Health, 
6 (1) 83-98. 
 
4. Amlogu, A.M., Tewfik, S., Wambebe, C. & Tewfik, I. (2014). Tailored 
Functional Recipe (TFR) approach to delay the progression of HIV to AIDS 
among People Living with HIV (PLWH) in Abuja, Nigeria. Scientific Research 
Journal of Pharmacology & Pharmacy, 5: 925 – 936 
  
5. Amlogu, A.M., Tewfik, S., Wambebe, C. & Tewfik, I. (2014). Innovative 
Nutritional approach to attenuate the progression of HIV to AIDS among People 
Living with HIV (PLWH): A study based in Abuja, Nigeria. Manuscript submitted 
for a Book chapter in ―African Indigenous Medical Knowledge and Human 
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Appendix 3.12 
 
List of International Conferences and Presentation 
 
S/N         DATE     CONFERENCE/PRESENTATION   VENUE                                     TOPIC    REMARKS 
1 4TH JULY, 
2011 
3RD HIV SYMPOSIUM The Royal London Hospital Public Health Nutrition 
Intervention to attenuate the 
progression of HIV to AIDS 
among People Living with HIV 
virus in Abuja, Nigeria 
 Poster 
2 26TH – 28TH 
OCT.2011 
World Association for Sustainable 
Development 9th International 
Conference, Atlantic City, USA, 
2011 






3 4th Dec. 2011 Royal Society of Tropical 
Medicine and Hygiene Research 
in Progress 2011: Short 
presentations and poster 
 University of London Same as above Oral 
presentation 
4 11th  - 12th 
May, 2013 
13th International Conference on 
Functional Food in Health and 
Disease Kyoto, Japan 
University of Medicine, 
Kyoto, Japan 
Tailored Food Recipes-TFR: 
Employing the European 
perspective on functional food 
science (FUFOSE) to promote 
effective dietary intervention 
in Africa 
Poster Abstract 




Federation of International 
Pharmacist (FIP) World Congress 
2013 
Dublin, Ireland Tailored Functional Recipe 
(TFR) approach to delay the 
progression of HIV to AID 
among PLWHIV in Abuja, 
Nigeria. 
Poster Abstract. 
Approved no: 
418 
 
 
 
 
